Master guide for poisoning with mnemonics in detail
| Letter | Feature |
|---|---|
| S | Salivation |
| L | Lacrimation |
| U | Urination |
| D | Defecation |
| G | GI distress (cramps, diarrhea) |
| E - | Emesis |
| B | Bradycardia |
| A | Abdominal pain |
| M | Miosis |
| Letter | Feature |
|---|---|
| D | Defecation, Diarrhea |
| U | Urination |
| M | Miosis |
| B | Bradycardia, Bronchospasm, Bronchorrhea |
| E | Emesis |
| L | Lacrimation |
| S | Salivation, Sweating |
| Feature | Mnemonic |
|---|---|
| Hyperthermia | "Hot as a Hare" |
| Mydriasis | "Blind as a Bat" |
| Dry skin/mucosa, urinary retention | "Dry as a Bone" |
| Flushing | "Red as a Beet" |
| Delirium, hallucinations | "Mad as a Hatter" |
| Tachycardia | |
| Decreased bowel sounds |
| Feature | Cholinergic | Anticholinergic | Sympathomimetic | Opioid | Sedative |
|---|---|---|---|---|---|
| HR | ↓ | ↑ | ↑ | ↓ | ↓ |
| BP | ↓ | ↑ | ↑ | ↓ | ↓ |
| Pupils | ↓ (miosis) | ↑ (mydriasis) | ↑ (mydriasis) | ↓ (miosis) | Normal |
| Temp | ↓ | ↑ | ↑ | ↓ | ↓ |
| Skin | Wet/sweaty | Dry/flushed | Diaphoretic | Normal | Normal |
| Bowel sounds | ↑ | ↓ | Normal | ↓ | ↓ |
| Secretions | ↑↑ (SLUDGE) | ↓ | Normal | ↓ | ↓ |
| Poison | Antidote | Mnemonic aid |
|---|---|---|
| Paracetamol (Acetaminophen) | N-Acetylcysteine (NAC) | "N-acetyl for N-Acetaminophen" |
| Organophosphates | Atropine + Pralidoxime | "2-PAM reactivates before aging" |
| Opioids | Naloxone | "Nal-oxone blocks opioid rece-one" |
| Benzodiazepines | Flumazenil | "Flu-maze-nil for benzo's fog" |
| Warfarin/Anticoagulants | Vitamin K + FFP | "K for Koagulation" |
| Iron | Deferoxamine | "De-FER-oxamine for FERrous iron" |
| Heavy metals (As, Pb, Hg) | BAL (Dimercaprol) / DMSA | "BAL chelates bivalent metals" |
| Cyanide | Hydroxocobalamin / Amyl nitrite + Sodium thiosulfate | "Cobalt binds cyanide" |
| Carbon monoxide | 100% O2 / Hyperbaric O2 | "Oxygen displaces CO from Hb" |
| Methanol/Ethylene glycol | Fomepizole (4-MP) / Ethanol | "Fomepizole blocks alcohol DH" |
| Digoxin | Digibind (Fab fragments) | "Anti-Dig Fab" |
| Beta-blockers | Glucagon + Calcium | "Glu-Ca for Beta block" |
| Tricyclics (TCAs) | Sodium bicarbonate | "Bicarb for TCA arrhythmia" |
| Heparin | Protamine sulfate | "Pro-tamine reverses Pro-tein heparin" |
| Isoniazid | Pyridoxine (Vit B6) | "B6 for INH seizures" |
| Methemoglobinemia | Methylene blue | "Blue for MetHb (also blue in color)" |
| Phase | Time | Features |
|---|---|---|
| I | 0-24h | N/V, malaise, pallor |
| II | 24-72h | RUQ pain, LFT elevation begins, apparent improvement |
| III | 72-96h | Peak hepatotoxicity (jaundice, coagulopathy, encephalopathy) |
| IV | 4 days-2 weeks | Recovery OR fulminant hepatic failure |
| Level | Features |
|---|---|
| <300 mg/L | Mild: tinnitus, N/V, vertigo |
| 300-700 mg/L | Moderate: dehydration, tachypnea, respiratory alkalosis → metabolic acidosis |
| >700 mg/L | Severe: arrhythmias, pulmonary edema, cerebral edema, seizures, coma, renal failure |
| COHb% | Features |
|---|---|
| 10-20% | Headache, nausea |
| 20-40% | Confusion, weakness |
| 40-60% | Syncope, seizures |
| >60% | Death |
| Stage | Timing | Features |
|---|---|---|
| A - GI | 0-6h | N/V, diarrhea, hematemesis |
| B - Latent | 6-12h | Apparent improvement (deceptive) |
| C - Cardiovascular | 12-24h | Shock, metabolic acidosis, coagulopathy |
| D - Delayed hepatic | 2-5 days | Hepatic failure |
| E - Enteric scarring | 2-8 weeks | GI obstruction from scarring |
| Metal | Key Feature | Antidote |
|---|---|---|
| Lead (Pb) | Burton's lines (blue-black gum line), basophilic stippling, neurological | DMSA (succimer), BAL for encephalopathy |
| Mercury (Hg) | "Mad Hatter" - tremor, erethism (neuropsych), Minamata disease | DMSA, BAL |
| Arsenic (As) | Mees' lines, Aldrich-Mees lines on nails, rain-drop pigmentation, garlic breath | BAL (dimercaprol), DMSA |
| Thallium | Alopecia (hair loss), Mees' lines, painful neuropathy | Prussian blue |
| Agent | Specific Antidote | Mechanism |
|---|---|---|
| Beta-blockers | Glucagon | Bypasses β-receptor, raises cAMP |
| CCBs | Calcium + High-dose insulin | Restores Ca2+ signaling |
| Both refractory | High-dose Insulin Euglycemia (HDIE) | Inotropic effect on carbohydrate metabolism |
| Both refractory | Lipid emulsion (Intralipid) | "Lipid sink" sequesters drug |
| Method | Best For | Drugs |
|---|---|---|
| Hemodialysis | Small volume of distribution, water-soluble | Methanol, ethylene glycol, lithium, salicylates |
| Hemoperfusion | High protein binding | Theophylline, carbamazepine |
| Urinary alkalinization | Weak acids | Salicylates, phenobarbital |
| Urinary acidification | Weak bases | Amphetamines (rarely used now) |
| MDAC | Enterohepatic circulation | See CAPS D above |
| Poison | Antidote | Dose/Notes |
|---|---|---|
| Acetaminophen | N-Acetylcysteine | 150 mg/kg IV loading |
| Opioids | Naloxone | 0.4-2 mg IV/IM/IN |
| Benzodiazepines | Flumazenil | 0.2 mg IV, cautiously |
| Organophosphates | Atropine + Pralidoxime | Atropine until secretions dry |
| Cyanide | Hydroxocobalamin | 5 g IV |
| CO | 100% O2 / HBO | |
| Methanol/EG | Fomepizole | 15 mg/kg IV loading |
| TCAs | Sodium bicarb | 1-2 mEq/kg IV |
| Digoxin | Digoxin Fab | Based on serum level |
| Iron | Deferoxamine | 15 mg/kg/h IV |
| Beta-blockers | Glucagon | 3-10 mg IV bolus |
| CCBs | Calcium + Insulin | Ca gluconate 3 g IV |
| Warfarin | Vitamin K + FFP | |
| Heparin | Protamine | 1 mg per 100 units heparin |
| INH (isoniazid) | Pyridoxine (B6) | Gram-for-gram if dose known |
| Methemoglobinemia | Methylene blue | 1-2 mg/kg IV |
| Heavy metals | BAL / DMSA / EDTA | Depends on metal |
| Arsenic/Lead/Mercury | BAL (dimercaprol) | |
| Thallium | Prussian blue | |
| Sulfonylureas | Octreotide | Prevents recurrent hypoglycemia |
| Dabigatran | Idarucizumab | 5 g IV |
| Rivaroxaban/Apixaban | Andexanet alfa |
| Toxin | Incubation | Key Feature |
|---|---|---|
| Staph aureus, B. cereus (short) | 1-6h | Preformed toxin, vomiting prominent |
| C. perfringens, B. cereus (long) | 8-16h | In-vivo toxin |
| ETEC, STEC, Salmonella, Vibrio | >16h | Invasive/in-vivo |
| Botulism | 12-36h | Descending flaccid paralysis |
| Agent | Damage type | Key feature |
|---|---|---|
| Acids | Coagulative necrosis | Self-limiting eschar; stomach > esophagus |
| Alkalis | Liquefaction necrosis | Deeper penetration; esophagus > stomach |
| Finding | Suspect Poison |
|---|---|
| Cherry red lividity | Carbon monoxide |
| Garlic odor | Arsenic, organophosphates, phosphorus |
| Almond odor | Cyanide |
| Yellow adipocere | Yellow phosphorus |
| Constricted pupils | Opioids, organophosphates |
| Hematemesis + corrosion | Acids/alkalis |
| Centrilobular necrosis | Paracetamol, carbon tetrachloride |
| Situation | Mnemonic | Meaning |
|---|---|---|
| Cholinergic features | SLUDGE / DUMBELS | Salivation, Lacrimation, Urination, Defecation, GI, Emesis |
| Anticholinergic | Hot Hare, Blind Bat, Dry Bone, Red Beet, Mad Hatter | Hyperthermia, Mydriasis, Dry skin, Flushing, Delirium |
| Decontamination | GET SAFE | Gastric lavage, External decon, Triggered emesis (avoid), Activated charcoal, Sodium bicarb, Fluids, Enhanced elimination |
| Charcoal ineffective | CHASM | Caustics, Heavy metals, Alcohols, Solvents, Minerals |
| Multi-dose charcoal | CAPS D | Carbamazepine, Amitriptyline/Dapsone, Phenobarbital, Salicylates/Theophylline, Digoxin |
| Hemodialysis | "AEIOU" | Alcohols (toxic), Ethylene glycol, Isopropanol, OU (outliers: lithium, salicylates) |
| Opioid triad | PIN | Pinpoint pupils, Impaired breathing, No consciousness |
| Salicylate acid-base | RAMMPAGE | Respiratory Alkalosis → Metabolic Acidosis |
| Botulism | 4 D's | Diplopia, Dysarthria, Dysphagia, Descending paralysis |
| Digoxin ECG | Scooped ST/Salvador Dali sign | Reversed tick ST depression |
| CO poisoning | CHERRY RED | Classic (rare in living patients) |
Generate a quick-reference guide on antidote dosing and administration protocols and give example clinical case with each different poisoning management.
| Parameter | Detail |
|---|---|
| Indication | Paracetamol (acetaminophen) overdose |
| Route | IV (preferred) or oral |
| IV Protocol (3-bag Prescott regimen) | |
| Bag 1 (loading) | 150 mg/kg in 200 mL D5W over 60 min |
| Bag 2 | 50 mg/kg in 500 mL D5W over 4 hours |
| Bag 3 | 100 mg/kg in 1000 mL D5W over 16 hours |
| Total IV dose | 300 mg/kg over 21 hours |
| Oral protocol | 140 mg/kg loading, then 70 mg/kg q4h x 17 doses |
| Time window | Most effective <8-10h; still give up to 24h+ in severe cases |
| Mechanism | Replenishes glutathione; neutralizes NAPQI |
| Side effects | Anaphylactoid reaction (esp. with loading dose) - slow infusion; treat with antihistamines |
| Parameter | Detail |
|---|---|
| Indication | Opioid overdose (respiratory depression, coma) |
| IV/IM/SC dose | 0.4-2 mg IV; repeat every 2-3 min (up to 10 mg total before re-evaluating diagnosis) |
| Intranasal | 4 mg/0.1 mL per nostril (FDA-approved) |
| Onset | IV: 1-2 min; IM/SC: 2-5 min; IN: 2-5 min |
| Duration | 30-90 min (SHORTER than most opioids) |
| Continuous infusion | "Wake-up dose" x 2/3 = hourly infusion rate (titrate to respiratory rate ≥12) |
| Neonates | 10 µg/kg IV/IM/SC |
| Long-acting opioids (methadone, fentanyl patches) | Infusion mandatory; admit to monitored unit |
| Discharge after heroin OD | Safe after 1h if normal vitals and mental status |
| Caution | Precipitates acute withdrawal in opioid-dependent patients - start low (0.04 mg) |
| Parameter | Detail |
|---|---|
| Indication | Cholinergic crisis (OP/carbamate, nerve agents, muscarine-containing mushrooms) |
| Initial dose | Adults: 1.2-3 mg IV (depending on severity); Children: 0.02 mg/kg IV |
| Titration | Double the dose every 5-10 min until secretions dry |
| End point | Drying of bronchial secretions + clear chest on auscultation + HR >80 bpm |
| NOT end point | Pupil dilation, tachycardia |
| Massive ingestions | Hundreds of mg may be required - pre-alert pharmacy |
| If no IV | 2-6 mg IM as first dose |
| Maintenance | 10-20% of total loading dose per hour by infusion |
| Caution | Tachycardia is NOT a contraindication (may reflect hypoxia from bronchospasm) |
| Parameter | Detail |
|---|---|
| Indication | Organophosphate poisoning ONLY (not carbamates - not needed/potentially harmful) |
| Mechanism | Reactivates cholinesterase BEFORE irreversible aging |
| Loading dose | 1-2 g IV over 15-30 min |
| Maintenance | 500 mg/h continuous infusion OR 1 g q4-6h |
| Time window | Must be given BEFORE aging; most OP compounds age within hours (soman: minutes) |
| Route | IV preferred; IM if no IV access |
| Stop when | Atropine no longer needed, fasciculations resolved |
| Parameter | Detail |
|---|---|
| Indication | Cyanide poisoning (fire victims, industrial exposure, laetrile, nitroprusside toxicity) |
| Dose | 5 g IV over 15 minutes (preferred first-line) |
| Repeat dose | 5 g IV if no clinical response (max cumulative 10 g) |
| Mechanism | Cobalt binds cyanide → forms cyanocobalamin (Vit B12) excreted renally |
| Side effects | Transient hypertension, tachycardia, red/pink discoloration of skin + urine (harmless); may interfere with pulse oximetry briefly |
| Alternative (if hydroxocobalamin unavailable) | Step 1: Sodium nitrite 300 mg (10 mL of 3% solution) IV over 5-20 min; Step 2: Sodium thiosulfate 12.5 g IV (50 mL of 25% solution) |
| Combined CO + CN | Hydroxocobalamin preferred (sodium nitrite worsens CO poisoning) |
| Key lab clue | Lactate ≥8-10 mmol/L in correct context = cyanide until proven otherwise |
| Parameter | Detail |
|---|---|
| Indication | Methanol or ethylene glycol poisoning |
| Loading dose | 15 mg/kg IV (infuse over 30 min) |
| Maintenance | 10 mg/kg IV q12h x 4 doses, then 15 mg/kg q12h (enzyme auto-induction occurs after 48h) |
| Stop when | Toxic alcohol level <20 mg/dL AND metabolic acidosis resolved |
| During hemodialysis | Give dose at start of HD; then q4h during HD; resume q12h after HD |
| Mechanism | Competitive inhibitor of alcohol dehydrogenase (ADH) → blocks toxic metabolite formation |
| Vitamins (adjunct) | Methanol: Folate/leucovorin 1 mg/kg (max 50 mg) IV q4-6h; EG: Thiamine 100 mg + Pyridoxine 50 mg IV |
| Hemodialysis indicated if | pH ≤7.15, coma, seizures, end-organ damage, very high levels |
| Parameter | Detail |
|---|---|
| Indication | Life-threatening digoxin toxicity (VT, VF, complete heart block, severe hyperkalemia K+ >5.5 in acute OD) |
| Dose calculation | Method 1: Dose (vials) = [Serum digoxin level (ng/mL) × weight (kg)] ÷ 100 |
| Method 2: Ingested dose (mg) × 0.8 ÷ 0.5 = number of vials | |
| Unknown amount | 10 vials empirically (acute); 6 vials (chronic) |
| Onset | 20-30 min; complete response by 4-6h |
| Route | IV over 30 min (bolus if cardiac arrest) |
| After Fab given | Total serum digoxin rises (bound Fab not active) - do not re-dose based on levels |
| Caution | Avoid calcium for hyperkalemia (may precipitate refractory VF) |
| Parameter | Detail |
|---|---|
| Indication | TCA poisoning with QRS >100 ms, ventricular arrhythmia, or refractory hypotension |
| Dose | 1-2 mEq/kg IV bolus (repeat until QRS narrows) |
| Target | Serum pH 7.45-7.55 (not >7.55) |
| Maintenance | 3 ampoules NaHCO3 in 1L D5W at 2x maintenance rate |
| Mechanism | Raises pH (reverses Na+ channel block) + increases Na+ gradient |
| ECG trigger | QRS >100 ms = seizure risk; QRS >160 ms = VT risk; R-wave in aVR >3 mm |
| Lipid emulsion | 1.5 mL/kg 20% Intralipid bolus for refractory cases |
| Avoid | Physostigmine, flumazenil (can worsen seizures) |
| Parameter | Detail |
|---|---|
| Indication | Serum iron >500 µg/dL; or toxic symptoms (shock, acidosis, altered consciousness) |
| Dose | 15 mg/kg/h IV continuous infusion |
| Max rate | 35 mg/kg/h (hypotension risk at faster rates) |
| Duration | Continue until "vin rosé" (wine-rose) color urine returns to normal |
| End points | Resolution of symptoms + serum iron <350 µg/dL + normal urine |
| Mechanism | Chelates free iron → ferrioxamine complex (renally excreted) |
| Urine color | Orange-rose ("vin rosé") = ferrioxamine being excreted |
| Parameter | Detail |
|---|---|
| Indication | Symptomatic methemoglobinemia >20-25%; or MetHb >30% even if asymptomatic |
| Dose | 1-2 mg/kg IV over 5 min (1-2% solution) |
| Repeat | Repeat in 1h if no response (max cumulative 7 mg/kg) |
| Mechanism | Acts as cofactor for NADPH to reduce MetHb back to functional Hb |
| Caution | Do NOT use if G6PD deficiency (will cause hemolysis; use ascorbic acid instead) |
| Paradox | High doses of methylene blue itself can cause methemoglobinemia |
| Parameter | Detail |
|---|---|
| Indication | INH overdose (seizures unresponsive to benzodiazepines) |
| Dose | Gram-for-gram: mg of INH ingested = mg of pyridoxine to give IV |
| Unknown amount | 5 g IV (adults); 70 mg/kg (children) |
| Route | IV over 5-10 min; IM if IV unavailable |
| Mechanism | INH depletes pyridoxal phosphate (GABA synthesis cofactor) → refractory seizures |
| Key teaching | Benzodiazepines alone fail in INH seizures - ALWAYS add pyridoxine |
| Parameter | Detail |
|---|---|
| Indication | Benzodiazepine OD (diagnostic + reversal) |
| Dose | 0.2 mg IV over 30 sec; repeat 0.3 mg at 1 min; then 0.5 mg q1min up to 3 mg total |
| Duration | 30-60 min only (MUCH shorter than BZDs) - re-sedation common |
| Contraindications | Chronic BZD users (precipitates seizures); TCA co-ingestion; epilepsy; increased ICP |
| Do NOT use for | Mixed overdoses; unknown ingestions; seizure patients |
| Parameter | Detail |
|---|---|
| Indication | Beta-blocker toxicity with bradycardia/hypotension unresponsive to atropine |
| Loading dose | 3-10 mg IV over 1-2 min |
| Infusion | 3-5 mg/h (adjust per response) |
| Mechanism | Bypasses β-receptor → activates adenylyl cyclase via glucagon receptor → ↑ cAMP → positive inotrope/chronotrope |
| Side effects | Nausea/vomiting (pretreat with antiemetics) |
| Also useful | Calcium channel blocker toxicity (adjunct) |
| Parameter | Detail |
|---|---|
| Indication | Refractory beta-blocker or calcium channel blocker toxicity |
| Bolus | Regular insulin 1 unit/kg IV + Dextrose 50% 50 mL (if glucose <400 mg/dL) |
| Infusion | Regular insulin 0.5-2 units/kg/h + Dextrose 10% infusion (titrate to glucose 100-200 mg/dL) |
| Monitor | Blood glucose q15-30min; potassium q1h |
| Mechanism | Carbohydrate metabolism in cardiac myocytes; positive inotropy independent of receptor |
A 24-year-old woman presents 5 hours after taking "a whole bottle of Tylenol" (approximately 15 g) after an argument. She appears well with mild nausea. Vitals: BP 118/76, HR 88, RR 16, Temp 37.1°C. Labs: Serum acetaminophen level = 280 µg/mL at 5 hours post-ingestion. LFTs normal. INR 1.0.
A 45-year-old farmer is brought in by family - found unconscious in his field. On exam: miosis, excessive salivation dripping from his mouth, wheezing, incontinence of urine and stool, HR 48, BP 80/50. Clothes smell of pesticide. Fasciculations noted in arms.
A 32-year-old man found unresponsive in a public bathroom. Empty syringe nearby. RR 4/min, GCS 3, pupils pinpoint bilaterally, cyanotic. BP 90/60, HR 52.
A 38-year-old firefighter rescued from a burning warehouse (synthetic materials). GCS 8, BP 80/50, HR 130, RR 28, O2 sat 88% on room air. Lactate = 14 mmol/L. COHb = 15%.
A 55-year-old homeless man presents with sudden severe visual blurring "like looking through a fog," and abdominal pain 12 hours after drinking from an unlabeled bottle. Visual acuity severely reduced. ABG: pH 7.12, HCO3 8 mEq/L. Anion gap = 28. Osmolar gap = 35.
A 19-year-old with depression took "all her amitriptyline pills" 2 hours ago. Initially drowsy, now GCS 7, HR 145, BP 80/50. ECG: QRS = 148 ms, right axis deviation, prominent R in aVR. Seizing on arrival.
A 65-year-old man presents confused and tachypneic after reportedly ingesting "a large amount of aspirin." Vitals: Temp 38.8°C, HR 118, RR 32. ABG: pH 7.48, pCO2 20 (low), HCO3 14 (low). Serum salicylate = 520 mg/L. Tinnitus reported by family.
A 78-year-old woman on digoxin 0.25 mg/day for AF presents with vomiting, yellow-tinged vision, and palpitations. ECG: bidirectional ventricular tachycardia, HR 42, complete heart block. Digoxin level = 4.8 ng/mL, K+ = 6.1 mEq/L, Creatinine = 2.4 mg/dL.
A 50-year-old man with hypertension takes all his metoprolol (approximately 2000 mg). He arrives drowsy, BP 70/40, HR 32, blood glucose 48 mg/dL (hypoglycemia from beta blockade).
A 35-year-old TB patient presents with refractory generalized seizures after accidentally ingesting his entire month's supply of isoniazid. Three rounds of diazepam and lorazepam have failed. Persistent status epilepticus.
A family of four is brought in from their home after their gas heater malfunctioned in winter. Father (40): headache, confusion, COHb 35%. Mother (38): syncope, COHb 28%. Two children (8 and 10 years): nausea/headache, COHb 18%. Mother is 16 weeks pregnant.
An 18-month-old (12 kg) is found with an empty children's chewable iron tablet bottle (50 tablets × 18 mg elemental iron = 900 mg). Currently vomiting blood and has bloody diarrhea 3 hours post-ingestion. BP 70/40 (shock). Serum iron = 620 µg/dL.
┌─────────────────────────────────────────────────────────────────┐
│ CRITICAL ANTIDOTES - MEMORY CARD │
├────────────────┬────────────────────┬───────────────────────────┤
│ POISON │ ANTIDOTE │ KEY DOSE │
├────────────────┼────────────────────┼───────────────────────────┤
│ Paracetamol │ NAC │ 150 mg/kg IV load │
│ Opioids │ Naloxone │ 0.4-2 mg IV; 2/3 rule │
│ OP/Carbamate │ Atropine + 2-PAM │ Atropine: double q5min │
│ Cyanide │ Hydroxocobalamin │ 5 g IV over 15 min │
│ CO │ 100% O2 / HBO │ 2.5 ATA if neurological │
│ Methanol/EG │ Fomepizole │ 15 mg/kg load; q12h │
│ Digoxin │ Digibind │ Level × wt ÷ 100 = vials │
│ TCA │ NaHCO3 │ 1-2 mEq/kg IV; pH 7.50 │
│ Iron │ Deferoxamine │ 15 mg/kg/h IV │
│ Beta-blocker │ Glucagon + HDI │ 5 mg bolus; 1 u/kg ins │
│ BZD │ Flumazenil │ 0.2 mg q1min up to 3 mg │
│ INH │ Pyridoxine B6 │ Gram for gram; 5 g if ? │
│ MetHb │ Methylene Blue │ 1-2 mg/kg IV │
│ Heavy metals │ BAL / DMSA │ BAL: 3-5 mg/kg IM q4h │
│ Warfarin │ Vit K + 4-factor │ Vit K 10 mg IV slow │
│ Heparin │ Protamine │ 1 mg per 100 units hep │
│ Dabigatran │ Idarucizumab │ 5 g IV (2 × 2.5 g) │
│ Rivaroxaban │ Andexanet alfa │ Weight/dose-based │
│ Sulfonylurea │ Octreotide │ 50 µg SC/IV q6-12h │
└────────────────┴────────────────────┴───────────────────────────┘
| Antidote | Monitor | Frequency |
|---|---|---|
| NAC | LFTs, INR, creatinine, paracetamol level | At 24h and 48h |
| Naloxone | RR, GCS, SpO2 | Continuous; q15 min |
| Atropine | Chest auscultation, HR, secretions | Every 5 min during titration |
| Hydroxocobalamin | Lactate, BP, skin/urine color | Continuous |
| Fomepizole | Methanol/EG level, pH, osmolar gap | q4-6h; during HD |
| Digibind | ECG, K+, digoxin level (after 6h) | Continuous ECG; K+ q2h |
| NaHCO3 (TCA) | QRS width, pH, K+ | Continuous ECG; q2h bloods |
| Deferoxamine | Urine color, Fe level, LFTs | Urine hourly; Fe q6h |
| HDI (BB/CCB) | Glucose, K+, BP | Glucose q15 min; K+ q1h |
| Methylene blue | SpO2 (misleading), MetHb level, Hb | MetHb level at 1h |
ICU DRUGS DILUTIONS MASTER GUIDE WITH CLINICAL CASE EXAMPLES COVERING ALL MEDICATION USED IN ICU
Standard ICU Dilution Convention: Most ICU infusions follow the "Rule of 6" or are expressed as mcg/kg/min or mcg/min. All rates given assume a 70 kg adult unless stated. Always use an infusion pump. Central line preferred for vasopressors and concentrated solutions.
| Parameter | Detail |
|---|---|
| Indication | Septic shock, distributive shock, hypotension (1st line per Surviving Sepsis Guidelines) |
| Available vial | 4 mg/4 mL (1 mg/mL) |
| Standard dilution | 4 mg (4 mL) in 250 mL NS = 16 mcg/mL |
| Concentrated dilution | 8 mg in 250 mL NS = 32 mcg/mL (fluid-restricted patients) |
| Dose range | 0.01-3 mcg/kg/min (usual effective: 0.1-0.5 mcg/kg/min) |
| Rate calculation | Rate (mL/h) = [Dose (mcg/kg/min) × Weight (kg) × 60] ÷ Concentration (mcg/mL) |
| Example (70 kg, 0.1 mcg/kg/min) | [0.1 × 70 × 60] ÷ 16 = 26 mL/h |
| Route | Central line required (peripheral only in emergency, max 12h) |
| Titration | Increase by 0.05-0.1 mcg/kg/min every 5-10 min to target MAP ≥65 mmHg |
| Side effects | Peripheral vasoconstriction, ischemia, bradycardia reflex, arrhythmias |
| Receptor activity | α1 > α2 > β1 |
| Parameter | Detail |
|---|---|
| Indication | Refractory shock, septic shock (add-on), anaphylaxis, cardiac arrest |
| Available vial | 1 mg/mL (1:1000) or 0.1 mg/mL (1:10,000) |
| Standard dilution | 4 mg in 250 mL NS = 16 mcg/mL |
| Dose range | 0.01-1 mcg/kg/min (ICU infusion); cardiac arrest: 1 mg IV q3-5 min |
| Example (70 kg, 0.1 mcg/kg/min) | [0.1 × 70 × 60] ÷ 16 = 26 mL/h |
| Anaphylaxis bolus | 0.3-0.5 mg IM (thigh); IV 0.1 mg of 1:10,000 slowly if in arrest |
| Receptor activity | β1 = β2 > α1 (low dose) → α1 dominates (high dose) |
| Side effects | Tachyarrhythmias, hyperglycemia, lactic acidosis (at high doses), myocardial ischemia |
| Parameter | Detail |
|---|---|
| Indication | Bradycardic hypotension; 2nd/3rd line in cardiogenic shock (now less preferred) |
| Available vial | 200 mg/5 mL (40 mg/mL) |
| Standard dilution | 400 mg in 250 mL NS = 1600 mcg/mL |
| Dose ranges (by receptor) | |
| Low dose (dopaminergic) | 1-3 mcg/kg/min: renal/splanchnic vasodilation (not clinically proven to be renoprotective) |
| Medium dose (β1 dominant) | 3-10 mcg/kg/min: positive inotrope + chronotrope |
| High dose (α1 dominant) | >10 mcg/kg/min: vasoconstriction |
| Example (70 kg, 5 mcg/kg/min) | [5 × 70 × 60] ÷ 1600 = 13 mL/h |
| Note | More arrhythmias than norepinephrine in septic shock - use with caution |
| Parameter | Detail |
|---|---|
| Indication | Septic shock refractory to norepinephrine (2nd-line vasopressor); vasodilatory shock |
| Available vial | 20 units/mL |
| Standard dilution | 40 units in 250 mL NS = 0.16 units/mL |
| Fixed dose | 0.03-0.04 units/min (NOT titrated to effect - fixed dose) |
| Rate at 0.03 units/min | [0.03 × 60] ÷ 0.16 = 11 mL/h |
| Maximum | 0.06 units/min (higher doses cause splanchnic/coronary ischemia) |
| Mechanism | V1 receptor → smooth muscle vasoconstriction (catecholamine-independent) |
| Advantage | Conserves endogenous vasopressin depleted in prolonged septic shock |
| Side effects | Hyponatremia, water retention, coronary ischemia at high doses, skin necrosis |
| Parameter | Detail |
|---|---|
| Indication | Hypotension with tachyarrhythmia (pure α1 = no increase in HR); intraoperative hypotension |
| Available vial | 10 mg/mL |
| Standard dilution | 100 mg in 250 mL NS = 400 mcg/mL |
| Dose range | 0.5-5 mcg/kg/min; bolus: 50-200 mcg IV |
| Example (70 kg, 1 mcg/kg/min) | [1 × 70 × 60] ÷ 400 = 10.5 mL/h |
| Advantage over NE | No tachycardia, safe in most arrhythmias |
| Caution | Reduces cardiac output (pure vasoconstriction increases afterload) |
| Parameter | Detail |
|---|---|
| Indication | Cardiogenic shock, low-output states, acute decompensated heart failure |
| Available vial | 250 mg/20 mL (12.5 mg/mL) |
| Standard dilution | 500 mg in 250 mL NS = 2000 mcg/mL |
| Dose range | 2-20 mcg/kg/min |
| Example (70 kg, 5 mcg/kg/min) | [5 × 70 × 60] ÷ 2000 = 10.5 mL/h |
| Receptor | β1 > β2 (inotrope + mild vasodilator) |
| Side effects | Tachycardia, arrhythmias, hypotension (vasodilation), tolerance with prolonged use |
| Note | NOT a vasopressor - may drop BP if patient is already vasodilated |
| Parameter | Detail |
|---|---|
| Indication | Low cardiac output, cardiogenic shock, heart failure (when β-receptors downregulated) |
| Available vial | 10 mg/10 mL (1 mg/mL) |
| Standard dilution | 40 mg in 200 mL NS = 200 mcg/mL |
| Loading dose | 50 mcg/kg over 10 min (often omitted in hypotensive patients) |
| Maintenance | 0.375-0.75 mcg/kg/min |
| Example (70 kg, 0.5 mcg/kg/min) | [0.5 × 70 × 60] ÷ 200 = 10.5 mL/h |
| Mechanism | Inhibits PDE-3 → ↑cAMP → inotropy + vasodilation (bypasses β-receptor) |
| Renal adjustment | Reduce dose in renal failure (renally cleared) |
| Side effects | Hypotension, ventricular arrhythmias, thrombocytopenia |
| Agent | Dose Range | α1 | β1 | β2 | DA | Primary Use |
|---|---|---|---|---|---|---|
| Norepinephrine | 0.01-3 mcg/kg/min | 4+ | 2+ | 0 | 0 | Septic shock (1st line) |
| Epinephrine | 0.01-1 mcg/kg/min | 4+ | 4+ | 4+ | 0 | Anaphylaxis, refractory shock |
| Dopamine | 1-20 mcg/kg/min | 2+ | 3+ | 1+ | 4+ | Bradycardic hypotension |
| Phenylephrine | 0.5-5 mcg/kg/min | 4+ | 0 | 0 | 0 | Tachycardic hypotension |
| Vasopressin | 0.03-0.04 units/min | V1 | 0 | 0 | 0 | Adjunct septic shock |
| Dobutamine | 2-20 mcg/kg/min | 0 | 4+ | 2+ | 0 | Cardiogenic shock |
SCCM PADIS Guidelines 2018: Target lightest effective sedation (RASS -1 to 0 for most patients). Analgesia-first approach. Daily SAT (Spontaneous Awakening Trial) + SBT (Spontaneous Breathing Trial).
| Parameter | Detail |
|---|---|
| Indication | ICU sedation (1st line for mechanically ventilated patients), procedural sedation |
| Available | 10 mg/mL (1% lipid emulsion) or 20 mg/mL (2%) |
| Supplied ready to use | NO dilution needed; use as supplied |
| Sedation dose | 5-50 mcg/kg/min (0.3-3 mg/kg/h) |
| Example (70 kg, 20 mcg/kg/min) | 20 × 70 × 60 ÷ 10,000 = 8.4 mL/h of 1% propofol |
| Induction (ICU rapid intubation) | 1-2 mg/kg IV |
| Caloric load | 1.1 kcal/mL (10% lipid) - account in nutrition! |
| Triglycerides | Check q48-72h if on >48h |
| Max dose to avoid PRIS | <4 mg/kg/h (67 mcg/kg/min) for <48h |
| PRIS (Propofol Infusion Syndrome) | Metabolic acidosis + rhabdomyolysis + cardiac failure - STOP propofol |
| Advantages | Short-acting, easy titration, reduces duration of MV vs. BZDs, anticonvulsant |
| Disadvantages | Hypotension, myocardial depression, hypertriglyceridemia, PRIS, no analgesia, no amnesia at low doses |
| Parameter | Detail |
|---|---|
| Indication | ICU sedation (2nd line), alcohol withdrawal, seizure prophylaxis in ICU |
| Available vial | 5 mg/mL |
| Standard dilution | 50 mg in 50 mL NS = 1 mg/mL (or 100 mg in 100 mL = 1 mg/mL) |
| Sedation infusion | 0.02-0.1 mg/kg/h |
| Example (70 kg, 0.05 mg/kg/h) | 0.05 × 70 = 3.5 mL/h (at 1 mg/mL) |
| Bolus for acute agitation | 1-5 mg IV slow push |
| Accumulation | Active metabolite (1-OH midazolam) accumulates in renal failure and obesity - prolonged awakening |
| Advantages | Amnesia, anxiolysis, anticonvulsant, antiemetic, inexpensive, good for alcohol withdrawal |
| Disadvantages | Longer ICU stay vs. propofol, delirium risk, accumulation in renal/hepatic impairment |
| Parameter | Detail |
|---|---|
| Indication | Light-to-moderate ICU sedation, post-extubation sedation, agitated delirium, alcohol/opioid withdrawal |
| Available vial | 200 mcg/2 mL (100 mcg/mL) |
| Standard dilution | 200 mcg in 48 mL NS = 4 mcg/mL (or 400 mcg in 100 mL = 4 mcg/mL) |
| Loading dose | 1 mcg/kg over 10 min (often omitted in hemodynamically unstable patients) |
| Maintenance | 0.2-0.7 mcg/kg/h (up to 1.5 mcg/kg/h) |
| Example (70 kg, 0.5 mcg/kg/h) | 0.5 × 70 ÷ 4 = 8.75 mL/h |
| Mechanism | α2-agonist → sedation without respiratory depression; anxiolysis; some analgesia |
| Key advantage | Patients arousable and cooperative; preserves respiratory drive; reduces delirium vs. BZDs |
| Disadvantages | Bradycardia and hypotension (especially with loading dose); expensive; NOT for deep sedation/paralysis |
| Duration | Onset 5-10 min; half-life ~2h; longer in hepatic impairment |
| Parameter | Detail |
|---|---|
| Indication | Analgesic adjunct in ICU, procedural sedation, bronchospasm, opioid-sparing |
| Available vial | 500 mg/10 mL (50 mg/mL) |
| Standard dilution for infusion | 500 mg in 500 mL NS = 1 mg/mL |
| Sub-anesthetic analgesic infusion | 1-2 mcg/kg/min (0.06-0.12 mg/kg/h) per Barash |
| Procedural sedation | 1-2 mg/kg IV (onset 60 sec, duration 10-15 min) |
| Induction/RSI | 1-2 mg/kg IV |
| Mechanism | NMDA receptor antagonist → dissociative analgesia + anesthesia |
| Advantages | Bronchodilator, maintains airway reflexes and hemodynamics, opioid-sparing, analgesia |
| Disadvantages | Emergence delirium, hallucinations (pretreat with midazolam 1-2 mg), raises ICP (controversial), increases secretions |
| Adjunct (midazolam) | 1-2 mg IV to prevent emergence phenomena |
| Parameter | Detail |
|---|---|
| Indication | ICU analgesia (1st line), mechanically ventilated patients |
| Available vial | 50 mcg/mL (2 mL = 100 mcg, 5 mL = 250 mcg) |
| Standard dilution | 1000 mcg in 100 mL NS = 10 mcg/mL |
| Infusion dose | 25-200 mcg/h (0.5-2 mcg/kg/h) |
| Example (70 kg, 1 mcg/kg/h) | 1 × 70 ÷ 10 = 7 mL/h |
| Bolus (procedural) | 25-100 mcg IV slow push |
| Advantages | Fast onset (1-2 min IV), short duration, no histamine release, safe in renal failure |
| Preferred over morphine | In renal failure, hemodynamic instability, and bronchospasm |
| Side effects | Respiratory depression, constipation, tolerance, chest rigidity (at high rapid doses) |
| Parameter | Detail |
|---|---|
| Indication | ICU analgesia, acute pulmonary edema (relieves dyspnea/preload), severe pain |
| Available vial | 10 mg/mL or 15 mg/mL |
| Standard dilution | 50 mg in 50 mL NS = 1 mg/mL |
| Infusion dose | 2-10 mg/h |
| Bolus | 2-4 mg IV q2-4h (titrate) |
| Side effects | Histamine release (avoid in asthma), hypotension, nausea |
| AVOID in renal failure | Active metabolite morphine-6-glucuronide accumulates → respiratory depression |
| Parameter | Detail |
|---|---|
| Indication | ICU analgesia; morphine-intolerant patients |
| Available vial | 2 mg/mL or 4 mg/mL |
| Standard dilution | 20 mg in 100 mL NS = 0.2 mg/mL |
| Infusion dose | 0.5-3 mg/h |
| Bolus | 0.2-0.6 mg IV q2-4h |
| Potency | 5-7x more potent than morphine |
| Advantage | Less histamine release, safer in mild renal impairment vs. morphine |
| Parameter | Detail |
|---|---|
| Indication | Seizures, alcohol withdrawal (preferred), acute agitation, procedural |
| Available vial | 2 mg/mL or 4 mg/mL |
| Standard dilution | 40 mg in 100 mL NS = 0.4 mg/mL |
| Infusion dose | 1-10 mg/h |
| Bolus | 0.5-4 mg IV q2-4h |
| Status epilepticus | 0.1 mg/kg IV (max 4 mg per dose, repeat in 10 min) |
| Advantage over midazolam | No active metabolites, safer in renal failure |
| Caution | Prolonged infusion → propylene glycol accumulation (osmolar gap acidosis) |
Indications in ICU: Ventilator dyssynchrony, ARDS (protective ventilation), raised ICP, tetanus, status epilepticus, during therapeutic hypothermia. Use alongside adequate sedation + analgesia ALWAYS. Monitor with TOF (Train of Four - target 1-2 twitches).
| Parameter | Detail |
|---|---|
| Indication | ARDS requiring paralysis, refractory ventilator dyssynchrony |
| Available vial | 2 mg/mL (10 mL) or 5 mg/mL |
| Standard dilution | 200 mg in 200 mL NS = 1 mg/mL (or 100 mg in 100 mL = 1 mg/mL) |
| Loading dose | 0.15-0.2 mg/kg IV (over 5-10 sec) |
| Maintenance infusion | 0.5-10 mcg/kg/min (usually 1-3 mcg/kg/min) |
| Example (70 kg, 3 mcg/kg/min) | [3 × 70 × 60] ÷ 1000 = 12.6 mL/h |
| Mechanism | Hofmann elimination (non-enzymatic) + ester hydrolysis → no organ dependency |
| Advantage | Safe in hepatic AND renal failure (unique); no histamine release; no autonomic effects |
| Monitoring | TOF 1-2 twitches of 4; stop daily for assessment (like SAT) |
| Parameter | Detail |
|---|---|
| Indication | Intubation, short-term paralysis in ICU |
| Available vial | 10 mg powder (reconstitute with 10 mL = 1 mg/mL) |
| Standard dilution | 100 mg in 100 mL NS = 1 mg/mL |
| Loading dose | 0.1 mg/kg IV (intubation); 0.01 mg/kg (maintenance bolus) |
| Infusion | 0.8-1.2 mcg/kg/min |
| Example (70 kg, 1 mcg/kg/min) | [1 × 70 × 60] ÷ 1000 = 4.2 mL/h |
| Caution | Accumulates in hepatic/renal failure; active metabolite (3-desacetylvecuronium) accumulates → prolonged paralysis |
| Parameter | Detail |
|---|---|
| Indication | RSI (when succinylcholine contraindicated), ICU paralysis |
| Available vial | 10 mg/mL (5 mL = 50 mg) |
| Standard dilution | 500 mg in 250 mL NS = 2 mg/mL |
| RSI dose | 1.2 mg/kg IV (onset ~60 sec at this dose) |
| Maintenance infusion | 10-12 mcg/kg/min |
| Reversal | Sugammadex 16 mg/kg IV for immediate reversal |
| Advantage over succinylcholine | Safe in hyperkalemia, burns, denervation, crush injury |
| Parameter | Detail |
|---|---|
| Indication | RSI (fastest onset - 45-60 sec) |
| Available vial | 20 mg/mL (200 mg/10 mL) |
| Dose | 1-1.5 mg/kg IV (intubation); 2 mg/kg (infants) |
| Duration | 5-10 min (ultra-short - depolarizing agent) |
| ABSOLUTE CONTRAINDICATIONS | Hyperkalemia, burns (>48h), spinal cord injury, crush injury, denervation, OP poisoning, myopathies |
| Caution | Raises K+ by ~0.5 mEq/L; malignant hyperthermia trigger |
| Parameter | Detail |
|---|---|
| Indication | Ventricular arrhythmias (VT, VF), AF with hemodynamic compromise, refractory tachyarrhythmias |
| Available vial | 150 mg/3 mL (50 mg/mL) |
| Standard dilution | 900 mg in 500 mL D5W = 1.8 mg/mL |
| Loading dose (VT/VF arrest) | 300 mg IV push (from prefilled syringe); repeat 150 mg if needed |
| Loading dose (stable VT/AF) | 150 mg in 100 mL D5W over 10 min |
| Maintenance infusion | 1 mg/min x 6 hours, then 0.5 mg/min x 18 hours |
| Rate at 1 mg/min | [1 × 60] ÷ 1.8 = 33 mL/h |
| Rate at 0.5 mg/min | [0.5 × 60] ÷ 1.8 = 16.7 mL/h |
| 24h max | 2.2 g/day |
| Oral loading | 200-400 mg TDS x 1 week, then 200 mg OD maintenance |
| Side effects | Hypotension (infusion-related), bradycardia, phlebitis (peripheral IV), pulmonary toxicity (chronic), thyroid dysfunction, hepatotoxicity, corneal deposits |
| Use D5W only | Precipitates with NS at concentrations >2 mg/mL |
| Parameter | Detail |
|---|---|
| Indication | Paroxysmal SVT (diagnosis + termination); Wolff-Parkinson-White (if narrow complex) |
| Available | 6 mg/2 mL (3 mg/mL) |
| No dilution - IV push only | |
| Dose | 6 mg rapid IV push → flush immediately with 20 mL NS; if no response in 1-2 min → 12 mg; repeat 12 mg once more |
| Half-life | <10 seconds (enzymatically degraded by adenosine deaminase) |
| Technique | MUST be given as rapid bolus into antecubital or larger vein + immediate flush |
| Side effects | Transient asystole (tell patient!), flushing, dyspnea, chest tightness (transient) |
| AVOID in | Asthma (bronchospasm), 2nd/3rd degree heart block, WPW with AF (wide complex) |
| Theophylline interaction | Theophylline blocks adenosine receptors → higher doses needed |
| Parameter | Detail |
|---|---|
| Indication | Rate control in AF/flutter, SVT, hypertensive urgency, NSTEMI |
| Available vial | 5 mg/5 mL (1 mg/mL) |
| IV dose | 5 mg IV over 5 min; repeat q5min x 3 (total 15 mg) |
| Oral transition | 25-100 mg PO BID (Metoprolol succinate XL) |
| Side effects | Bradycardia, hypotension, bronchospasm (avoid in asthma) |
| Parameter | Detail |
|---|---|
| Indication | Rate control in AF with preserved LV function |
| Available vial | 25 mg/5 mL (5 mg/mL) |
| Standard dilution | 125 mg in 125 mL NS = 1 mg/mL |
| Bolus dose | 0.25 mg/kg IV over 2 min (typical 20 mg); if no response: 0.35 mg/kg (25 mg) |
| Maintenance infusion | 5-15 mg/h |
| Example at 10 mg/h | 10 mL/h (at 1 mg/mL) |
| AVOID in | Systolic HF (EF <40%), hypotension, pre-excitation syndromes, wide complex tachycardia |
| Parameter | Detail |
|---|---|
| Indication | Hypertensive emergency/urgency (preferred in neurological emergencies) |
| Available vial | 25 mg/250 mL premixed = 0.1 mg/mL |
| Standard dilution | 25 mg in 250 mL NS = 0.1 mg/mL |
| Initial dose | 5 mg/h |
| Titration | Increase by 2.5 mg/h every 5-15 min |
| Maximum | 15 mg/h |
| Rate at 5 mg/h | 50 mL/h (at 0.1 mg/mL) |
| Side effects | Headache, flushing, tachycardia, phlebitis |
| Parameter | Detail |
|---|---|
| Indication | Hypertensive emergency (especially post-stroke, aortic dissection, pre-eclampsia) |
| Available vial | 100 mg/20 mL (5 mg/mL) |
| Standard dilution | 200 mg in 200 mL NS = 1 mg/mL |
| Bolus | 20 mg IV over 2 min; repeat 40-80 mg q10min (max 300 mg total) |
| Infusion | 0.5-2 mg/min = 30-120 mL/h (at 1 mg/mL) |
| Mechanism | Combined α1 + β1 + β2 blockade (1:7 ratio) |
| Advantage | Does not increase HR; safe in aortic dissection; first-line in stroke hypertension |
| Parameter | Detail |
|---|---|
| Indication | Hypertensive emergency, acute aortic dissection, acute HF (afterload reduction) |
| Available vial | 50 mg/2 mL |
| Standard dilution | 50 mg in 250 mL D5W = 200 mcg/mL (protect from light with foil) |
| Dose range | 0.3-10 mcg/kg/min |
| Example (70 kg, 1 mcg/kg/min) | [1 × 70 × 60] ÷ 200 = 21 mL/h |
| Maximum duration | Short-term only (<72h at <3 mcg/kg/min) due to cyanide toxicity risk |
| Cyanide toxicity | Monitor for lactic acidosis, altered mental status - treat with hydroxocobalamin |
| Light sensitive | Wrap syringe and tubing in foil |
| Parameter | Detail |
|---|---|
| Indication | Acute coronary syndromes, hypertensive emergency, acute pulmonary edema |
| Available | 50 mg/10 mL (5 mg/mL) |
| Standard dilution | 50 mg in 250 mL D5W = 200 mcg/mL (non-PVC tubing - adsorbs to PVC) |
| Dose range | 5-200 mcg/min |
| Example at 20 mcg/min | [20 × 60] ÷ 200 = 6 mL/h |
| Side effects | Headache, hypotension, reflex tachycardia, methemoglobinemia (high doses) |
| Tolerance | Develops within 24h of continuous infusion |
| Non-PVC tubing essential | Standard PVC tubing absorbs up to 80% of the drug |
| Parameter | Detail |
|---|---|
| Indication | DVT/PE treatment, ACS, mechanical heart valves, VTE prophylaxis, CRRT |
| Available | 5000 units/mL or 25,000 units/500 mL = 50 units/mL |
| Standard dilution (infusion) | 25,000 units in 250 mL NS = 100 units/mL |
| VTE treatment loading dose | 80 units/kg IV bolus (max 5000 units for most) |
| VTE maintenance infusion | 18 units/kg/h → adjust per aPTT nomogram |
| Example (70 kg) | Load: 5600 units; Maintenance start: 1260 units/h = 12.6 mL/h (at 100 units/mL) |
| Target aPTT | 60-100 seconds (1.5-2.5x normal) for therapeutic anticoagulation |
| aPTT Adjustment Nomogram | aPTT <40: Bolus 80 units/kg + ↑ rate 4 units/kg/h; aPTT 40-59: Bolus 40 units/kg + ↑ 2 units/kg/h; aPTT 60-100: No change; aPTT 101-120: ↓ 2 units/kg/h; aPTT >120: Hold 1h then ↓ 3 units/kg/h |
| VTE prophylaxis | 5000 units SC q8-12h (no infusion) |
| Reversal | Protamine sulfate: 1 mg per 100 units heparin given in last 2h |
| HIT monitoring | Check platelets q2-3 days; if HIT suspected, STOP heparin → use argatroban or fondaparinux |
| Parameter | Detail |
|---|---|
| Indication | DVT/PE treatment and prophylaxis, ACS |
| VTE treatment | 1 mg/kg SC q12h OR 1.5 mg/kg SC q24h |
| Prophylaxis | 40 mg SC q24h (high-risk medical/surgical) |
| Renal impairment | CrCl <30 mL/min: 1 mg/kg SC q24h for treatment; 30 mg q24h for prophylaxis |
| Monitoring | Anti-Xa level (peak 4h post-dose): therapeutic 0.6-1.0 IU/mL (q12h dosing) |
| Reversal | Protamine sulfate 1 mg per 1 mg enoxaparin (partial reversal only - protamine doesn't fully reverse LMWH) |
| AVOID if | CrCl <15 mL/min (use UFH); morbid obesity (renal clearance altered - monitor anti-Xa) |
| Parameter | Detail |
|---|---|
| Indication | Heparin-induced thrombocytopenia (HIT), when heparin anticoagulation needed but HIT present |
| Available | 250 mg/2.5 mL (100 mg/mL) |
| Standard dilution | 250 mg in 250 mL NS = 1 mg/mL |
| Starting infusion | 2 mcg/kg/min (reduce to 0.5 mcg/kg/min in hepatic impairment) |
| Example (70 kg) | 2 × 70 = 140 mcg/min × 60 = 8400 mcg/h = 8.4 mL/h |
| Target aPTT | 1.5-3x baseline (45-100 sec) |
| Check aPTT | 2h after start, then adjust; check q2-4h until stable |
| Renal adjustment | None required (hepatically metabolized) |
| Parameter | Detail |
|---|---|
| Indication | ICU hyperglycemia >180 mg/dL (10 mmol/L) - per SCCM/ADA guidelines |
| Target glucose | 140-180 mg/dL (7.8-10 mmol/L) for most ICU patients |
| Available | Regular (soluble) insulin 100 units/mL |
| Standard dilution | 100 units Regular insulin in 100 mL NS = 1 unit/mL |
| Starting infusion | 0.5-1 unit/h; adjust per ICU insulin protocol (glucose-based algorithm) |
| Common algorithm | Glucose 180-240: 1 unit/h; 241-300: 2 units/h; 301-360: 3 units/h; >360: 4 units/h |
| Bolus (acute correction) | 0.1 unit/kg IV for glucose >300 mg/dL unresponsive to infusion |
| Monitoring frequency | q1h until stable on protocol; q2h when stable for 4h; q4h when very stable |
| Hypoglycemia protocol | Glucose <70: Stop infusion + D50% 25 mL IV; recheck in 15 min |
| Insulin requirement increases with | Steroids, sepsis, TPN/EN, catecholamine infusions |
| Note | Avoid <110 mg/dL (Normoglycemia NOT beneficial - increases mortality per NICE-SUGAR trial) |
| Parameter | Detail |
|---|---|
| Indication | Hypokalemia (K+ <3.5 mEq/L) |
| Oral (preferred when tolerated) | 40-80 mEq PO for K+ 3.0-3.5; 80-120 mEq for K+ <3.0 |
| IV concentration (peripheral) | MAX 10 mEq/100 mL → max 10-20 mEq/h |
| IV concentration (central) | MAX 20-40 mEq/100 mL → up to 40 mEq/h (with cardiac monitoring) |
| NEVER IV push | Fatal arrhythmias/cardiac arrest |
| Continuous cardiac monitoring | Required for IV KCl infusion |
| Recheck | Serum K+ 1-2h after each replacement; recheck Mg2+ (correct hypomagnesemia - refractory hypokalemia until Mg corrected) |
| Parameter | Detail |
|---|---|
| Indication | Hypomagnesemia, Torsades de Pointes, eclampsia/pre-eclampsia, severe asthma |
| Available | 2 g/10 mL (20%) or 4 g/20 mL (20%) |
| Torsades de Pointes | 2 g IV over 1-2 min (bolus) |
| Eclampsia loading | 4 g IV over 20-30 min → maintenance 1-2 g/h |
| Hypomagnesemia | 2-4 g in 100 mL NS over 1h (peripheral) or 20 min (central) |
| Severe asthma | 2 g IV over 20 min |
| Monitoring | Urine output, deep tendon reflexes (loss of DTR at 7-10 mEq/L), respiratory rate |
| Toxicity levels | Loss of DTR: 5-9 mg/dL; Respiratory arrest: 10-13 mg/dL; Cardiac arrest: >15 mg/dL |
| Antidote for toxicity | Calcium gluconate 1 g IV over 3 min |
| Parameter | Detail |
|---|---|
| Indication | Hypocalcemia, hyperkalemia (cardiac protection), hypermagnesemia |
| Calcium gluconate | 1-3 g IV over 10-30 min (peripheral line safe) - provides 90 mg elemental Ca2+ per g |
| Calcium chloride | 1 g IV over 5-10 min (central line preferred - very vesicant) - provides 270 mg elemental Ca2+ per g (3x more potent) |
| Hyperkalemia (cardiac protection) | Calcium gluconate 1-3 g IV over 2-5 min; onset 1-3 min, duration 30-60 min |
| Cardiac arrest (hypocalcemia) | Calcium chloride 1 g IV push |
| CCB toxicity | Calcium chloride 1-3 g IV over 5-10 min |
| Parameter | Detail |
|---|---|
| Indication | Metabolic acidosis, hyperkalemia (redistribution), TCA OD, urinary alkalinization |
| Available | 8.4% (1 mEq/mL), 50 mL ampoule = 50 mEq |
| Metabolic acidosis | Dose (mEq) = 0.3 × Weight (kg) × Base Deficit; give half over first 4-6h |
| Cardiac arrest | 1 mEq/kg IV; repeat 0.5 mEq/kg q10 min |
| TCA toxicity | 1-2 mEq/kg IV bolus; target pH 7.45-7.55 |
| Hyperkalemia (temporary) | 50-100 mEq IV over 5-10 min (redistributes K+ into cells) |
| Parameter | Detail |
|---|---|
| Indication | Hypophosphatemia (PO4 <1.5 mg/dL or symptomatic) |
| Available | Sodium phosphate 3 mmol/mL (15 mmol per 5 mL vial) |
| Mild (2.3-3.0 mg/dL) | Oral phosphate supplements preferred |
| Moderate (1.5-2.3 mg/dL) | 0.16-0.32 mmol/kg IV over 4-6h (≈15 mmol in 250 mL NS) |
| Severe (<1.5 mg/dL) | 0.32-0.64 mmol/kg IV over 8-12h |
| Refeeding syndrome | Aggressive phosphate + K+ + Mg2+ replacement |
| Parameter | Detail |
|---|---|
| Indication | Status epilepticus (2nd line after BZDs), seizure prophylaxis |
| Phenytoin dilution | Only in NS (precipitates in dextrose); max 50 mg/min rate |
| Phenytoin loading dose | 15-20 mg/kg IV at max 50 mg/min (cardiac monitoring required) |
| Example (70 kg) | 1050-1400 mg at ≤50 mg/min = minimum 21-28 minutes |
| Maintenance | 5-7 mg/kg/day in divided doses q8h |
| Fosphenytoin loading | 15-20 mg PE/kg IV at max 150 mg PE/min (faster, safer, water-soluble) |
| Target serum level | Total: 10-20 mcg/mL; Free: 1-2 mcg/mL |
| Side effects | Cardiac (hypotension, arrhythmia - from rapid infusion), "purple glove" syndrome (phenytoin extravasation), nystagmus, ataxia |
| Parameter | Detail |
|---|---|
| Indication | Seizures, status epilepticus, prophylaxis (TBI, post-neurosurgery) |
| Available | 500 mg/5 mL (100 mg/mL) |
| Standard dilution | 1500 mg in 100 mL NS = 15 mg/mL |
| Loading dose | 20-60 mg/kg IV (max 4500 mg) over 15 min |
| Standard load | 1500-3000 mg IV over 15 min |
| Maintenance | 500-1500 mg IV/PO q12h |
| Renal adjustment | Reduce dose if CrCl <50 mL/min |
| Advantages | Fewer drug interactions, no hepatic metabolism, safe in liver disease, no QT prolongation |
| Side effects | Behavioral disturbance (agitation, psychosis), somnolence |
| Parameter | Detail |
|---|---|
| Indication | Status epilepticus (3rd line), generalized seizures, migraine |
| Available | 500 mg/5 mL (100 mg/mL) |
| Loading dose | 20-40 mg/kg IV over 10 min |
| Maintenance | 10-20 mg/kg/day divided q6-8h |
| AVOID in | Liver disease, urea cycle disorders, pregnancy (teratogenic), mitochondrial disease |
| Monitor | LFTs, ammonia, coagulation, platelets |
| Parameter | Detail |
|---|---|
| Indication | Stress ulcer prophylaxis (MV >48h, coagulopathy), acute upper GI bleed |
| Available | Pantoprazole 40 mg/vial (reconstitute in 10 mL NS = 4 mg/mL) |
| Prophylaxis | Pantoprazole 40 mg IV q24h |
| GI bleed treatment | Pantoprazole 80 mg IV bolus → 8 mg/h infusion for 72h |
| Standard dilution for infusion | 80 mg in 100 mL NS = 0.8 mg/mL; 8 mg/h = 10 mL/h |
| Parameter | Detail |
|---|---|
| Indication | Gastric dysmotility, gastroparesis in ICU (promoting EN), nausea/vomiting |
| Dose | 10 mg IV q6-8h (slow IV over 3-5 min) |
| Side effects | Extrapyramidal reactions (acute dystonia, tardive dyskinesia with prolonged use), QT prolongation |
| Limit use | <5 days to avoid tardive dyskinesia |
Note: Doses given for normal renal function (70 kg adult). Always adjust for renal/hepatic impairment and use PK/PD principles in ICU.
| Antibiotic | Standard ICU Dose | Dilution | Notes |
|---|---|---|---|
| Piperacillin-Tazobactam | 4.5 g IV q6h (extended 4h infusion) | 4.5 g in 100 mL NS | Extended infusion improves PK for time-dependent killing |
| Meropenem | 1-2 g IV q8h | 1g in 100 mL NS over 30 min (3h for resistant organisms) | Carbapenem; reduce dose in renal failure |
| Vancomycin | 15-25 mg/kg IV q8-12h OR AUC-guided | 500-1000 mg in 250 mL NS over 60-90 min | Target AUC/MIC 400-600; TDM essential; red man syndrome if too fast |
| Linezolid | 600 mg IV q12h | Premixed 2 mg/mL over 30-120 min | MRSA alternative; MAO inhibitor - serotonin syndrome risk |
| Ceftriaxone | 1-2 g IV q12-24h | 1-2g in 100 mL NS over 30 min | Biliary excretion |
| Metronidazole | 500 mg IV q8h | Premixed 500 mg/100 mL over 30-60 min | Anaerobes, C. diff |
| Ciprofloxacin | 400 mg IV q8-12h | 400 mg/200 mL premixed over 60 min | QT prolongation risk |
| Colistin | Loading 9 million IU → 4.5 MIU q12h | Dilute in 50-100 mL NS | MDR gram-negative last resort; nephrotoxic |
| Fluconazole | 400-800 mg IV q24h (load 800 mg) | Premixed 2 mg/mL over 60-120 min | Azole; QT, drug interactions |
| Micafungin | 100-150 mg IV q24h | 150 mg in 100 mL NS over 60 min | Echinocandin; 1st line invasive candidiasis |
| Amphotericin B (liposomal) | 3-5 mg/kg IV q24h | In D5W 1-2 mg/mL over 2h | Only in D5W; premedicate with antipyretics |
| Acyclovir (HSV encephalitis) | 10 mg/kg IV q8h | Dilute in NS to ≤7 mg/mL over 1h | Renal toxicity - ensure hydration |
| Gentamicin (once-daily) | 5-7 mg/kg IV q24h | In 100 mL NS over 30-60 min | Hartford nomogram for dosing; TDM for trough <1 |
| Daptomycin | 6-10 mg/kg IV q24h | In NS over 30 min | MRSA bacteremia/endocarditis; check CPK weekly |
| Parameter | Detail |
|---|---|
| Indication | Acute variceal bleeding, carcinoid crisis, sulfonylurea-induced hypoglycemia |
| Standard dilution | 500 mcg in 50 mL NS = 10 mcg/mL |
| Variceal bleed bolus | 50-100 mcg IV push |
| Maintenance infusion | 25-50 mcg/h × 72-120 hours |
| Rate at 25 mcg/h | 2.5 mL/h (at 10 mcg/mL) |
| Sulfonylurea OD | 50-100 mcg SC/IV q6-12h (prevents recurrent hypoglycemia) |
| Parameter | Detail |
|---|---|
| Bag 1 (Loading) | 150 mg/kg in 200 mL D5W over 60 min |
| Bag 2 | 50 mg/kg in 500 mL D5W over 4 hours |
| Bag 3 | 100 mg/kg in 1000 mL D5W over 16 hours |
| Total | 300 mg/kg over 21 hours |
| Caution | Anaphylactoid: slow infusion + antihistamine if reaction occurs |
| Parameter | Detail |
|---|---|
| Indication | Hepatorenal syndrome type 1, refractory variceal bleed |
| Dose (HRS) | 0.5-2 mg IV q4-6h (bolus) |
| Dose (variceal bleed) | 2 mg IV q4h, then 1 mg q4h if bleeding controlled |
| Duration | Up to 14 days for HRS |
| Side effects | Hyponatremia, ischemia (cardiac, splanchnic, peripheral) |
| Parameter | Detail |
|---|---|
| Indication | Bacterial meningitis (before 1st antibiotic dose), ARDS (COVID protocol), CINV prophylaxis, cord compression, severe community pneumonia |
| Bacterial meningitis | 0.15 mg/kg IV q6h × 4 days (start 15-20 min before 1st antibiotics) |
| ARDS / COVID | 6 mg IV/PO q24h × 10 days (RECOVERY trial) |
| Cerebral edema | 4-8 mg IV q6h |
| Anti-emetic | 4-8 mg IV once |
A 62-year-old diabetic man admitted with community-acquired pneumonia (CURB-65 = 4). Despite 3L crystalloid, BP = 72/45 mmHg, MAP 54 mmHg, HR 126, SpO2 88%, RR 34, GCS 13. Lactate = 4.2 mmol/L. Temp 39.4°C. Intubated. Cultures drawn.
A 45-year-old woman (70 kg) with influenza pneumonia, PaO2/FiO2 ratio = 80, bilateral infiltrates, no cardiac cause. Intubated. Severe ventilator dyssynchrony despite deep sedation. RASS -5 not achievable on propofol + fentanyl alone.
A 68-year-old man post-anterior STEMI (door-to-balloon 90 min). BP 85/60, HR 105, cold clammy extremities, JVP elevated, bibasal crackles, SpO2 90%, cardiac output low on Swan-Ganz (CI 1.6 L/min/m2), PCWP 26 mmHg. Intubated for respiratory failure.
A 55-year-old man with known hypertension presents with BP 220/130 mmHg, severe headache, blurred vision, papilledema, creatinine acutely risen to 3.2 mg/dL. ECG: LVH. No stroke on CT head.
A 30-year-old woman with known epilepsy, convulsing for 35 minutes without stopping (refractory status epilepticus). Now intubated. GCS 5 post-ictal.
Post-operative day 1 after aortic valve replacement. Patient develops rapid AF at HR 148, BP 100/65, SpO2 94%. Echo shows preserved EF 55%. No pre-excitation.
A 22-year-old with Type 1 DM, vomiting for 2 days. Glucose 520 mg/dL, pH 7.05, HCO3 8 mEq/L, K+ 3.2 mEq/L, anion gap 32, urine ketones 4+, BP 90/60 (dehydrated), HR 128. Intubated for GCS 8.
╔══════════════════╦═══════════════════════════╦════════════════════╗
║ DRUG ║ STANDARD DILUTION ║ CONCENTRATION ║
╠══════════════════╬═══════════════════════════╬════════════════════╣
║ Norepinephrine ║ 4 mg in 250 mL NS ║ 16 mcg/mL ║
║ Epinephrine ║ 4 mg in 250 mL NS ║ 16 mcg/mL ║
║ Dopamine ║ 400 mg in 250 mL NS ║ 1600 mcg/mL ║
║ Vasopressin ║ 40 units in 250 mL NS ║ 0.16 units/mL ║
║ Phenylephrine ║ 100 mg in 250 mL NS ║ 400 mcg/mL ║
║ Dobutamine ║ 500 mg in 250 mL NS ║ 2000 mcg/mL ║
║ Milrinone ║ 40 mg in 200 mL NS ║ 200 mcg/mL ║
╠══════════════════╬═══════════════════════════╬════════════════════╣
║ Propofol 1% ║ Ready to use ║ 10 mg/mL ║
║ Midazolam ║ 50 mg in 50 mL NS ║ 1 mg/mL ║
║ Dexmedetomidine ║ 200 mcg in 48 mL NS ║ 4 mcg/mL ║
║ Ketamine ║ 500 mg in 500 mL NS ║ 1 mg/mL ║
║ Fentanyl ║ 1000 mcg in 100 mL NS ║ 10 mcg/mL ║
║ Morphine ║ 50 mg in 50 mL NS ║ 1 mg/mL ║
║ Lorazepam ║ 40 mg in 100 mL NS ║ 0.4 mg/mL ║
╠══════════════════╬═══════════════════════════╬════════════════════╣
║ Cisatracurium ║ 200 mg in 200 mL NS ║ 1 mg/mL ║
║ Vecuronium ║ 100 mg in 100 mL NS ║ 1 mg/mL ║
╠══════════════════╬═══════════════════════════╬════════════════════╣
║ Amiodarone ║ 900 mg in 500 mL D5W ║ 1.8 mg/mL ║
║ Diltiazem ║ 125 mg in 125 mL NS ║ 1 mg/mL ║
║ Nicardipine ║ 25 mg in 250 mL NS ║ 0.1 mg/mL ║
║ Labetalol ║ 200 mg in 200 mL NS ║ 1 mg/mL ║
║ Nitroprusside ║ 50 mg in 250 mL D5W ║ 200 mcg/mL ║
║ GTN ║ 50 mg in 250 mL D5W ║ 200 mcg/mL ║
╠══════════════════╬═══════════════════════════╬════════════════════╣
║ Heparin UFH ║ 25,000 units in 250 mL NS ║ 100 units/mL ║
║ Argatroban ║ 250 mg in 250 mL NS ║ 1 mg/mL ║
║ Insulin (Regular)║ 100 units in 100 mL NS ║ 1 unit/mL ║
╠══════════════════╬═══════════════════════════╬════════════════════╣
║ MgSO4 (eclampsia)║ 4 g in 100 mL NS ║ 40 mg/mL ║
║ KCl ║ 40 mEq in 1000 mL NS ║ 40 mEq/L ║
║ NaHCO3 8.4% ║ Ready to use ║ 1 mEq/mL ║
╠══════════════════╬═══════════════════════════╬════════════════════╣
║ Octreotide ║ 500 mcg in 50 mL NS ║ 10 mcg/mL ║
║ Pantoprazole ║ 80 mg in 100 mL NS ║ 0.8 mg/mL ║
╚══════════════════╩═══════════════════════════╩════════════════════╝
┌─────────────────────────────────────────────────────────────┐
│ INFUSION RATE (mL/h) = │
│ │
│ Dose (mcg/kg/min) × Weight (kg) × 60 min/h │
│ ───────────────────────────────────────────── │
│ Concentration (mcg/mL) │
│ │
│ OR for non-weight-based drugs: │
│ │
│ Dose (mg/h or mcg/min × 60) ÷ Concentration (mg/mL) │
└─────────────────────────────────────────────────────────────┘
| Rule | Details |
|---|---|
| Amiodarone | D5W only (not NS at >2 mg/mL); protect from light |
| GTN / Nitroprusside | Non-PVC tubing mandatory; protect nitroprusside from light |
| KCl | NEVER IV push; max 40 mEq/h via central line with cardiac monitoring |
| Potassium | Always correct Mg2+ simultaneously - refractory hypokalemia until Mg replaced |
| Propofol | Check triglycerides q48-72h; account for lipid calories; change tubing q12h |
| Vancomycin | Infuse over minimum 60 min (red man syndrome); AUC-guided dosing |
| Cisatracurium | NEVER without adequate sedation + analgesia + TOF monitoring |
| Succinylcholine | Check for hyperkalemia risk before use |
| Insulin infusion | Glucose and K+ monitoring q1h minimum initially |
| Vasopressors | Central line preferred; if peripheral, check site q1-2h for extravasation |
| Fentanyl | Do not mix with other drugs; separate line preferred |
Post-mortem report in proper full format for death due to Electric shock,drowning,hanging,RTA,CARDIAC ARREST,POISONING and other common modes of deaths for FMT MEDICAL OFFICER For medico legal cases with different common forms used in medico
┌─────────────────────────────────────────────────────────────────────────┐
│ INQUEST PANCHNAMA / REQUISITION FOR POST-MORTEM │
│ (Under Sec. 174 / 176 Cr.P.C.) │
│ [Now under BNSS 2023 - Sec. 194 / 195] │
├─────────────────────────────────────────────────────────────────────────┤
│ To, │
│ The Medical Officer / Forensic Medicine Department, │
│ _________________________ Hospital / Medical College │
│ │
│ Sir, │
│ You are hereby requested to conduct the Post-Mortem Examination of │
│ the dead body described below and furnish a report regarding the │
│ cause of death. │
│ │
│ CR No. / Station Diary No.: _______________________ │
│ Under Section: _____________________ IPC / BNS │
│ │
│ DETAILS OF THE DECEASED: │
│ Name: _______________________________ Age: _____ Sex: __________ │
│ Address: ___________________________________________________ │
│ Religion: __________________ Occupation: ___________________ │
│ │
│ CIRCUMSTANCES: │
│ Date & Time of Alleged Death: ______________________________ │
│ Date & Time Body Found: ____________________________________ │
│ Place of Death/Found: ______________________________________ │
│ Circumstances as Reported: _________________________________ │
│ ____________________________________________________________ │
│ │
│ Body identified by: ________________________ (Name & relation) │
│ │
│ Seal of body: Intact / Broken │
│ Labels: Present / Absent │
│ │
│ Inquest conducted by: │
│ Name: _________________________ Designation: ___________________ │
│ Station: ________________ District: ___________________________ │
│ │
│ Date: __________________ Signature: ___________________________ │
└─────────────────────────────────────────────────────────────────────────┘
┌─────────────────────────────────────────────────────────────────────────┐
│ POST-MORTEM EXAMINATION REPORT │
│ (Medico-Legal Case - Government of India) │
├─────────────────────────────────────────────────────────────────────────┤
│ PM Report No.: _____________ Date: _____________ Time: _____________ │
│ Hospital/Institution: __________________________________________ │
│ Department of Forensic Medicine & Toxicology │
├─────────────────────────────────────────────────────────────────────────┤
│ SECTION I: IDENTIFICATION DATA │
│ │
│ Name of Deceased: ___________________________ Age: ____ Sex: ______ │
│ Religion: _______________ Occupation: ____________________________ │
│ Address: _______________________________________________________ │
│ Name of Relative/Identifier: _______________________________ │
│ Relation: __________________ │
│ │
│ Requisition from: ______________ No.: _________ Date: _________ │
│ Police Station: ________________ District: ____________________ │
│ CR/FIR No.: _________________ Under Section: __________________ │
├─────────────────────────────────────────────────────────────────────────┤
│ SECTION II: BODY DETAILS ON ARRIVAL │
│ │
│ Body received on: ____________ Time: ____________ │
│ Examination started: _________ Time: ____________ │
│ Examination completed: _______ Time: ____________ │
│ │
│ Body wrapped in: ___________ Seals: Intact / Broken │
│ Labels: Present / Absent │
│ Accompanied by: ___________________________________________ │
├─────────────────────────────────────────────────────────────────────────┤
│ SECTION III: EXTERNAL EXAMINATION │
│ │
│ A. Build: Well-nourished / Average / Thin / Obese / Emaciated │
│ B. Nutrition: Good / Moderate / Poor │
│ C. Height: _______ cm Weight: _______ kg │
│ │
│ POSTMORTEM CHANGES: │
│ 1. Postmortem Lividity (Livor Mortis): │
│ Distribution: ________________________ │
│ Color: _______________________________ │
│ Fixed / Shifting: ____________________ │
│ Estimated PMI: _______________________ │
│ │
│ 2. Rigor Mortis: │
│ Present / Absent / Partially resolved │
│ Distribution: ________________________ │
│ Estimated PMI: _______________________ │
│ │
│ 3. Decomposition: │
│ Absent / Early / Advanced │
│ Features: ____________________________ │
│ │
│ EXTERNAL INJURIES (describe each with location, size, nature): │
│ 1. ____________________________________________________________ │
│ 2. ____________________________________________________________ │
│ 3. ____________________________________________________________ │
│ (Attach injury diagram if needed) │
│ │
│ EYES: │
│ Cornea: Clear / Opaque Conjunctiva: Pale / Congested / Petechiae │
│ Pupils: Dilated / Constricted / Equal / Unequal │
│ Size R: _____ mm L: _____ mm │
│ │
│ FACE: Cyanosed / Pale / Congested / Normal │
│ │
│ MOUTH/LIPS: │
│ Color: ____________ Froth: Present / Absent │
│ Teeth: Complete / Missing _______ Bite marks: ___________ │
│ Tongue: Bitten / Not bitten Protruding / Not protruding │
│ │
│ NECK: │
│ Ligature mark: Present / Absent │
│ If present: Position / Direction / Width / Depth / Character │
│ ___________________________________________________________ │
│ │
│ CHEST: Symmetrical / Asymmetrical │
│ │
│ ABDOMEN: Distended / Normal / Scaphoid │
│ │
│ GENITALIA: Normal / Abnormal ___________ │
│ Evidence of sexual assault: Yes / No │
│ │
│ LOWER LIMBS / UPPER LIMBS: │
│ Venepuncture marks: ________ │
│ Other marks: _______________ │
│ │
│ CLOTHING: │
│ Description: ___________________________________________ │
│ Condition: Intact / Torn / Stained / Absent │
│ Staining: Blood / Mud / Soot / Others: ________________ │
├─────────────────────────────────────────────────────────────────────────┤
│ SECTION IV: INTERNAL EXAMINATION │
│ │
│ SCALP: ____________________________________________________ │
│ SKULL: Fracture: Yes / No Site: ___________________________ │
│ BRAIN: │
│ Weight: _______ g (Normal: 1200-1450 g) │
│ Cerebral edema: Present / Absent │
│ Contusions: ____________ Lacerations: _________________ │
│ Epidural/Subdural/Subarachnoid hemorrhage: _______________ │
│ Petechiae: _______________ │
│ Gyri: Flattened / Normal Herniations: ____________________ │
│ │
│ NECK DISSECTION: │
│ Hyoid bone: Intact / Fractured Site: ___________________ │
│ Thyroid cartilage: Intact / Fractured │
│ Cricoid: Intact / Fractured │
│ Larynx: Congested / Edematous / Normal │
│ Trachea: _______________________________________________ │
│ Carotid arteries: ______________________________________ │
│ Neck muscles: __________________________________________ │
│ Cervical vertebrae: ____________________________________ │
│ Spinal cord: ____________________________________________ │
│ │
│ CHEST CAVITY: │
│ Pleural cavity: Fluid: _____ mL (R) / _____ mL (L) │
│ Pneumothorax: Present / Absent │
│ Ribs: Fractures at: _____________________________________ │
│ Sternum: _______________________________________________ │
│ │
│ HEART: │
│ Weight: _______ g (Normal: 250-350 g) │
│ Pericardium: Intact / Hemopericardium _____ mL │
│ Chambers: Dilated / Normal Right / Left │
│ Coronary arteries: ______________________________________ │
│ Myocardium: Pale / Normal / Hemorrhagic │
│ Valves: Normal / Diseased: __________________________ │
│ Aorta: ___________________________________________________ │
│ │
│ LUNGS: │
│ Weight: R: _______ g L: _______ g (Normal: ~400 g each) │
│ Color: ____________ Consistency: _______________ │
│ Crepitations: Present / Absent │
│ Cut surface: ___________________________________________ │
│ Froth: Present / Absent Blood-stained: Yes / No │
│ Petechiae (Tardieu spots): Present / Absent │
│ Pulmonary edema: Present / Absent │
│ Consolidation: ________ Emphysema: ____________________ │
│ │
│ ABDOMEN: │
│ Peritoneum: _____________________________________________ │
│ Free fluid: _______ mL Nature: _______________________ │
│ Bowel: ___________________________________________________ │
│ │
│ LIVER: │
│ Weight: _______ g (Normal: 1400-1600 g) │
│ Color/Texture: ___________________________________________ │
│ Congestion: ____________ Necrosis: ____________________ │
│ │
│ SPLEEN: │
│ Weight: _______ g (Normal: 150-200 g) │
│ Congestion: ____________ │
│ │
│ KIDNEYS: (each) │
│ Weight: R: _____ g L: _____ g (Normal: 120-160 g each) │
│ Cortex: ___________________________________________________ │
│ │
│ STOMACH: │
│ Contents: ________________________________________________ │
│ Volume: ________ mL Nature: ____________________________ │
│ Mucosa: Congested / Hemorrhagic / Normal │
│ │
│ SMALL INTESTINE / LARGE INTESTINE: ___________________________ │
│ │
│ URINARY BLADDER: ___________________________________________ │
│ Contents: _________ mL │
│ Urine: Normal / Abnormal _______________ │
│ │
│ UTERUS / OVARIES / TESTES (if applicable): ___________________ │
│ │
│ ADRENALS: ___________________________________________________ │
│ │
│ VERTEBRAL COLUMN / SPINAL CORD: ____________________________ │
├─────────────────────────────────────────────────────────────────────────┤
│ SECTION V: SAMPLES PRESERVED │
│ │
│ For Chemical Analysis / Histopathology: │
│ 1. Stomach + contents: Yes / No │
│ 2. Small intestine (30 cm): Yes / No │
│ 3. Liver (500 g): Yes / No │
│ 4. Kidney (one whole): Yes / No │
│ 5. Blood (50-100 mL in sealed container): Yes / No │
│ 6. Urine: Yes / No │
│ 7. Bile: Yes / No │
│ 8. Vitreous humor: Yes / No │
│ 9. Brain tissue: Yes / No │
│ 10. Lung tissue: Yes / No │
│ 11. Fingernail clippings: Yes / No │
│ 12. Hair (root included): Yes / No │
│ 13. Bone (if chronic poisoning suspected): Yes / No │
│ 14. Swabs (if sexual assault): Yes / No │
│ 15. Histopathology sections: Yes / No │
│ │
│ Preserved in: Saturated NaCl solution / Rectified spirit / No │
│ preservative (for alcohol analysis) │
│ │
│ Sent to: FSL / Chemical Examiner on: ___________ │
│ Reference No.: ______________________________________________ │
├─────────────────────────────────────────────────────────────────────────┤
│ SECTION VI: OPINION │
│ │
│ CAUSE OF DEATH: │
│ │
│ I (a): ______________________________________________________ │
│ (Immediate cause) │
│ │
│ I (b): ______________________________________________________ │
│ (Antecedent cause) │
│ │
│ II: ______________________________________________________ │
│ (Contributing conditions) │
│ │
│ Manner of Death: Natural / Accident / Suicide / Homicide / │
│ Undetermined │
│ │
│ Estimated Time Since Death (PMI): ___________________ │
│ │
│ Age as assessed: ___________________________________________ │
│ │
│ Any other opinion: _________________________________________ │
├─────────────────────────────────────────────────────────────────────────┤
│ SECTION VII: CERTIFICATION │
│ │
│ Examined by: │
│ │
│ Name: _______________________________ Qualification: ___________ │
│ Designation: _______________________________________________ │
│ Department: ________________________________________________ │
│ Institution: _______________________________________________ │
│ │
│ Signature: _________________________ │
│ │
│ Witnessed by: │
│ 1. Name: _____________________ Designation: ________________ │
│ 2. Name: _____________________ Designation: ________________ │
│ │
│ Seal of Institution: ________________ │
│ Date: _______________________ │
└─────────────────────────────────────────────────────────────────────────┘
┌─────────────────────────────────────────────────────────────────────────┐
│ POST-MORTEM EXAMINATION REPORT │
│ DEATH BY HANGING │
├─────────────────────────────────────────────────────────────────────────┤
│ PM Report No.: 01/2026 Date: 09/07/2026 Time: 10:00 AM │
│ Hospital: General Hospital, ________________ │
│ Dept. of Forensic Medicine & Toxicology │
├─────────────────────────────────────────────────────────────────────────┤
│ DECEASED: Ramesh Kumar, 35 years, Male │
│ Occupation: Farmer Address: Village _________, Dist. _________ │
│ Requisition: PI ____________, PS _____________, CR No. _______ │
│ Under Section: 194 BNSS (formerly 174 CrPC) │
│ Body received: 09/07/2026 at 08:00 AM │
├─────────────────────────────────────────────────────────────────────────┤
│ EXTERNAL EXAMINATION: │
│ │
│ Build: Average. Nutrition: Moderate. │
│ Height: 165 cm. Weight: 58 kg. │
│ │
│ POSTMORTEM CHANGES: │
│ Livor Mortis: Present over lower extremities and distal parts of │
│ forearms (consistent with erect or semi-erect suspension position). │
│ Color: Bluish-purple. FIXED - consistent with PMI 8-12 hours. │
│ Rigor Mortis: Present in all groups of muscles. Fully established. │
│ PMI estimated: 8-12 hours prior to examination. │
│ │
│ FACE: Congested. Cyanosed. │
│ │
│ EYES: │
│ Conjunctivae: Congested bilaterally with petechial hemorrhages │
│ (Tardieu spots). Cornea: Clear. │
│ Pupils: Dilated, equal (5 mm each). │
│ │
│ MOUTH: Lips cyanosed. Froth (fine, slightly blood-tinged) at │
│ corners of mouth. Tongue: Protruding slightly beyond teeth. Tip │
│ of tongue bluish. No bite mark. │
│ │
│ NECK - LIGATURE MARK (KEY FINDING): │
│ A well-defined, oblique, pale-yellowish/brownish parchment-like │
│ ligature mark is present encircling the neck. │
│ Position: Lower third of neck, above larynx │
│ Direction: Oblique, runs upward toward point of suspension │
│ (left mastoid region - consistent with knot position) │
│ Width: Approximately 2.5 cm (consistent with rope used) │
│ Depth: Well-impressed groove, deeper on right side, less marked │
│ on left (toward knot - inverted V pattern) │
│ Character: Parchment-like, dry, firm, yellowish-brown │
│ Extent: Incomplete - does not encircle neck posteriorly │
│ (interrupted at point of suspension - TYPICAL of hanging) │
│ Abrasions: Present along inferior border of mark │
│ │
│ No other external injuries noted. │
│ No defense injuries on hands/forearms. │
│ │
│ INTERNAL EXAMINATION: │
│ │
│ SCALP: No contusion. SKULL: No fracture. │
│ BRAIN: Weight 1350 g. Congested. Petechial hemorrhages on surface. │
│ Cerebral edema present. Gyri: Slightly flattened. │
│ │
│ NECK DISSECTION (done layer by layer from behind): │
│ Skin at ligature mark: Shows fibrous compression, dryness. │
│ Subcutaneous tissue: Dry, compressed whitish band beneath mark. │
│ Petechial hemorrhages around ligature mark in subcutaneous tissue. │
│ Neck muscles: Above ligature mark - congested. │
│ Below ligature mark - relatively normal. │
│ Hyoid bone: INTACT (commonly intact in hanging vs strangulation). │
│ (Note: Fracture in ~25% cases of hanging, esp. elderly) │
│ Thyroid cartilage: INTACT. No fracture. │
│ Cricoid cartilage: Intact. │
│ Larynx: Congested mucosa. │
│ Trachea: Congested. No foreign body. │
│ Cervical vertebrae: C1-C7 intact. No fracture-dislocation. │
│ (Note: Fracture-dislocation of C2 = judicial hanging/"hangman's │
│ fracture" - NOT present in this case of incomplete suspension) │
│ Carotid arteries: Intimal tears with sub-intimal hemorrhage │
│ (sign of ante-mortem suspension). │
│ │
│ PLEURA: No hemothorax. No pneumothorax. │
│ │
│ HEART: Weight 290 g. Chambers: Right heart - dilated, engorged │
│ with dark fluid blood. Left heart - relatively empty. Coronary │
│ arteries: No significant stenosis. Myocardium: Pale, no infarction. │
│ │
│ LUNGS: R: 490 g, L: 460 g. CONGESTED. Edematous. Subpleural │
│ petechial hemorrhages (Tardieu spots) present on both surfaces. │
│ Cut surface: Frothy blood-stained fluid oozes on compression. │
│ │
│ STOMACH: Contains ~150 mL of partially digested food. │
│ Mucosa: Normal. No corrosion. │
│ │
│ LIVER: Weight 1550 g. Congested. No necrosis. │
│ SPLEEN: Weight 180 g. Congested. │
│ KIDNEYS: Both normal weight. Congested cortex. │
│ URINARY BLADDER: Contains 80 mL urine. (Incontinence may occur │
│ at time of death - consistent with history.) │
│ │
│ GENITALS: Penile erection had occurred (consistent with hanging │
│ - cadaveric priapism from venous engorgement). │
├─────────────────────────────────────────────────────────────────────────┤
│ SAMPLES PRESERVED: │
│ Viscera (stomach + liver + kidney + intestine) in saturated NaCl. │
│ Blood in plain container (no preservative) for alcohol. │
│ Urine preserved. │
│ Histopathology: Lung, brain, heart tissue fixed in 10% formalin. │
├─────────────────────────────────────────────────────────────────────────┤
│ OPINION: │
│ │
│ CAUSE OF DEATH: │
│ I (a): Asphyxia due to hanging. │
│ I (b): Compression of neck structures by ligature. │
│ II: Nil. │
│ │
│ MANNER: Consistent with SUICIDE (suicidal hanging). │
│ │
│ BASIS: │
│ 1. Oblique, ascending ligature mark typical of hanging (not │
│ horizontal as in strangulation). │
│ 2. Mark incomplete - typical of suicidal hanging. │
│ 3. No defense injuries. │
│ 4. Internal neck injuries consistent with ante-mortem suspension. │
│ 5. Generalized asphyxial changes: Congestion, petechiae, edema. │
│ │
│ PMI: Approximately 8-12 hours prior to examination. │
│ Age as assessed: 30-40 years. │
│ │
│ Examining Officer: Dr. ___________________ │
│ Qualification: MD/MS (FMT) Designation: Medical Officer │
│ Date: _____________ Signature: _____________ │
└─────────────────────────────────────────────────────────────────────────┘
| Feature | Hanging | Manual Strangulation |
|---|---|---|
| Ligature mark direction | Oblique/ascending | Horizontal |
| Mark completeness | Incomplete (open at knot) | Complete, encircles neck |
| Mark width | Depends on material | Finger-width marks |
| Hyoid fracture | Rare (25%) | Common (50%+) |
| Petechiae | Present but less | Very prominent |
| Manner | Usually suicide | Usually homicide |
| Carotid dissection | Common | May be present |
| Defense injuries | Absent | Usually present |
┌─────────────────────────────────────────────────────────────────────────┐
│ POST-MORTEM EXAMINATION REPORT │
│ DEATH BY DROWNING │
├─────────────────────────────────────────────────────────────────────────┤
│ PM Report No.: 02/2026 Date: 09/07/2026 Time: 11:00 AM │
│ DECEASED: Suresh Patel, 28 years, Male │
│ Circumstances: Body found floating in river/well/pond │
│ CR No.: __________ Under Section: 174/194 BNSS │
├─────────────────────────────────────────────────────────────────────────┤
│ EXTERNAL EXAMINATION: │
│ │
│ Build: Average. Height: 168 cm. Weight: 62 kg. │
│ │
│ POSTMORTEM CHANGES: │
│ Livor Mortis: PINK/RED color (due to cold water environment). │
│ Distribution: Over posterior surfaces. │
│ Rigor Mortis: Present in all muscle groups. │
│ │
│ SKIN: │
│ Generalized GOOSE SKIN (cutis anserina / anserina skin): │
│ Erection of hair follicles due to cold water - seen on arms, thighs. │
│ WASHERWOMAN'S HANDS (macerated, pale, wrinkled skin of palms, │
│ soles, fingertips): Present - suggests prolonged immersion. │
│ Skin: Pale, sodden, wrinkled. │
│ │
│ FACE: Pale / slightly cyanosed. Congested. │
│ │
│ EYES: Conjunctivae: Congested. Petechial hemorrhages. Cornea: Clear. │
│ Pupils: Dilated. │
│ │
│ MOUTH/NOSE: │
│ FINE WHITE FROTH at mouth and nostrils (characteristic of drowning). │
│ Froth: Copious, fine, persistent, mushroom-shaped on exposure to air. │
│ (Formed by mixing of air, mucus, and water in airways) │
│ │
│ HANDS: Grasping of weeds/mud/grass may be present (cadaveric spasm - │
│ sign of ante-mortem entry into water). │
│ │
│ No external injuries (except possible impact injuries if jumped/fell). │
│ No ligature marks. │
│ │
│ INTERNAL EXAMINATION: │
│ │
│ SKULL: No fracture. BRAIN: Edematous. Weight 1380 g. │
│ Cerebral edema present. Petechiae. │
│ │
│ NECK: Hyoid intact. No ligature mark. No injury. │
│ │
│ CHEST CAVITY: │
│ Ribs: Intact. Pleura: Bilateral pleural effusion (water) may be │
│ present. No pneumothorax. │
│ │
│ LUNGS (MOST IMPORTANT ORGAN IN DROWNING): │
│ Weight: R: 820 g, L: 790 g (MARKEDLY INCREASED - normal 400 g each). │
│ WATERLOGGED - heavy, voluminous, pit on finger pressure. │
│ Color: Pale pink to bluish-grey. │
│ Crepitations: PRESENT on palpation (crepitant). │
│ EMPHYSEMA AQUOSUM: Over-inflation with water, markings of ribs visible │
│ on surface (Rib markings present). │
│ Cut surface: Frothy, pale, blood-stained fluid oozes freely. │
│ Subpleural petechial hemorrhages (TARDIEU SPOTS): Present. │
│ Pleural surfaces: Impression of ribs visible (Paltauf's sign/spots). │
│ PALTAUF'S HEMORRHAGES: Subpleural pale pink hemorrhagic areas │
│ (dilution of blood by water in fresh water drowning). │
│ │
│ HEART: Right chambers dilated, engorged. Left - normal/empty. │
│ Weight 300 g. No coronary disease. │
│ │
│ STOMACH: │
│ WATER IN STOMACH: Contains 200-500 mL of muddy/turbid water. │
│ (Swallowed during struggle - confirms ante-mortem drowning.) │
│ Sand, weeds, debris may be present. │
│ Mucosa: Congested, hemorrhagic in places. │
│ │
│ DUODENUM/INTESTINES: May contain water (confirm drowning). │
│ │
│ MIDDLE EAR: Hemorrhage into middle ear (Rodriques sign). │
│ │
│ SPHENOID SINUS: Water/mud present (confirmatory sign of drowning). │
│ │
│ LIVER: Weight 1600 g. Congested. │
│ SPLEEN: Normal. KIDNEYS: Congested. │
├─────────────────────────────────────────────────────────────────────────┤
│ SPECIAL INVESTIGATIONS: │
│ │
│ 1. DIATOM TEST (Pfaff's method): │
│ Bone marrow / Femur / Kidney sent for diatom examination. │
│ Presence of diatoms identical to those in drowning medium │
│ = CONFIRMATORY of ante-mortem drowning (diatoms reach circulation │
│ while heart still pumping - not in post-mortem immersion). │
│ │
│ 2. GETTLER'S TEST (Chloride test): │
│ Blood chloride: Left heart vs. Right heart comparison. │
│ Fresh water drowning: Left heart blood MORE dilute than right. │
│ (Osmotic dilution from absorbed fresh water.) │
│ │
│ 3. STRONTIUM TEST: Serum strontium levels. │
│ │
│ 4. Swabs from genitalia (if sexual assault suspected). │
│ │
│ Samples: Viscera, blood, urine, lung, bone marrow preserved. │
├─────────────────────────────────────────────────────────────────────────┤
│ OPINION: │
│ │
│ CAUSE OF DEATH: │
│ I (a): Asphyxia due to drowning. │
│ I (b): Immersion in water with aspiration. │
│ II: Nil. │
│ │
│ MANNER: Consistent with ACCIDENTAL drowning. │
│ (Suicide/Homicide cannot be excluded without further │
│ investigation - deferred to Investigating Officer.) │
│ │
│ Basis: Waterlogged lungs, froth at mouth/nose, water in stomach, │
│ goose skin, Paltauf's hemorrhages, emphysema aquosum. │
│ │
│ PMI: Difficult to estimate due to water immersion. Body may have │
│ been in water approximately 12-24 hours. │
│ │
│ Signature: Dr. _______________ Date: _______________ │
└─────────────────────────────────────────────────────────────────────────┘
┌─────────────────────────────────────────────────────────────────────────┐
│ POST-MORTEM EXAMINATION REPORT │
│ DEATH BY ELECTROCUTION │
├─────────────────────────────────────────────────────────────────────────┤
│ PM Report No.: 03/2026 Date: 09/07/2026 │
│ DECEASED: Mohan Lal, 22 years, Male │
│ Circumstances: Found near live electric wire / Contact with appliance │
│ CR No.: __________ Under Section: 174/194 BNSS │
├─────────────────────────────────────────────────────────────────────────┤
│ EXTERNAL EXAMINATION: │
│ │
│ Build: Average. Height: 170 cm. Weight: 65 kg. │
│ │
│ POSTMORTEM CHANGES: │
│ Livor Mortis: Present over posterior surfaces. Bluish-purple. │
│ Rigor Mortis: Present in all groups. │
│ PMI: Approximately 4-6 hours. │
│ │
│ FACE: Congested. Cyanosed. │
│ EYES: Conjunctivae petechiae. Dilated pupils. │
│ │
│ ELECTRIC MARK (JOULE BURN / ENTRY WOUND - KEY FINDING): │
│ Present on: Right palm (web space between thumb and index finger) │
│ Size: 2 x 1.5 cm │
│ Shape: Irregular, central pale crater with surrounding brownish-red │
│ hyperemia; raised edges; dry, yellowish parchment center. │
│ Character: Hard, firm, leathery; surrounding blistering present. │
│ ARBORESCENT (LIGHTNING-TREE/LICHTENBERG FIGURE) markings: │
│ Present on right forearm - fern-like branching reddish streaks │
│ along skin. │
│ │
│ EXIT WOUND (if present): │
│ Present on: Right foot/heel │
│ Size: 3 x 2 cm │
│ Character: Larger and more explosive than entry; irregular; blowout │
│ appearance. │
│ (Note: Exit wound usually larger and more explosive than entry) │
│ │
│ SINGING OF HAIR: Present over right hand and forearm. │
│ METALLIZATION: Copper/metalite particles embedded in skin │
│ (demonstrate with X-ray or chemical analysis). │
│ │
│ CLOTHING: Burnt / torn at entry and exit sites. │
│ Shoes: Sole may show melted/exit site. │
│ │
│ INTERNAL EXAMINATION: │
│ │
│ SKULL: No fracture (unless thrown by current). BRAIN: Edematous. │
│ Weight 1360 g. Petechial hemorrhages. Cerebral edema. │
│ │
│ NECK: No injury. Hyoid intact. │
│ │
│ HEART: │
│ Weight 305 g. Cardiac arrhythmia is cause of death (cannot be seen │
│ on autopsy - diagnosis made from history + electrical evidence). │
│ Subendocardial hemorrhages may be present. │
│ Contraction band necrosis on histopathology (if taken). │
│ Right chambers: Engorged, dilated. │
│ Coronary arteries: Patent. │
│ │
│ LUNGS: Weight 450 g each. Congested. Edematous. │
│ Subpleural petechiae. Pulmonary edema present. │
│ │
│ MUSCLES ALONG PATH OF CURRENT: │
│ Right forearm and arm muscles: Vacuolization, disruption visible on │
│ section. Hemorrhage in muscle bundles. │
│ │
│ STOMACH: Normal contents. No corrosion. │
│ LIVER: Congested. SPLEEN: Congested. KIDNEYS: Congested. │
│ │
│ SPINAL CORD: Hemorrhagic foci may be seen (path of current). │
│ │
│ FRACTURES: Vertebral compression fractures possible if thrown. │
│ TONGUE: Bite mark possible (tetanic jaw spasm at moment of shock). │
│ │
│ HISTOPATHOLOGY (IMPORTANT - send sections from entry wound): │
│ Entry wound: Vacuolization of keratinocytes, "streaming" of nuclear │
│ chromatin along the direction of current flow. │
│ "Nuclear elongation" pattern at bases of rete ridges. │
│ Contraction band necrosis in myocardium. │
├─────────────────────────────────────────────────────────────────────────┤
│ SAMPLES: │
│ Viscera for chemical analysis. Blood. Urine. │
│ Tissue from entry/exit wound in formalin (histopathology). │
│ Cardiac tissue in formalin. │
│ Muscle along path of current. │
├─────────────────────────────────────────────────────────────────────────┤
│ OPINION: │
│ │
│ CAUSE OF DEATH: │
│ I (a): Cardiac arrhythmia (ventricular fibrillation) due to │
│ electrocution. │
│ I (b): Passage of high-voltage electrical current through body. │
│ II: Cerebral edema, pulmonary edema. │
│ │
│ MANNER: Accidental (Occupational/domestic electrocution). │
│ Homicidal electrocution rare but cannot be excluded. │
│ │
│ Basis: Presence of entry and exit electrical burns with characteristic │
│ Joule burn morphology, arborescent markings, metallization, and │
│ generalized asphyxial changes. │
│ │
│ Note: In lightning strike - multiple entry/exit sites, Lichtenberg │
│ figures more prominent, clothes blown off, keraunoparalysis, │
│ ruptured eardrums, cataracts. │
│ │
│ PMI: Approximately 4-6 hours. │
│ Signature: Dr. _______________ Date: _______________ │
└─────────────────────────────────────────────────────────────────────────┘
┌─────────────────────────────────────────────────────────────────────────┐
│ POST-MORTEM EXAMINATION REPORT │
│ ROAD TRAFFIC ACCIDENT (RTA) │
├─────────────────────────────────────────────────────────────────────────┤
│ PM Report No.: 04/2026 Date: 09/07/2026 │
│ DECEASED: Anil Singh, 40 years, Male │
│ Circumstances: Hit by vehicle on highway / Two-wheeler accident │
│ FIR No.: __________ Under Section: 304A/304 IPC / BNS │
│ Police Station: ______________ Investigating Officer: ___________ │
├─────────────────────────────────────────────────────────────────────────┤
│ EXTERNAL EXAMINATION: │
│ │
│ Build: Average. Height: 168 cm. Weight: 66 kg. │
│ │
│ POSTMORTEM CHANGES: │
│ Livor Mortis: Present posteriorly. Color: Bluish-red. Fixed. │
│ Rigor Mortis: Present in jaw, limbs - Fully established. │
│ PMI: 6-12 hours. │
│ │
│ CLOTHING: Torn, soiled with mud and blood at multiple sites. │
│ Tire marks/tread impressions: Present on right side of chest. │
│ │
│ INJURIES - RTA CLASSIFICATION: │
│ │
│ A. PRIMARY IMPACT (Direct contact with vehicle): │
│ 1. Bumper injury: │
│ Depressed fracture/contusion, anterior aspect left tibia 10 cm │
│ above ankle (H: 52 cm from heel = bumper height indicator). │
│ 2. Radiator/Hood impact: │
│ Multiple lacerations and contusions: Right shoulder, chest wall. │
│ │
│ B. SECONDARY IMPACT (Body thrown onto bonnet/windshield): │
│ 3. Laceration: Scalp, vertex, 6 x 2 cm, bone deep. │
│ 4. Subdural hematoma (found internally). │
│ 5. Contusion: Right temporal region 5 x 4 cm. │
│ │
│ C. TERTIARY IMPACT (Fallen to ground): │
│ 6. Road rash (graze/abrasion): Extensive, right side of face, │
│ right elbow, right hip - dirt embedded, parallel linear pattern │
│ (direction indicates direction of fall/skid). │
│ 7. Contusion: Right forearm, 8 x 5 cm. │
│ │
│ D. CRUSH/RUNOVER INJURIES (if runover): │
│ 8. Tire tread mark: Oblique impression across right chest wall. │
│ 9. Patterned contusion matching tire tread present. │
│ 10. Crushing fractures: Multiple ribs right side 3rd-7th. │
│ │
│ HEAD: │
│ Scalp laceration: Vertex - 6 x 2 cm (see above). │
│ Contusions: Right temporal x2, left parietal x1. │
│ Face: Multiple abrasions. Nose: Fractured (deviated). │
│ │
│ EYES: Right eye: Subconjunctival hemorrhage. Left: Normal. │
│ │
│ CHEST: Multiple rib fractures R: 3rd-7th, L: 5th-7th. │
│ Paradoxical movement present. │
│ │
│ ABDOMEN: Distended. Superficial lacerations over left side. │
│ │
│ PELVIS: Acetabular fracture - right side. │
│ │
│ LIMBS: Right tibial fracture (bumper injury). │
│ Left radius fracture (defensive - raised arm). │
│ │
│ INTERNAL EXAMINATION: │
│ │
│ SCALP: Contusions, lacerations as described. │
│ SKULL FRACTURES: │
│ Compound depressed fracture: Right temporal-parietal region 7 x 4 cm. │
│ Contre-coup fracture: Left temporal fossa (fracture opposite to impact).│
│ │
│ BRAIN: Weight 1380 g. │
│ Subdural hematoma: Right side - 80 mL dark clotted blood. │
│ Extradural hematoma: Right temporal - 40 mL fresh blood. │
│ Contrecoup contusion: Left temporal/frontal lobe - hemorrhagic. │
│ Coup contusion: Right temporal lobe. │
│ Cerebral edema: SEVERE. Gyri flattened, herniations of uncus. │
│ Diffuse axonal injury suspected (histopathology required). │
│ Brainstem: Petechial hemorrhages. Duret hemorrhages present. │
│ │
│ NECK: No fracture. Hyoid intact. │
│ Cervical vertebrae: C4-C5 fracture-subluxation noted. │
│ │
│ CHEST: │
│ BILATERAL HEMOTHORAX: R: 600 mL, L: 300 mL dark blood. │
│ Pneumothorax: Left. │
│ Lung lacerations: Right lower lobe - 2 sites. │
│ Contused lung: Left lower lobe. │
│ CARDIAC TAMPONADE: Hemopericardium 50 mL. │
│ HEART: Myocardial contusion: Anterior wall. Right atrium tear. │
│ AORTA: Transection of aorta at isthmus (just distal to left │
│ subclavian origin) - traumatic aortic rupture. │
│ │
│ ABDOMEN: │
│ Free blood in peritoneal cavity: 800 mL. │
│ LIVER: Ruptured, multiple lacerations right lobe. │
│ SPLEEN: Ruptured, central hematoma. │
│ KIDNEY: Left kidney contusion. Right: Normal. │
│ BLADDER: Ruptured (if full at time of impact). │
│ MESENTERY: Contusion, hemorrhage. │
│ PELVIS: Acetabular fracture R + iliac crest fracture L. │
├─────────────────────────────────────────────────────────────────────────┤
│ SAMPLES: Blood (for alcohol - no preservative), urine, vitreous humor, │
│ histopathology (brain for DAI - beta-APP staining). │
├─────────────────────────────────────────────────────────────────────────┤
│ OPINION: │
│ │
│ CAUSE OF DEATH: │
│ I (a): Hemorrhagic shock and traumatic brain injury. │
│ I (b): Multiple organ injuries due to blunt force trauma. │
│ II: Bilateral hemothorax, pneumothorax, traumatic aortic rupture, │
│ hepatic and splenic laceration. │
│ │
│ MANNER: ACCIDENTAL - Road Traffic Accident. │
│ │
│ All injuries are consistent with RTA - blunt force trauma, patterned │
│ contusions, and tire impressions consistent with vehicle impact. │
│ │
│ Bumper height: 52 cm from heel consistent with [car type]. │
│ │
│ Blood alcohol concentration requested (chemical analysis). │
│ PMI: 6-12 hours. Age: 38-42 years. │
│ │
│ Signature: Dr. _______________ Date: _______________ │
└─────────────────────────────────────────────────────────────────────────┘
┌─────────────────────────────────────────────────────────────────────────┐
│ POST-MORTEM EXAMINATION REPORT │
│ DEATH DUE TO CARDIAC CAUSE │
├─────────────────────────────────────────────────────────────────────────┤
│ PM Report No.: 05/2026 Date: 09/07/2026 │
│ DECEASED: Rajesh Verma, 58 years, Male │
│ Circumstances: Found dead at home; known hypertensive, diabetic. │
│ CR No.: __________ Under Section: 174/194 BNSS │
├─────────────────────────────────────────────────────────────────────────┤
│ EXTERNAL EXAMINATION: │
│ │
│ Build: Obese. Height: 168 cm. Weight: 88 kg. BMI: ~31. │
│ │
│ POSTMORTEM CHANGES: │
│ Livor Mortis: Present over posterior surfaces. Dark bluish-purple. │
│ Fixed. PMI: 8-12 hours. │
│ Rigor Mortis: Fully established. │
│ │
│ Face: Pale / slightly congested. │
│ Eyes: Petechiae absent. Arcus senilis present. │
│ Mouth: No froth. No cyanosis. Tongue: Not protruding. │
│ Neck: No ligature mark. No injury. │
│ Chest: Surgical scar (if previous CABG/sternotomy): ___________ │
│ Abdomen: Obese. No injury. │
│ Limbs: Lower limb edema: Bilateral pitting, up to ankles. │
│ No external injuries. │
│ │
│ INTERNAL EXAMINATION: │
│ │
│ SKULL: No fracture. BRAIN: Weight 1400 g. Mild edema. Old ischemic │
│ infarct may be present in basal ganglia (chronic hypertension). │
│ │
│ NECK: Hyoid intact. Atheromatous carotid arteries. │
│ │
│ CHEST: │
│ No hemothorax. Bilateral pleural effusion: R: 200 mL, L: 180 mL │
│ (consistent with cardiac failure / CCF). │
│ │
│ HEART - PRIMARY ORGAN OF INTEREST: │
│ Weight: 480 g (INCREASED - normal 250-350 g). │
│ Shape: Globular (evidence of cardiomegaly). │
│ │
│ PERICARDIUM: Intact. Pericardial fluid: 50 mL straw-colored. │
│ │
│ LEFT VENTRICLE: │
│ Wall thickness: 1.8 cm (THICKENED - normal 0.8-1.2 cm). │
│ CONCENTRIC HYPERTROPHY - consistent with long-standing hypertension. │
│ │
│ RIGHT VENTRICLE: Wall thickness 0.5 cm. Normal. │
│ │
│ CORONARY ARTERIES: │
│ LAD (Left Anterior Descending): SEVERE stenosis - 90% occlusion at │
│ proximal one-third. Atheromatous plaque, calcified. Lumen reduced │
│ to 1 mm. │
│ LCX (Left Circumflex): Moderate stenosis 60%. │
│ RCA (Right Coronary): Moderate stenosis 50%. │
│ FRESH THROMBUS: Present in LAD lumen (acute coronary event). │
│ │
│ MYOCARDIUM: │
│ Area of infarction: Anterior wall, interventricular septum. │
│ Character: Pale, yellowish, soft (48-72 hour old infarct); │
│ OR Dark mottled (24-48h); OR Pale grey (>1 week old). │
│ PALLOR and MOTTLING: Present in anterior wall. │
│ Subendocardial hemorrhage: Present. │
│ Old infarct scars (fibrous pale areas): Present in posterior wall │
│ (chronic ischemic heart disease). │
│ │
│ AORTA: Atherosclerosis - severe. Multiple calcified plaques. │
│ No dissection. │
│ │
│ VALVES: Mitral: Thickened, calcified. Aortic: Calcified (aortic │
│ sclerosis). No vegetations. │
│ │
│ LUNGS: Weight: R: 620 g, L: 590 g (INCREASED - pulmonary edema). │
│ Color: Congested, pink, waterlogged. Cut surface: Frothy fluid. │
│ Hemosiderin-laden macrophages ("heart failure cells") on smear. │
│ │
│ LIVER: Weight 1800 g (INCREASED). "NUTMEG LIVER" pattern: │
│ Congested, dark red center with pale periphery on cut section. │
│ Consistent with chronic passive venous congestion (right heart failure).│
│ │
│ KIDNEYS: Enlarged, congested. Cortex: Granular surface ("granular │
│ contracted kidney" - hypertensive nephropathy). │
│ │
│ SPLEEN: Weight 250 g. Congested, firm. │
│ │
│ STOMACH: Empty or minimal contents. Normal mucosa. │
│ PANCREAS: Features of diabetes mellitus (islet atrophy, fibrosis). │
│ │
│ ADRENALS: Normal. │
│ │
│ HISTOPATHOLOGY: │
│ Myocardium: Contraction band necrosis (very early ischemia, <1h). │
│ Coagulative necrosis (>4-6h). │
│ Inflammatory infiltrate (>24h - PMN, then macrophages). │
│ Granulation tissue (5-10 days). │
│ Fibrosis (>2-3 weeks). │
├─────────────────────────────────────────────────────────────────────────┤
│ SAMPLES: Blood, urine, vitreous humor (for electrolytes - sudden │
│ cardiac death). Cardiac tissue for histopathology. │
├─────────────────────────────────────────────────────────────────────────┤
│ OPINION: │
│ │
│ CAUSE OF DEATH: │
│ I (a): Acute myocardial infarction. │
│ I (b): Acute coronary thrombosis of LAD. │
│ II: Severe coronary artery disease (atherosclerosis), hypertensive │
│ heart disease (LVH), diabetes mellitus, obesity. │
│ │
│ MANNER: NATURAL. │
│ │
│ This is consistent with sudden natural death due to acute coronary │
│ event on a background of long-standing ischemic heart disease. │
│ │
│ PMI: Approximately 8-12 hours. │
│ Age: 55-62 years (consistent with stated age). │
│ │
│ Signature: Dr. _______________ Date: _______________ │
└─────────────────────────────────────────────────────────────────────────┘
┌─────────────────────────────────────────────────────────────────────────┐
│ POST-MORTEM EXAMINATION REPORT │
│ DEATH BY POISONING (OP COMPOUND) │
├─────────────────────────────────────────────────────────────────────────┤
│ PM Report No.: 06/2026 Date: 09/07/2026 │
│ DECEASED: Savitri Devi, 30 years, Female │
│ Circumstances: Found unconscious after allegedly consuming pesticide. │
│ CR No.: __________ Under Section: 302/304/306 IPC (BNS) │
├─────────────────────────────────────────────────────────────────────────┤
│ EXTERNAL EXAMINATION: │
│ │
│ Build: Average. Height: 155 cm. Weight: 50 kg. │
│ │
│ POSTMORTEM CHANGES: │
│ Livor Mortis: Present posteriorly. Bluish-purple. Fixed. │
│ Rigor Mortis: Fully established. PMI: 6-10 hours. │
│ │
│ BODY ODOR: Strong garlic-like / pungent odor from mouth/body fluids. │
│ (Characteristic of organophosphate/sulphur compounds.) │
│ │
│ FACE: Congested, cyanosed. │
│ │
│ EYES: │
│ PUPILS: CONSTRICTED (MIOSIS) bilaterally - 2 mm each (HALLMARK). │
│ Conjunctivae: Congested, petechiae present. │
│ │
│ MOUTH: │
│ Profuse frothing at mouth - copious, white froth. │
│ Tongue: Moist. Not bitten. Excess salivation noted. │
│ │
│ SKIN: Diaphoresis (sweating). Skin appears moist. │
│ │
│ NO EXTERNAL INJURIES. │
│ No ligature marks. No needle marks (unless IV attempted in hospital). │
│ │
│ CLOTHING: May show pesticide stain. │
│ │
│ INTERNAL EXAMINATION: │
│ │
│ SKULL: Intact. BRAIN: Weight 1340 g. CONGESTED. Edematous. │
│ Petechiae on surface. Cerebral edema. │
│ │
│ NECK: No injury. Hyoid intact. │
│ │
│ CHEST: No hemothorax. │
│ │
│ LUNGS: Weight: R: 590 g, L: 560 g (INCREASED due to edema). │
│ Color: CONGESTED, pink-red, heavy, waterlogged. │
│ Cut surface: COPIOUS FROTHY FLUID - blood-stained, abundant. │
│ (Bronchorrhea - excess secretions in bronchi.) │
│ Subpleural petechiae (Tardieu spots): Present. │
│ Bronchi: Contain frothy fluid. │
│ Bronchospasm features: Distended with trapped air. │
│ │
│ HEART: Weight 290 g. Dilated. Engorged right chambers. │
│ Subendocardial hemorrhages. │
│ │
│ STOMACH: │
│ Contents: STRONG PUNGENT SMELL - garlic/sulphur odor on opening. │
│ Volume: ~300 mL greenish-brown liquid. │
│ Mucosa: HYPEREMIC, hemorrhagic, erosions present. │
│ Chemical irritant effect visible. │
│ Corrosion: Not present (OP compounds - no direct corrosion). │
│ │
│ SMALL INTESTINE: Hyperemic mucosa. Increased secretions. │
│ │
│ LIVER: Weight 1580 g. Congested. No necrosis in OP poisoning. │
│ (Note: In paracetamol - centrilobular necrosis would be present.) │
│ │
│ SPLEEN: Congested. KIDNEYS: Congested. │
│ │
│ URINARY BLADDER: FULL of urine (involuntary urination - cholinergic). │
│ Urine: ~200 mL. Preserved for toxicology. │
│ │
│ ADRENALS: Normal. │
├─────────────────────────────────────────────────────────────────────────┤
│ SAMPLES PRESERVED (CRITICAL FOR CHEMICAL ANALYSIS): │
│ 1. Stomach + contents (in separate sealed container, NO preservative). │
│ 2. Liver (500 g) in saturated NaCl. │
│ 3. Kidney (one complete) in saturated NaCl. │
│ 4. Small intestine (30 cm with contents) in saturated NaCl. │
│ 5. Blood: 50 mL in plain container - NO PRESERVATIVE (for OP). │
│ 6. Urine: 50 mL plain container. │
│ 7. Vitreous humor: 5 mL. │
│ 8. Bile: 10 mL. │
│ 9. Brain tissue: 200 g. │
│ 10. Lung tissue for histopathology. │
│ NOTE: All samples sealed separately and labeled with case no. + content.│
│ Sent to: Chemical Examiner, FSL __________________ on ___________ │
│ Ref No.: _________________ │
│ Analysis requested: Organophosphate screen, Cholinesterase activity. │
├─────────────────────────────────────────────────────────────────────────┤
│ OPINION: │
│ │
│ CAUSE OF DEATH: │
│ I (a): Respiratory failure and acute pulmonary edema. │
│ I (b): Organophosphate compound poisoning. │
│ II: Cholinergic crisis with bronchorrhea and bronchospasm. │
│ │
│ MANNER: Consistent with SUICIDAL poisoning (pending chemical │
│ analysis confirmation). │
│ │
│ Basis: Miosis, profuse bronchorrhea, copious froth, garlic odor, │
│ hyperemic GI mucosa - SLUDGE syndrome features present on PM. │
│ │
│ NOTE: Final opinion subject to chemical analysis results. │
│ Red blood cell cholinesterase activity confirmation essential. │
│ │
│ PMI: 6-10 hours. Age: 28-32 years. │
│ │
│ Signature: Dr. _______________ Date: _______________ │
└─────────────────────────────────────────────────────────────────────────┘
┌─────────────────────────────────────────────────────────────────────────┐
│ POST-MORTEM EXAMINATION REPORT │
│ DEATH DUE TO BURNS │
├─────────────────────────────────────────────────────────────────────────┤
│ PM Report No.: 07/2026 Date: 09/07/2026 │
│ DECEASED: Geeta Sharma, 24 years, Female │
│ Circumstances: Burns (bride burning / accidental kerosene burn) │
│ CR No.: __________ Under Section: 302/304B/306 IPC │
├─────────────────────────────────────────────────────────────────────────┤
│ EXTERNAL EXAMINATION: │
│ │
│ BODY WEIGHT: Severely reduced due to fluid loss. │
│ │
│ BURNS ASSESSMENT: │
│ Using RULE OF NINES: │
│ Head and neck: 9% Right arm: 9% Left arm: 9% │
│ Anterior trunk: 18% Posterior trunk: 18% │
│ Right leg: 18% Left leg: 18% Perineum: 1% │
│ Total BSA Burned: _____% (Document carefully) │
│ │
│ DEGREE OF BURNS: │
│ 1st degree (erythema only): Areas: _________________ │
│ 2nd degree (blistering): Areas: ____________________ │
│ 3rd degree (full thickness - charring, leathery): Areas: ___________ │
│ │
│ CLOTHING: Burnt/charred at sites corresponding to burn areas. │
│ Kerosene/petrol odor: Present / Absent. │
│ │
│ VITAL REACTION (ANTE-MORTEM BURNS): │
│ 1. Vital blistering (fluid inside blisters with protein and leucocytes).│
│ 2. Hyperemia and inflammatory reaction at burn margins. │
│ 3. Soot in airways (below glottis = ante-mortem). │
│ 4. Pugilistic posture (boxing stance): Due to heat-induced muscle │
│ contraction - NOT a sign of fighting. │
│ │
│ POST-MORTEM BURNS: │
│ Dry, leathery, split skin. Peeling. No fluid in blisters. No vital │
│ reaction at margins. │
│ │
│ INTERNAL EXAMINATION: │
│ │
│ RESPIRATORY TRACT: │
│ SOOT: Soot deposits in trachea, bronchi (BELOW CORDS = ante-mortem). │
│ (Above cords only = post-mortem smoke entry.) │
│ Larynx: Edematous, soot-stained. │
│ Trachea: Soot-lined mucosa. │
│ Bronchi: Contain carbonaceous material. │
│ │
│ LUNGS: CHERRY RED color (Carbon monoxide poisoning concurrent). │
│ Edematous. Congested. Weight increased. │
│ │
│ BLOOD: Cherry red (carboxyhemoglobin - CO poisoning from smoke). │
│ COHb levels requested from FSL. │
│ │
│ BRAIN: Edematous. Cherry red coloration. │
│ │
│ STOMACH: Stress ulcers (Curling's ulcers) may be present. │
│ Submucosal hemorrhages along greater curvature. │
│ │
│ HEART: Subendocardial hemorrhages. Fatty changes. │
│ │
│ SKULL: Epidural "heat hematoma" (lenticular, dark red, in temples) │
│ - NOT a sign of trauma - artifact of heat in burning. │
│ Note: True traumatic EDH is bright red and has fracture usually. │
│ │
│ HEAT FRACTURES: Skull may show "explosion" type fractures from │
│ steam pressure in diploe - NOT ante-mortem blunt force. │
├─────────────────────────────────────────────────────────────────────────┤
│ SAMPLES: │
│ Blood in plain sealed vial (for COHb estimation - to FSL URGENTLY). │
│ Vitreous humor. Viscera. Blistered skin biopsy (histopathology). │
│ Soot swab from airways. Urine for cyanide (if synthetic material burnt).│
├─────────────────────────────────────────────────────────────────────────┤
│ OPINION: │
│ │
│ CAUSE OF DEATH: │
│ I (a): Carboxyhemoglobin poisoning and respiratory failure. │
│ I (b): Inhalation of smoke and toxic gases. │
│ II: Burns involving ____% BSA (2nd-3rd degree), burn shock. │
│ │
│ MANNER: To be determined by investigation. Burns are ANTE-MORTEM │
│ (vital reaction present; soot below glottis). │
│ │
│ Note: No evidence of blunt force trauma pre-mortem. No fractures │
│ inconsistent with heat effects. No restraint marks. │
│ │
│ Final opinion: Pending chemical analysis for COHb levels and toxicology.│
│ │
│ Signature: Dr. _______________ Date: _______________ │
└─────────────────────────────────────────────────────────────────────────┘
┌─────────────────────────────────────────────────────────────────────────┐
│ POST-MORTEM EXAMINATION REPORT │
│ DEATH BY FIREARM INJURY │
├─────────────────────────────────────────────────────────────────────────┤
│ PM Report No.: 08/2026 Date: 09/07/2026 │
│ DECEASED: Vikram Singh, 32 years, Male │
│ Circumstances: Gunshot wound │
│ CR No.: __________ Under Section: 302/307 IPC / BNS │
│ Request by: Inspector _________, PS __________ │
├─────────────────────────────────────────────────────────────────────────┤
│ EXTERNAL EXAMINATION: │
│ │
│ ENTRY WOUND: │
│ Location: Right temporal region, 3 cm above the right ear. │
│ Size: 1.2 x 1.2 cm │
│ Shape: Circular, punched-out appearance. │
│ Edges: INVERTED (pushing inward) - ENTRY. │
│ Marginal abrasion collar: Present (2-3 mm wide, around entry). │
│ Powder tattooing/stippling: Present within 60 cm radius around wound. │
│ Blackening: Present (contact/close range). │
│ Burns of skin/hair: Present (very close/contact range). │
│ Contusion ring/abrasion ring: Present. │
│ Muzzle stamp: Present (star-shaped laceration if contact - applied │
│ muzzle to skin over bone). │
│ │
│ EXIT WOUND: │
│ Location: Left temporal region. │
│ Size: 3 x 2.5 cm │
│ Shape: IRREGULAR, stellate, explosive. │
│ Edges: EVERTED (pushed outward) - EXIT. │
│ NO abrasion collar at exit. NO tattooing. NO blackening. │
│ Size LARGER than entry. │
│ │
│ RANGE DETERMINATION: │
│ Contact shot: Muzzle stamp + cruciate laceration + smoke deposit │
│ under skin edge. │
│ Close range (<15 cm): Blackening + tattooing + burning. │
│ Medium range (15-60 cm): Tattooing without blackening. │
│ Long range (>60 cm): Abrasion collar + contusion ring only. │
│ THIS CASE: Close range (blackening + stippling present). │
│ │
│ INTERNAL EXAMINATION: │
│ │
│ SKULL: Beveling of skull: │
│ Entry wound: Internal bevel (inner table larger than outer) - ENTRY. │
│ Exit wound: External bevel (outer table larger than inner) - EXIT. │
│ Fracture lines: Radiating from both entry and exit. │
│ │
│ BRAIN: Destroyed right temporal lobe. Bullet track visible: │
│ Hemorrhagic lacerated track from right to left temporal lobe. │
│ Gunshot residue in track. │
│ Mass hemorrhage. Brain weight: Significantly reduced. │
│ Left: Contre-coup laceration. │
│ │
│ BULLET RECOVERED: Yes / No (if present - describe, photograph, │
│ handle with gloves, preserve in separate container, hand to police). │
│ │
│ CHEST/ABDOMEN: No injury (unless multiple shots). │
│ HEART: Pale. No injury. │
│ LUNGS: Congested. No direct injury. │
├─────────────────────────────────────────────────────────────────────────┤
│ SAMPLES: │
│ Wound swabs for GSR (gunshot residue). │
│ Blood, urine, vitreous for toxicology. │
│ Bullet (if recovered) handed to IO with proper documentation. │
│ Skull bone from entry and exit for beveling demonstration. │
│ Clothing (with GSR markings) handed to FSL. │
├─────────────────────────────────────────────────────────────────────────┤
│ OPINION: │
│ │
│ CAUSE OF DEATH: │
│ I (a): Destruction of brain and massive intracranial hemorrhage. │
│ I (b): Penetrating gunshot wound to head. │
│ II: Nil. │
│ │
│ MANNER: HOMICIDAL (single close-range shot, not typical of suicide). │
│ (Suicidal firearms typically: contact range, temporal/mouth; │
│ homicidal: variable range, back of head, multiple shots.) │
│ │
│ Range of fire: CLOSE RANGE (<15 cm) based on blackening and tattooing. │
│ │
│ Direction of fire: Right to left (entry right temporal, exit left). │
│ │
│ Signature: Dr. _______________ Date: _______________ │
└─────────────────────────────────────────────────────────────────────────┘
┌─────────────────────────────────────────────────────────────────────────┐
│ WOUND CERTIFICATE / INJURY REPORT │
│ (MLC Form - Outpatient/Casualty) │
├─────────────────────────────────────────────────────────────────────────┤
│ MLC No.: _______________ Date: _______________ Time: ________________ │
│ Hospital: ___________________________________________________________ │
│ │
│ PATIENT DETAILS: │
│ Name: ________________________________ Age: ______ Sex: ____________ │
│ Address: ___________________________________________________________ │
│ Brought by: _________________________ Relation: ____________________ │
│ │
│ REFERRING AUTHORITY: │
│ Police / Magistrate / Self / Relative │
│ FIR No.: ____________ PS: _____________ Date: ______________________ │
│ Referred by (Officer name): ______________________________________ │
│ │
│ HISTORY AS GIVEN BY PATIENT / INFORMANT: │
│ _____________________________________________________________ │
│ _____________________________________________________________ │
│ │
│ GENERAL CONDITION ON ADMISSION: │
│ Conscious / Unconscious / Semiconscious BP: ______ Pulse: _____ │
│ RR: _____ SpO2: _____ Temperature: _____ │
│ │
│ INJURIES NOTED (each injury described individually): │
│ │
│ Injury 1: │
│ Nature: Abrasion / Contusion / Laceration / Incised wound / Firearm │
│ Site: _________________________________ Size: ___________________ │
│ Shape: __________________ Edges: __________________ │
│ Depth: ___________________ │
│ Surroundings: __________________________________________ │
│ Age of injury: Fresh / Old / Intermediate (approx _____ hours/days) │
│ Ante-mortem / Post-mortem: ___________________ │
│ │
│ Injury 2: (repeat as above for each injury) │
│ │
│ RADIOLOGICAL FINDINGS: (if X-ray done) │
│ _____________________________________________________________ │
│ │
│ OPINION: │
│ 1. Nature of injuries: │
│ Simple / Grievous (as per IPC Sec 319-320 / BNS equivalent) │
│ │
│ 2. Probable cause: │
│ Blunt force / Sharp force / Firearm / Self-inflicted / Others │
│ │
│ 3. Age of injuries: │
│ Consistent with alleged time of assault: Yes / No │
│ │
│ 4. Probable weapon used: __________________________________ │
│ │
│ 5. Whether injuries are sufficient to cause: │
│ Death / Grievous injury / Simple injury │
│ │
│ Name: ________________________ Qualification: _____________________ │
│ Designation: ___________________ Signature: _______________________ │
│ Institution: ____________________ Date: ___________________________ │
└─────────────────────────────────────────────────────────────────────────┘
┌─────────────────────────────────────────────────────────────────────────┐
│ VISCERA FORWARDING MEMO │
│ (For Chemical Analysis by FSL / Chemical Examiner) │
├─────────────────────────────────────────────────────────────────────────┤
│ To, │
│ The Director, Forensic Science Laboratory / Chemical Examiner │
│ Government of _____________________ │
│ │
│ From, │
│ Dr. ____________________________ │
│ Department of Forensic Medicine │
│ ________________________ Hospital │
│ │
│ Reference: PM Report No. _______________ Date: ________________________ │
│ CR / FIR No.: _______________ PS: ___________________________________ │
│ │
│ Details of deceased: Name: _________________ Age: _____ Sex: _____ │
│ Date of PM: _________________ Time: ___________________________________ │
│ │
│ VISCERA/SAMPLES SENT: │
│ │
│ Container No. | Contents | Preservative | Quantity │
│ ─────────────┼───────────────────┼───────────────────┼───────────── │
│ 1 │ Stomach+contents │ Sat. NaCl soln. │ Whole │
│ 2 │ Small intestine │ Sat. NaCl soln. │ 30 cm + cont. │
│ 3 │ Liver │ Sat. NaCl soln. │ 500 g │
│ 4 │ Kidney │ Sat. NaCl soln. │ 1 whole │
│ 5 │ Blood │ None (plain) │ 50 mL │
│ 6 │ Urine │ None (plain) │ 50 mL │
│ 7 │ Vitreous humor │ None │ Both eyes │
│ 8 │ Bile │ None │ All │
│ 9 │ Brain │ Sat. NaCl soln. │ 200 g │
│ 10 │ Lung │ Sat. NaCl soln. │ 100 g │
│ 11 │ _______________ │ _________________ │ _____________ │
│ │
│ Analysis requested: │
│ [ ] Organophosphate / Carbamate screen │
│ [ ] Alcohol (ethanol) estimation │
│ [ ] Heavy metals (As, Pb, Hg, Tl) │
│ [ ] Cyanide │
│ [ ] Carbon monoxide (COHb) estimation │
│ [ ] Drug screen (opiates, benzodiazepines, barbiturates) │
│ [ ] Corrosives (acid, alkali) │
│ [ ] Paracetamol / Salicylate levels │
│ [ ] All poisons │
│ [ ] Others: ________________________ │
│ │
│ CLINICAL SUSPICION: _________________________________________________ │
│ │
│ All containers sealed with: Wax seal / Tape seal │
│ Sealed in the presence of: ________________________________________ │
│ (2 witnesses to sign) │
│ Witness 1: _______________________ Signature: ____________________ │
│ Witness 2: _______________________ Signature: ____________________ │
│ │
│ Forwarded through: Police (IO Name: __________________________) │
│ Date of forwarding: ____________________ │
│ │
│ Signature of MO: ____________________ Date: _______________________ │
│ Designation: _________________________ │
└─────────────────────────────────────────────────────────────────────────┘
┌─────────────────────────────────────────────────────────────────────────┐
│ HISTOPATHOLOGY REQUISITION / SUPPLEMENTARY OPINION │
├─────────────────────────────────────────────────────────────────────────┤
│ To, │
│ The Head, Department of Pathology │
│ ___________________________ Hospital / Medical College │
│ │
│ PM Report No.: ____________ Date: _____________ CR No.: ____________ │
│ Name of Deceased: ___________________________ Age: _____ Sex: _____ │
│ │
│ TISSUES SENT: │
│ 1. Heart (myocardium, coronary artery cross sections) │
│ 2. Lung (bilateral) │
│ 3. Brain (cortex, brainstem, cerebellum) │
│ 4. Liver (portal zone + centrilobular) │
│ 5. Kidney (cortex + medulla) │
│ 6. Specific tissues: __________________ │
│ │
│ All fixed in 10% neutral buffered formalin. │
│ │
│ STAINS REQUESTED: │
│ [ ] Routine H&E (all tissues) │
│ [ ] Special stains: PAS / Masson's trichrome / Perl's Prussian blue │
│ [ ] Congo red (if amyloid suspected) │
│ [ ] Oil Red O (fat embolism) │
│ [ ] Beta-APP immunostaining (diffuse axonal injury) │
│ [ ] CD68 (macrophage infiltration - age of infarction) │
│ │
│ Clinical question: _______________________________________________ │
│ │
│ Signature: Dr. _______________ Date: _______________ │
└─────────────────────────────────────────────────────────────────────────┘
┌─────────────────────────────────────────────────────────────────────────┐
│ DIATOM EXAMINATION REQUEST (DROWNING CASES) │
├─────────────────────────────────────────────────────────────────────────┤
│ To, │
│ The Director, Forensic Science Laboratory │
│ _____________________________ │
│ │
│ PM Report No.: ___________ CR No.: ___________ Date: ___________ │
│ Deceased: _______________________________ │
│ │
│ SAMPLES SENT FOR DIATOM EXAMINATION: │
│ 1. Bone marrow (from femur) - 50 g │
│ 2. Kidney tissue - 50 g │
│ 3. Brain tissue - 50 g │
│ 4. Liver tissue - 50 g │
│ 5. Lung tissue - 50 g │
│ 6. Water sample from alleged drowning site - 500 mL │
│ │
│ Purpose: Comparison of diatom species and morphology between body │
│ tissues and drowning medium to confirm/exclude ante-mortem drowning. │
│ │
│ Basis: Diatoms entering alveoli during active breathing penetrate │
│ blood-lung barrier and are carried to distant organs (bone marrow, │
│ kidney, brain). Presence in bone marrow = strong evidence of │
│ ante-mortem drowning. │
│ │
│ Signature: Dr. _______________ Date: _______________ │
└─────────────────────────────────────────────────────────────────────────┘
| Mode of Death | Hallmark External Findings | Hallmark Internal Findings | Key Test |
|---|---|---|---|
| Hanging | Oblique ascending incomplete ligature mark, cyanosis, petechiae, penile erection | Dry subcutaneous band under mark, carotid intimal tears, petechiae on brain/lungs, right heart distended | - |
| Ligature strangulation | Horizontal complete ligature mark, petechiae, cyanosis | Hyoid/thyroid fracture common, laryngeal edema, asphyxial changes | - |
| Drowning | Washerwoman's hands, goose skin, froth at mouth/nose, pink lividity | Waterlogged lungs (2x weight), emphysema aquosum, water in stomach/sinuses, Paltauf's hemorrhages | Diatom test, Gettler's chloride test |
| Electric shock | Joule burn (entry), arborescent marks, exit wound (larger), singeing | Contraction band necrosis (histology), cerebral/pulmonary edema, NO pathognomonic internal finding | Histopathology of wound |
| RTA | Patterned contusions (tire marks), bumper injury, abrasions (road rash) | Skull fractures, cerebral hemorrhage/DAI, hemothorax, organ lacerations, aortic transection | BAC (alcohol), DAI staining |
| Cardiac arrest | Obese, no external injuries, edema | Cardiomegaly, LVH, coronary stenosis+thrombus, myocardial infarction, nutmeg liver, pulmonary edema | Histopathology (coronary + myocardium) |
| OP Poisoning | Miosis, profuse froth, garlic odor, moist skin | Pulmonary edema, bronchorrhea, hyperemic GI mucosa, congested organs | Chemical analysis (FSL), RBC cholinesterase |
| Burns | % BSA burns, vital reaction at margin, pugilistic posture | Soot BELOW glottis, cherry-red blood, Curling's ulcers, heat hematoma (NOT trauma) | COHb estimation |
| Firearm | Entry (small, inverted edges, collar) vs. Exit (large, everted), GSR | Skull beveling, brain laceration/track, bullet if present | GSR, ballistic analysis |
| Cyanide | Bitter almond odor, pink/cherry lividity, no external trauma | Bright red blood + venous blood, congestion everywhere, rapid death changes | Chemical analysis for HCN |
| CO poisoning | Cherry-red lividity, cherry-red skin/mucosa, no external injuries | Cherry-red all organs, pulmonary edema, carboxyhemoglobin in blood | COHb blood level (FSL) |
| Finding | Time Estimate |
|---|---|
| Algor mortis: Warm body | <2 hours |
| Body cool to touch | 4-6 hours |
| Body cold at core | >10-12 hours |
| Livor Mortis appears | 2-4 hours |
| Livor Mortis deepens/spreads | 4-8 hours |
| Livor Mortis FIXED | 8-12 hours |
| Rigor Mortis begins (jaw/neck) | 1-3 hours |
| Rigor Mortis fully established | 6-12 hours |
| Rigor Mortis passing (secondary flaccidity) | 24-48 hours |
| Early decomposition (greenish discoloration RIF) | 36-72 hours |
| Marbling | 4-7 days |
| Bloating / Gas | 5-10 days |
| Skeletonization | Weeks to months |
| Provision | Purpose |
|---|---|
| Sec. 174 CrPC / Sec. 194 BNSS | Police inquest in cases of unnatural/suspicious death |
| Sec. 176 CrPC / Sec. 195 BNSS | Magistrate inquest (dowry death, custodial death, suicide) |
| Sec. 45 Indian Evidence Act | Expert opinion admissible as evidence |
| Sec. 302 IPC / Sec. 101 BNS | Murder |
| Sec. 304A IPC / Sec. 106 BNS | Causing death by negligence (RTA) |
| Sec. 304B IPC / Sec. 80 BNS | Dowry death |
| Sec. 306 IPC / Sec. 108 BNS | Abetment of suicide |
| Sec. 309 IPC / Sec. 226 BNS | Attempt to suicide (decriminalized now) |
| Sec. 174A IPC | Preservation of viscera |
Important Note: All PM reports are legal documents. They must be written clearly, objectively, and signed by the examining officer. Opinions should be confined to findings observed. The final manner of death in suspicious cases should always be given with the qualifier "pending chemical analysis/further investigation" where applicable. Any corrections must be initialed. Do not overwrite.
Master guide for iPd clinical cases
What does 'iPD clinical cases' mean in your context? · What scope/specialty are you looking for?
1. PRESENTING COMPLAINTS (PC) → Chief symptom + duration
2. HISTORY OF PRESENTING ILLNESS → Chronological story of the illness
(HOPI)
3. PAST HISTORY (PH) → Similar illness, surgeries, admissions
4. PERSONAL HISTORY → Diet, sleep, bowel, bladder, menstrual,
addictions, occupation
5. FAMILY HISTORY (FH) → Hereditary/communicable conditions
6. SOCIOECONOMIC HISTORY → SES, living conditions, water/sanitation
7. TREATMENT HISTORY → Current and past medications
8. GENERAL PHYSICAL EXAMINATION → Built, nourishment, pallor, icterus,
(GPE) cyanosis, clubbing, lymphadenopathy,
edema, JVP, pulse, BP, RR, Temp, SpO2
9. SYSTEMIC EXAMINATION → Focused system(s) in detail
10. PROVISIONAL DIAGNOSIS → Based on clinical findings
11. DIFFERENTIAL DIAGNOSIS → 2-3 alternatives
12. INVESTIGATIONS → In logical order (bedside → labs → imaging)
13. FINAL DIAGNOSIS → After results
14. TREATMENT → Non-pharmacological + pharmacological
15. PROGRESS NOTES → Day-by-day in-patient notes
16. DISCHARGE SUMMARY → Condition on discharge + follow-up
A 58-year-old male, hypertensive, smoker, admitted with severe crushing substernal chest pain radiating to left arm and jaw, with sweating and breathlessness for 2 hours.
| Parameter | Finding |
|---|---|
| Built | Average |
| Nourishment | Adequate |
| Pallor | Present (mild) |
| Icterus | Absent |
| Cyanosis | Absent |
| Clubbing | Absent |
| Lymphadenopathy | Absent |
| Edema | Absent |
| Pulse | 96/min, irregular, low volume |
| BP | 100/70 mmHg (hypotension) |
| RR | 24/min |
| Temp | 37.2°C |
| SpO2 | 94% on room air |
| JVP | Elevated (4 cm above sternal angle) |
| Drug | Dose | Route | Purpose |
|---|---|---|---|
| O2 | 2-4 L/min (if SpO2 <90%) | Nasal prongs | Hypoxia correction |
| Aspirin | 300 mg STAT (chew) | Oral | Antiplatelet |
| Clopidogrel | 300 mg STAT (loading) | Oral | Antiplatelet |
| Morphine | 2-4 mg IV | IV slow | Pain relief |
| GTN | 0.4 mg sublingual × 3 (if SBP >90) | SL | Vasodilation |
| Heparin | 60 units/kg IV bolus → 12 units/kg/h | IV | Anticoagulation |
| Atorvastatin | 80 mg | Oral | Statin (high intensity) |
A 45-year-old male presents with high-grade fever, productive cough with rusty sputum, right-sided pleuritic chest pain, and breathlessness for 5 days.
| Parameter | Finding |
|---|---|
| Pallor | Mild |
| Pulse | 108/min, regular |
| BP | 100/70 mmHg |
| RR | 28/min |
| Temp | 39.4°C |
| SpO2 | 91% on room air |
| Drug | Dose | Route | Frequency |
|---|---|---|---|
| Inj. Ceftriaxone | 1 g | IV | 12 hourly |
| Tab. Azithromycin | 500 mg | Oral | OD × 5 days |
| Tab. Paracetamol | 500 mg | Oral | SOS for fever |
| Inj. Heparin | 5000 units | SC | BD (DVT prophylaxis) |
| Mucolytic (Ambroxol) | 30 mg | Oral | TDS |
A 24-year-old known Type 1 diabetic female admitted with vomiting, abdominal pain, deep rapid breathing, and confusion for 12 hours. Omitted insulin for 2 days.
| Parameter | Finding |
|---|---|
| GCS | 12/15 (E3V4M5) |
| Pulse | 118/min, weak, thready |
| BP | 96/70 mmHg |
| RR | 32/min (Kussmaul breathing) |
| Temp | 37.8°C |
| SpO2 | 98% |
| Breath | Fruity/acetone odor (ketones) |
| Dehydration | Severe (dry mucosa, sunken eyes, poor turgor) |
| Pallor | Mild |
| Test | Value | Normal |
|---|---|---|
| Blood glucose | 542 mg/dL | 70-100 |
| ABG: pH | 7.06 | 7.35-7.45 |
| ABG: HCO3 | 8 mEq/L | 22-26 |
| ABG: PCO2 | 22 (compensatory) | 35-45 |
| Anion gap | 32 mEq/L | 8-12 |
| Serum Na+ | 128 mEq/L (corrected Na 136) | 136-145 |
| Serum K+ | 3.2 mEq/L (BEFORE insulin - may be depleted) | 3.5-5.0 |
| BUN | 42 mg/dL (dehydration) | 7-20 |
| Creatinine | 1.8 mg/dL | 0.6-1.2 |
| Serum ketones | Strongly positive | - |
| CBC | TLC 14,200 (infection/stress) | - |
A 50-year-old male with known alcoholic liver cirrhosis admitted with hematemesis (2 large episodes, ~500 mL fresh blood) and melena for 6 hours.
| Parameter | Finding |
|---|---|
| GCS | 13/15 |
| Pallor | Severe +++ |
| Jaundice | Present ++ |
| Pulse | 122/min, thready, weak |
| BP | 86/50 mmHg (supine) |
| Postural drop | +25 mmHg systolic |
| RR | 24/min |
| SpO2 | 95% |
| Drug | Dose | Route | Duration |
|---|---|---|---|
| Terlipressin | 2 mg IV q4h → 1 mg q4h | IV bolus | 72 hours |
| Somatostatin/Octreotide | 50 mcg bolus → 25-50 mcg/h | IV infusion | 72 hours |
| Pantoprazole | 80 mg bolus → 8 mg/h | IV infusion | 72 hours |
| Ceftriaxone | 1 g IV OD | IV | 7 days (SBP prophylaxis) |
A 65-year-old hypertensive male with sudden onset left-sided weakness, facial deviation, and slurred speech for 2 hours.
| Parameter | Finding |
|---|---|
| GCS | 14/15 |
| BP | 178/102 (both arms) |
| Pulse | 82/min, irregular |
| RR | 18/min |
A 72-year-old diabetic male admitted with high fever, low BP, confusion, and decreased urine output for 24 hours (source: UTI).
| Parameter | Finding |
|---|---|
| GCS | 10/15 |
| Temp | 39.6°C |
| HR | 118/min, weak |
| BP | 82/52 mmHg |
| RR | 26/min |
| SpO2 | 94% |
| UO | <0.5 mL/kg/h |
A 22-year-old male with pain starting around the navel and shifting to right iliac fossa over 24 hours, with nausea, vomiting, and fever.
| Parameter | Score |
|---|---|
| Migration of pain to RIF | 1 |
| Anorexia | 1 |
| Nausea/vomiting | 1 |
| Tenderness in RIF | 2 |
| Rebound tenderness | 1 |
| Elevated temperature | 1 |
| Leucocytosis | 2 |
| Shift to left | 1 |
| Total | 9/10 → HIGH RISK (≥7 = operate) |
A 24-year-old primigravida at 35 weeks gestation admitted with convulsions at home, BP 180/120, and pedal edema for 2 weeks.
| Parameter | Finding |
|---|---|
| GCS | 12/15 (post-ictal) |
| BP | 182/118 mmHg |
| Pulse | 106/min |
| RR | 20/min |
| SpO2 | 96% |
| Pedal edema | Bilateral pitting, up to knees |
| Facial puffiness | Present |
| Drug | Dose | Route |
|---|---|---|
| MgSO4 (Zuspan regimen) - FIRST LINE | ||
| Loading | 4 g in 20 mL NS over 20 min IV | IV slow |
| Maintenance | 1-2 g/h continuous infusion | IV infusion |
| Total treatment | 24h after delivery or last seizure | - |
| MONITOR FOR MgSO4 TOXICITY: | ||
| Knee jerks | Loss = toxicity (>7 mEq/L) | Check hourly |
| Urine output | >25 mL/h required | Foley catheter |
| RR | >12/min required | |
| Antidote if toxicity: | Calcium gluconate 1 g IV | IV push |
A 14-month-old male child brought with high fever and 2 episodes of generalized tonic-clonic convulsions lasting >5 minutes each, with bulging fontanelle and neck stiffness.
| Parameter | Finding | (Z-score) |
|---|---|---|
| Weight | 9.8 kg | (Normal for age) |
| Temp | 40.2°C | |
| HR | 164/min | Tachycardia |
| RR | 36/min | Tachypnea |
| BP | 90/60 mmHg | |
| SpO2 | 97% | |
| Anterior fontanelle | Bulging | Raised ICP |
| Skin | Macular purpuric rash on legs (non-blanching) | Meningococcemia? |
| CSF Parameter | Value | Interpretation |
|---|---|---|
| Opening pressure | 320 mm H2O | Raised |
| Appearance | Turbid, purulent | Bacterial |
| Glucose | 15 mg/dL | Low (<40% of blood) |
| Protein | 280 mg/dL | High |
| Cells | 3200 WBC (95% PMN) | Bacterial |
| Gram stain | Gram-negative diplococci | N. meningitidis |
| Drug | Dose | Route | Frequency |
|---|---|---|---|
| Inj. Cefotaxime | 100 mg/kg/day | IV | q6h (divided) |
| OR Ceftriaxone | 100 mg/kg/day | IV | q12h (divided) |
| Duration | 7-10 days for N. meningitidis |
┌──────────────────────────────────────────────────────────────┐
│ DATE: ___________ TIME: ___________ DAY: Day ___ of IPD │
│ Ward: ________ Bed No.: _______ IP No.: ________________ │
├──────────────────────────────────────────────────────────────┤
│ SUBJECTIVE (Patient's complaints): │
│ ____________________________________________________________ │
│ │
│ OBJECTIVE (Clinical findings today): │
│ Temp: ____°C HR: ____/min BP: ____mmHg RR: ____/min │
│ SpO2: ____% on ____L O2 Weight: ____kg UO: ____mL/h │
│ │
│ Examination: │
│ General: ___________________________________________________ │
│ System-specific: ___________________________________________ │
│ │
│ Investigation results today: │
│ ____________________________________________________________ │
│ │
│ ASSESSMENT: │
│ ____________________________________________________________ │
│ │
│ PLAN (for next 24 hours): │
│ 1. __________________________________________________________ │
│ 2. __________________________________________________________ │
│ 3. __________________________________________________________ │
│ │
│ Signature: _____________ Designation: _________________ │
└──────────────────────────────────────────────────────────────┘
┌──────────────────────────────────────────────────────────────┐
│ DISCHARGE SUMMARY │
│ IP No.: ________ Ward: ________ Bed: _______ │
├──────────────────────────────────────────────────────────────┤
│ Patient: ________________ Age: ___ Sex: ___ │
│ DOA (Date of Admission): ________ Time: ________ │
│ DOD (Date of Discharge): ________ Time: ________ │
│ Length of Stay: _________ days │
│ Admitted under: Dr. _________________________ │
├──────────────────────────────────────────────────────────────┤
│ PRESENTING COMPLAINTS: ______________________________________ │
│ │
│ DIAGNOSIS (Final): │
│ Primary: ___________________________________________________ │
│ Secondary: _________________________________________________ │
│ Comorbidities: _____________________________________________ │
├──────────────────────────────────────────────────────────────┤
│ HOSPITAL COURSE (Brief summary): │
│ ____________________________________________________________ │
│ ____________________________________________________________ │
├──────────────────────────────────────────────────────────────┤
│ KEY INVESTIGATIONS: │
│ ____________________________________________________________ │
├──────────────────────────────────────────────────────────────┤
│ PROCEDURES DONE: │
│ ____________________________________________________________ │
├──────────────────────────────────────────────────────────────┤
│ CONDITION AT DISCHARGE: │
│ □ Stable □ Improved □ Unchanged □ LAMA □ DAMA │
│ □ Referred to ___________________ │
├──────────────────────────────────────────────────────────────┤
│ DISCHARGE MEDICATIONS: │
│ 1. __________________________________________________________ │
│ 2. __________________________________________________________ │
│ 3. __________________________________________________________ │
│ (Attach separate prescription) │
├──────────────────────────────────────────────────────────────┤
│ DIETARY ADVICE: ____________________________________________ │
│ PHYSICAL ACTIVITY: _________________________________________ │
│ SPECIAL INSTRUCTIONS: ______________________________________ │
├──────────────────────────────────────────────────────────────┤
│ FOLLOW-UP: │
│ OPD: ________________________ Date: ______________________ │
│ Tests to bring: _____________________________________________│
│ Emergency: Return immediately if ___________________________ │
├──────────────────────────────────────────────────────────────┤
│ Consultant: Dr. ________________________ Sign: _________ │
│ Resident: Dr. __________________________ Sign: _________ │
│ Institution Stamp: ____________________ │
└──────────────────────────────────────────────────────────────┘
| Specialty | Case | Key Diagnosis Feature | Emergency Treatment |
|---|---|---|---|
| Medicine | STEMI | ST elevation ECG + Troponin | Aspirin + tPA / PCI |
| CAP | Consolidation + neutrophilia | Ceftriaxone + Azithromycin | |
| DKA | Glucose >250 + AG metabolic acidosis | Fluids + insulin (after K+) | |
| Stroke | NIHSS + CT head | Alteplase within 4.5h | |
| Sepsis | SOFA ≥2 + infection | 1-hour bundle | |
| UGI bleed | Hematemesis + melaena | Resuscitate + endoscopy | |
| Surgery | Acute appendicitis | Alvarado ≥7 + USG | Laparoscopic appendicectomy |
| Acute cholecystitis | Murphy's sign + gallstones | Antibiotics + cholecystectomy | |
| Intestinal obstruction | Absolute constipation + dilated loops | NG decompression + surgery | |
| Hernia (strangulated) | Tender irreducible swelling | Emergency repair | |
| Obs-Gyne | Eclampsia | Seizures + HTN + proteinuria | MgSO4 + antihypertensives + deliver |
| PPH | Blood loss >500 mL post-delivery | Oxytocin + uterine massage + bimanual | |
| Ectopic pregnancy | Amenorrhea + pain + free fluid | Emergency laparoscopy | |
| APH | Antepartum bleeding | Depends on placenta praevia vs. abruption | |
| Paediatrics | Meningitis | Neck stiffness + CSF findings | Ceftriaxone + dexamethasone |
| Bronchiolitis | Wheeze + hyperinflation in <2y | Oxygen + hydration | |
| Severe malnutrition | MUAC <11.5 cm + kwashiorkor/marasmus | F-75 → F-100 rehabilitation | |
| Febrile seizure | Fever + seizure, 6m-5yr | Rule out meningitis; diazepam | |
| Psychiatry | OD/self-harm | Toxidrome + psychiatric hx | Antidote + psychiatry |
| Acute psychosis | Hallucinations + delusions | Haloperidol/olanzapine | |
| Ortho | # NOF | Elderly + fall + short-limb externally rotated | Hemiarthroplasty |
| Compartment syndrome | 6 Ps: Pain, Pressure, Paresthesia, Paralysis, Pallor, Pulselessness | Fasciotomy STAT |
Generate a Word document with 10 more IPD cases (other specialties)
mkdir -p /home/daytona/workspace/ipd-cases && ls /home/daytona/workspace/ipd-cases/
~/ipd-cases/generate.js
const {
Document, Packer, Paragraph, TextRun, Table, TableRow, TableCell,
HeadingLevel, AlignmentType, BorderStyle, WidthType, ShadingType,
VerticalAlign, PageBreak, TableOfContents, PageNumber, Footer,
Header, NumberFormat
} = require('docx');
const fs = require('fs');
// ─── Helpers ──────────────────────────────────────────────────────────────────
const BLUE = "1F3864";
const LBLUE = "2E75B6";
const TEAL = "0070C0";
const GREY = "F2F2F2";
const WHITE = "FFFFFF";
const DKGREY = "595959";
function h1(text) {
return new Paragraph({
text, heading: HeadingLevel.HEADING_1,
spacing: { before: 400, after: 120 },
run: { color: WHITE }
});
}
function h2(text) {
return new Paragraph({
text, heading: HeadingLevel.HEADING_2,
spacing: { before: 300, after: 80 },
});
}
function h3(text) {
return new Paragraph({
children: [new TextRun({ text, bold: true, color: TEAL, size: 22 })],
spacing: { before: 200, after: 60 },
});
}
function h4(text) {
return new Paragraph({
children: [new TextRun({ text, bold: true, color: DKGREY, size: 20 })],
spacing: { before: 160, after: 40 },
});
}
function body(text, opts = {}) {
return new Paragraph({
children: [new TextRun({ text, size: 20, ...opts })],
spacing: { before: 60, after: 60 },
});
}
function bullet(text, level = 0) {
return new Paragraph({
children: [new TextRun({ text, size: 20 })],
bullet: { level },
spacing: { before: 40, after: 40 },
});
}
function pageBreak() {
return new Paragraph({ children: [new PageBreak()] });
}
function sectionBanner(text) {
return new Paragraph({
children: [new TextRun({ text, bold: true, color: WHITE, size: 28 })],
shading: { type: ShadingType.CLEAR, fill: LBLUE },
spacing: { before: 300, after: 200 },
alignment: AlignmentType.CENTER,
});
}
function caseHeader(num, title, specialty) {
return new Paragraph({
children: [
new TextRun({ text: `CASE ${num}: `, bold: true, color: WHITE, size: 26 }),
new TextRun({ text: title, bold: true, color: WHITE, size: 26 }),
new TextRun({ text: ` [${specialty}]`, color: "C9D1D9", size: 22 }),
],
shading: { type: ShadingType.CLEAR, fill: BLUE },
spacing: { before: 400, after: 200 },
indent: { left: 200 },
});
}
function subHeader(text) {
return new Paragraph({
children: [new TextRun({ text, bold: true, color: WHITE, size: 20 })],
shading: { type: ShadingType.CLEAR, fill: TEAL },
spacing: { before: 160, after: 80 },
indent: { left: 100 },
});
}
function note(text) {
return new Paragraph({
children: [new TextRun({ text: `📌 Note: ${text}`, italics: true, size: 18, color: "7030A0" })],
spacing: { before: 80, after: 80 },
indent: { left: 400 },
});
}
// Simple 2-col key-value table
function kvTable(rows) {
return new Table({
width: { size: 100, type: WidthType.PERCENTAGE },
rows: rows.map(([k, v]) => new TableRow({
children: [
new TableCell({
children: [new Paragraph({ children: [new TextRun({ text: k, bold: true, size: 18 })] })],
shading: { type: ShadingType.CLEAR, fill: GREY },
width: { size: 35, type: WidthType.PERCENTAGE },
}),
new TableCell({
children: [new Paragraph({ children: [new TextRun({ text: v, size: 18 })] })],
width: { size: 65, type: WidthType.PERCENTAGE },
}),
],
})),
margins: { top: 60, bottom: 60, left: 80, right: 80 },
});
}
// Multi-column header table
function headerTable(cols, rows) {
return new Table({
width: { size: 100, type: WidthType.PERCENTAGE },
rows: [
new TableRow({
children: cols.map(c => new TableCell({
children: [new Paragraph({ children: [new TextRun({ text: c, bold: true, size: 18, color: WHITE })] })],
shading: { type: ShadingType.CLEAR, fill: LBLUE },
verticalAlign: VerticalAlign.CENTER,
})),
tableHeader: true,
}),
...rows.map(row => new TableRow({
children: row.map((cell, i) => new TableCell({
children: [new Paragraph({ children: [new TextRun({ text: cell, size: 18 })] })],
shading: { type: ShadingType.CLEAR, fill: i === 0 ? GREY : WHITE },
})),
})),
],
margins: { top: 60, bottom: 60, left: 80, right: 80 },
});
}
function spacer() {
return new Paragraph({ text: "", spacing: { before: 80, after: 80 } });
}
// ─── Document Content ─────────────────────────────────────────────────────────
const children = [
// ── COVER PAGE ──────────────────────────────────────────────────────────────
new Paragraph({
children: [new TextRun({ text: "🏥 IPD CLINICAL CASES", bold: true, size: 56, color: BLUE })],
alignment: AlignmentType.CENTER,
spacing: { before: 1200, after: 200 },
}),
new Paragraph({
children: [new TextRun({ text: "Master Guide — 10 Additional Cases Across Specialties", size: 28, color: DKGREY, italics: true })],
alignment: AlignmentType.CENTER,
spacing: { before: 0, after: 600 },
}),
kvTable([
["Specialties Covered", "Nephrology · Pulmonology · Orthopaedics · Gastroenterology · Psychiatry · ENT · Ophthalmology · Haematology · Endocrinology · Dermatology"],
["Format", "PC → HOPI → PH → GPE → Systemic Exam → Diagnosis → Investigations → Treatment → Progress Notes → Discharge"],
["Purpose", "Ward rounds, clinical postings, MBBS / PG exam preparation, intern training"],
["Sources", "Goldman-Cecil Medicine · Harrison's Principles 22e · Schwartz's Surgery · Brenner & Rector's Kidney · Tintinalli's EM"],
]),
pageBreak(),
// ══════════════════════════════════════════════════════════════════════════
// CASE 1 — NEPHROLOGY: Acute Kidney Injury (AKI)
// ══════════════════════════════════════════════════════════════════════════
caseHeader(1, "ACUTE KIDNEY INJURY (AKI) — POST-OPERATIVE", "Nephrology"),
subHeader("PRESENTING COMPLAINTS"),
bullet("Decreased urine output — 24 hours"),
bullet("Swelling of face and lower limbs — 12 hours"),
bullet("Nausea and vomiting — 8 hours"),
bullet("Recent abdominal surgery (lap cholecystectomy) — 3 days ago"),
spacer(),
subHeader("HISTORY OF PRESENTING ILLNESS"),
body("60-year-old male, 3 days post laparoscopic cholecystectomy for acute cholecystitis. Day 1 post-op was uneventful. On Day 2, urine output began declining (<0.5 mL/kg/h). By Day 3, oliguric (<200 mL/day), facial and pedal edema appeared. Nausea and vomiting preventing oral intake. Pre-operative creatinine was 1.0 mg/dL. Received gentamicin + metronidazole post-op. History of hypertension and NSAID use for back pain for 6 months."),
spacer(),
subHeader("PAST / PERSONAL HISTORY"),
bullet("Hypertension — 8 years, on Amlodipine"),
bullet("NSAID (Diclofenac 50mg BD) × 6 months (nephrotoxic risk)"),
bullet("No prior CKD, no diabetes"),
spacer(),
subHeader("GENERAL PHYSICAL EXAMINATION"),
headerTable(["Parameter","Finding"],
[["Pulse","96/min"],["BP","158/100 mmHg"],["RR","20/min"],["SpO2","97%"],["Pedal edema","Bilateral pitting +++"],["Facial puffiness","Present"],["JVP","Elevated 5 cm"],["Urine output","80 mL in last 8h (oliguria)"]]),
spacer(),
subHeader("SYSTEMIC EXAMINATION"),
bullet("Cardiovascular: S1 S2 heard, no murmurs. JVP elevated."),
bullet("Respiratory: Bilateral basal crackles (fluid overload)"),
bullet("Abdomen: Surgical wound healing well. No peritonism."),
bullet("CNS: Alert, mildly confused (uraemic encephalopathy early)"),
spacer(),
subHeader("PROVISIONAL DIAGNOSIS"),
body("Acute Kidney Injury — Stage 2 (KDIGO) — Mixed Aetiology: Post-operative + aminoglycoside nephrotoxicity + NSAID-induced renal vasoconstriction", { bold: true }),
spacer(),
subHeader("DIFFERENTIAL DIAGNOSIS"),
bullet("Pre-renal AKI (inadequate post-op fluids)"),
bullet("Obstructive (ureteric injury post-surgery)"),
bullet("Acute tubular necrosis (ATN) from gentamicin"),
spacer(),
subHeader("INVESTIGATIONS"),
headerTable(["Test","Value","Interpretation"],
[["Serum Creatinine","4.2 mg/dL (baseline 1.0)","KDIGO Stage 2-3 AKI"],
["BUN","78 mg/dL","Uraemia"],
["Serum K+","5.8 mEq/L","Hyperkalaemia"],
["Na+","128 mEq/L","Dilutional hyponatraemia"],
["Bicarbonate","14 mEq/L","Metabolic acidosis"],
["CBC","TLC 14,200, Hb 9.8","Anaemia"],
["Urine Na+","<20 mEq/L (pre-renal component)","Tubular preservation"],
["FENa","<1%","Pre-renal or early ATN"],
["USG KUB","No hydronephrosis, normal echogenicity","No obstruction"],
["ECG","Peaked T-waves","Hyperkalaemia effect"],
["CXR","Pulmonary venous congestion","Fluid overload"]]),
spacer(),
subHeader("KDIGO AKI STAGING"),
headerTable(["Stage","Creatinine Criterion","Urine Output"],
[["1","1.5–1.9× baseline OR rise ≥0.3 mg/dL in 48h",">0.5 mL/kg/h"],
["2","2.0–2.9× baseline","0.5 mL/kg/h × 12h"],
["3 (This patient)","≥3× baseline OR Cr ≥4 mg/dL","<0.3 mL/kg/h × 24h or anuria 12h"]]),
spacer(),
subHeader("TREATMENT"),
h4("Immediate Management"),
bullet("STOP nephrotoxins: Gentamicin stopped, NSAIDs stopped, ACE inhibitors held"),
bullet("IV access — central line for monitoring"),
bullet("Foley catheter — strict input/output hourly"),
bullet("Fluid challenge (if pre-renal component): 250 mL NS bolus over 30 min → assess response"),
spacer(),
h4("Hyperkalaemia (K+ 5.8 — URGENT)"),
headerTable(["Drug","Dose","Mechanism","Onset"],
[["Calcium gluconate 10%","10 mL IV over 3 min","Cardiac membrane stabilisation","Immediate"],
["Insulin + Dextrose","10 units + 50 mL D50 IV","Shifts K+ intracellularly","15–30 min"],
["Sodium bicarbonate","50 mEq IV (if acidotic)","K+ redistribution","30 min"],
["Resonium (Kayexalate)","15g PO TDS","GI K+ removal","Hours"],
["Haemodialysis","If K+ >6.5 or ECG changes","Definitive removal","Immediate"]]),
spacer(),
h4("Fluid Management"),
bullet("No aggressive fluid loading — already fluid overloaded (JVP elevated, crackles)"),
bullet("Restrict fluids to insensible losses + previous hour urine output"),
bullet("Consider early dialysis for refractory fluid overload"),
spacer(),
h4("Metabolic Acidosis"),
bullet("If pH <7.2: Sodium bicarbonate 50-100 mEq IV infusion"),
bullet("Target pH >7.25"),
spacer(),
h4("Renal Replacement Therapy (RRT) Indications — AEIOU"),
bullet("A — Acidosis (pH <7.2 refractory)"),
bullet("E — Electrolytes (K+ >6.5 / refractory)"),
bullet("I — Intoxication (drug removal)"),
bullet("O — Overload (pulmonary oedema refractory to diuretics)"),
bullet("U — Uraemia (encephalopathy / pericarditis / Cr >10)"),
note("This patient meets 3 AEIOU criteria — nephrology consulted for CRRT/IHD"),
spacer(),
subHeader("PROGRESS NOTES"),
bullet("Day 1: Creatinine 4.2. K+ managed with insulin/dextrose + resonium. Fluid restricted. CRRT initiated."),
bullet("Day 3: Creatinine 3.8. Urine output improving to 0.8 mL/kg/h. K+ 4.9. Crackles reducing."),
bullet("Day 5: Creatinine 2.4. CRRT weaned. Diuretic phase begun (furosemide 80mg IV)."),
bullet("Day 8: Creatinine 1.6. Urine output 2 mL/kg/h (polyuric recovery phase). Oral diet tolerated."),
spacer(),
subHeader("DISCHARGE SUMMARY"),
bullet("Diagnosis: AKI Stage 3 — ATN + Nephrotoxic — recovered"),
bullet("Discharge creatinine: 1.4 mg/dL (near baseline)"),
bullet("Discharge medications: Antihypertensive resumed, no NSAIDs ever, no aminoglycosides"),
bullet("Follow-up: Nephrology OPD in 2 weeks with repeat RFT"),
bullet("Patient counselled: Avoid nephrotoxins (NSAIDs, ibuprofen, contrast agents)"),
pageBreak(),
// ══════════════════════════════════════════════════════════════════════════
// CASE 2 — PULMONOLOGY: Acute Exacerbation of COPD
// ══════════════════════════════════════════════════════════════════════════
caseHeader(2, "ACUTE EXACERBATION OF COPD (AECOPD)", "Pulmonology / Respiratory Medicine"),
subHeader("PRESENTING COMPLAINTS"),
bullet("Worsening breathlessness — 3 days"),
bullet("Increased cough with purulent (yellow-green) sputum — 5 days"),
bullet("Fever — 2 days"),
bullet("Unable to speak full sentences — 1 day"),
spacer(),
subHeader("HISTORY OF PRESENTING ILLNESS"),
body("68-year-old male, heavy smoker (45 pack-years, still smoking), known COPD on Tiotropium + LABA/ICS inhaler. Baseline dyspnoea: MRC Grade 3 (stops after walking 100m on flat). 3 days ago, breathlessness worsened acutely (now at rest), cough increased with thick purulent sputum (Anthonisen Type 1 exacerbation). Mild fever. No haemoptysis. No chest pain. Last exacerbation 4 months ago requiring hospitalisation. Has received influenza vaccine but not pneumococcal."),
spacer(),
subHeader("GENERAL PHYSICAL EXAMINATION"),
headerTable(["Parameter","Finding"],
[["Pulse","106/min"],["BP","142/88 mmHg"],["RR","28/min"],["SpO2","82% on room air"],["Temp","38.4°C"],["Cyanosis","Peripheral cyanosis present"],["Pursed-lip breathing","Present"],["Use of accessory muscles","Present (sternomastoid, scalenes)"],["Barrel chest","Present (AP diameter increased)"]]),
spacer(),
subHeader("SYSTEMIC EXAMINATION — RESPIRATORY"),
bullet("Inspection: Barrel-shaped chest, restricted chest expansion, accessory muscle use"),
bullet("Palpation: Trachea central, reduced tactile fremitus bilateral"),
bullet("Percussion: HYPERRESONANCE bilateral (air trapping)"),
bullet("Auscultation: Prolonged expiration, widespread expiratory wheeze + coarse crackles"),
bullet("No bronchial breathing (rules out consolidation currently)"),
spacer(),
subHeader("INVESTIGATIONS"),
headerTable(["Test","Value","Significance"],
[["ABG (on room air)","pH 7.31 / PaCO2 68 / PaO2 48 / HCO3 32","Type 2 RF + Compensated resp. acidosis"],
["SpO2","82% → 90% on controlled O2 2L","Hypoxaemia"],
["CXR","Hyperinflated lungs, flat diaphragm, no consolidation","Emphysema pattern"],
["Sputum C/S","H. influenzae — Ampicillin-sensitive","Infective exacerbation"],
["ECG","P pulmonale, RBBB pattern","Cor pulmonale (RVH)"],
["Echo","RV dilatation, PA pressure 52 mmHg","Pulmonary hypertension"],
["FEV1/FVC","0.55 (46% predicted)","GOLD Stage 3 COPD"],
["CBC","TLC 14,800, neutrophilia","Bacterial infection"],
["CRP","112 mg/L","Inflammation"]]),
spacer(),
subHeader("TREATMENT"),
h4("Controlled Oxygen Therapy (CRITICAL — hypercapnic drive)"),
bullet("Target SpO2 88–92% (NOT 96–100% — hyperoxia worsens CO2 retention)"),
bullet("24% or 28% Venturi mask (NOT NRB mask)"),
bullet("Repeat ABG in 30–60 min to check CO2 response"),
spacer(),
h4("Bronchodilators"),
headerTable(["Drug","Dose","Route","Frequency"],
[["Salbutamol (SABA)","2.5 mg","Nebuliser","Every 20 min × 3 then q4h"],
["Ipratropium (SAMA)","0.5 mg","Nebuliser","q6h (add to SABA neb)"],
["Aminophylline","5 mg/kg loading → 0.5 mg/kg/h","IV (if severe)","Continuous if nebulisers fail"]]),
spacer(),
h4("Corticosteroids"),
bullet("Prednisolone 40 mg PO OD × 5 days (or IV methylprednisolone 40 mg OD if PO not tolerated)"),
bullet("Reduces recovery time, treatment failure, length of stay"),
spacer(),
h4("Antibiotics (Anthonisen Type 1 — all 3 criteria: increased dyspnoea + sputum volume + purulence)"),
bullet("Amoxicillin-Clavulanate 625 mg PO TDS × 5–7 days"),
bullet("If Pseudomonas risk (frequent exacerbations, severe GOLD): Ciprofloxacin 400 mg IV BD"),
spacer(),
h4("Non-Invasive Ventilation (NIV — BiPAP)"),
bullet("Indication: pH <7.35 + PaCO2 >45 + RR >25 despite above measures"),
bullet("Settings: IPAP 12-20 cmH2O, EPAP 4-6 cmH2O"),
bullet("This patient: pH 7.31 → NIV INITIATED"),
bullet("Repeat ABG in 1-2h: pH 7.37, PaCO2 58 → Good response to NIV"),
spacer(),
h4("Invasive Ventilation Triggers"),
bullet("Failure of NIV (pH <7.25 on NIV), GCS <8, haemodynamic instability"),
spacer(),
subHeader("PROGRESS NOTES"),
bullet("Day 1: NIV started. SpO2 91%. pH improved to 7.37. Antibiotics + steroids started."),
bullet("Day 2: Off NIV 4h trials. SpO2 90% on 28% Venturi. Sputum less purulent."),
bullet("Day 3: Tolerating off NIV. Nebulisers q6h. Oral steroids continued."),
bullet("Day 5: SpO2 93% on room air. Wheeze reducing. Started weaning to MDI inhalers."),
spacer(),
subHeader("DISCHARGE"),
bullet("COPD review — upgrade to GOLD Group D management"),
bullet("Tiotropium 18 mcg OD + Indacaterol/Glycopyrronium (LABA/LAMA) + ICS (Budesonide/Formoterol)"),
bullet("Pulmonary rehabilitation referral"),
bullet("Pneumococcal vaccine today + Influenza annual"),
bullet("STRICT SMOKING CESSATION — NRT prescribed + counselling"),
bullet("Home O2 assessment (if SpO2 <88% on 6-min walk test)"),
pageBreak(),
// ══════════════════════════════════════════════════════════════════════════
// CASE 3 — ORTHOPAEDICS: Fracture Neck of Femur
// ══════════════════════════════════════════════════════════════════════════
caseHeader(3, "FRACTURE NECK OF FEMUR (# NOF)", "Orthopaedics"),
subHeader("PRESENTING COMPLAINTS"),
bullet("Fall from standing height — 6 hours ago"),
bullet("Pain in right hip — since fall"),
bullet("Inability to walk or bear weight — since fall"),
spacer(),
subHeader("HISTORY OF PRESENTING ILLNESS"),
body("78-year-old female with known osteoporosis (on bisphosphonate irregularly). Mechanical fall at home while going to bathroom at night. Immediate severe right hip pain. Unable to get up or weight-bear. No head injury, no loss of consciousness. Brought to hospital by family. Known hypertensive, on aspirin for AF."),
spacer(),
subHeader("GENERAL PHYSICAL EXAMINATION"),
headerTable(["Parameter","Finding"],
[["General","Anxious, in pain, co-operative"],["BP","138/84 mmHg"],["HR","88/min, irregular (AF)"],["Temp","37.0°C"],["SpO2","97%"],["Right lower limb","SHORTENED + EXTERNALLY ROTATED (classic)"],["Active movement","Absent (pain)"],["Passive movement","Severely restricted, pain on log-rolling"]]),
spacer(),
subHeader("SYSTEMIC EXAMINATION — ORTHOPAEDIC"),
bullet("Shortening: True shortening of right lower limb (2.5 cm vs left)"),
bullet("External rotation: Heel points outward ~90° (no internal rotation possible)"),
bullet("Tenderness: Groin/hip tenderness on axial loading"),
bullet("Neurovascular: Distal pulses palpable, sensation intact, toes moving"),
bullet("Bryant's triangle: Abnormal — loss of triangle on right"),
spacer(),
subHeader("INVESTIGATIONS"),
headerTable(["Test","Value","Significance"],
[["X-Ray Hip (AP + Lateral)","Displaced subcapital # neck of femur — Garden Grade IV","Surgical — hemiarthroplasty"],
["CBC","Hb 10.2, PLT 180,000","Pre-op anaemia"],
["PT/INR","1.2 (aspirin held)","Acceptable for surgery"],
["RFT","Normal","No CKD"],
["ECG","AF with normal ventricular rate","Rate controlled"],
["Echo","EF 58%, no significant valve disease","Fit for surgery"],
["DEXA scan (planned)","T-score −3.2 (osteoporosis)","Fragility fracture confirmed"],
["Blood group + crossmatch","A+ve","For operative blood loss"]]),
spacer(),
h4("Garden Classification"),
headerTable(["Grade","Description"],
[["I","Incomplete / valgus impacted — undisplaced"],
["II","Complete but undisplaced"],
["III","Complete, partially displaced"],
["IV (This patient)","Complete, fully displaced — avascular necrosis risk HIGH"]]),
spacer(),
subHeader("TREATMENT"),
h4("Pre-operative"),
bullet("Analgesia: Fascia iliaca block (nerve block) + Paracetamol 1g IV q6h"),
bullet("Avoid NSAIDs (age + renal risk + on aspirin)"),
bullet("Aspirin held 5 days before surgery (if time permits) — urgent case, proceed"),
bullet("Anticoagulation: Enoxaparin 20 mg SC (prophylactic dose until surgery, then therapeutic post-op for AF)"),
bullet("Blood transfusion if Hb <8 g/dL pre-op"),
bullet("Urinary catheter"),
bullet("IV fluids: Hartmann's 1L over 12h"),
bullet("NBM from midnight"),
spacer(),
h4("Surgical Management"),
bullet("CEMENTED HEMIARTHROPLASTY (Austin Moore or Thompson prosthesis) — preferred for displaced # NOF in elderly"),
bullet("Total Hip Replacement (THR): If pre-existing hip OA or high functional demand"),
bullet("Internal fixation (DHS/cannulated screws): For undisplaced # NOF (Garden I/II)"),
bullet("Timing: Surgery within 48h of admission → reduces mortality by 30%"),
spacer(),
h4("Post-operative"),
bullet("Day 1: Weight-bear as tolerated with frame (physiotherapy mobilisation)"),
bullet("Enoxaparin 40 mg SC OD × 28-35 days (VTE prophylaxis — high risk)"),
bullet("Transition AF anticoagulation: Start DOAC (Apixaban) Day 2 post-op"),
bullet("Fall prevention assessment: OT evaluation, bed rails, hip protectors"),
bullet("Pressure ulcer prevention: Regular turning, pressure mattress"),
spacer(),
h4("Osteoporosis Management (Secondary Fracture Prevention)"),
bullet("Zoledronic acid 5 mg IV infusion once yearly (preferred post # NOF)"),
bullet("Calcium 1200 mg + Vitamin D3 800-1000 IU OD (lifelong)"),
bullet("DEXA follow-up"),
spacer(),
subHeader("DISCHARGE"),
bullet("Day 5-7 post-op (when mobilising safely with frame)"),
bullet("Physiotherapy OPD × 6 weeks"),
bullet("Zoledronic acid infusion arranged"),
bullet("DOAC (Apixaban) for AF + extended VTE prophylaxis"),
bullet("Geriatric assessment: Falls risk, cognitive assessment, medication review"),
pageBreak(),
// ══════════════════════════════════════════════════════════════════════════
// CASE 4 — GASTROENTEROLOGY: Acute Pancreatitis
// ══════════════════════════════════════════════════════════════════════════
caseHeader(4, "ACUTE PANCREATITIS (SEVERE)", "Gastroenterology / Surgery"),
subHeader("PRESENTING COMPLAINTS"),
bullet("Severe epigastric pain radiating to back — 12 hours"),
bullet("Nausea and vomiting × 8 episodes — 12 hours"),
bullet("Fever — 6 hours"),
spacer(),
subHeader("HISTORY OF PRESENTING ILLNESS"),
body("48-year-old male, heavy alcohol drinker (daily ETOH, binge last night). Sudden onset severe epigastric pain, 10/10, band-like, radiating to back, partially relieved by leaning forward. Persistent vomiting. Fever. Similar but milder episode 6 months ago (not investigated). No gallstones known. No recent ERCP."),
spacer(),
subHeader("GENERAL PHYSICAL EXAMINATION"),
headerTable(["Parameter","Finding"],
[["Pulse","118/min (SIRS)"],["BP","94/62 mmHg (shock)"],["RR","26/min"],["Temp","38.8°C"],["SpO2","93%"],["Abdomen","Distended, exquisitely tender epigastrium"],["Grey Turner sign","Bruising in flanks (haemorrhagic pancreatitis)"],["Cullen sign","Periumbilical bruising (severe)"],["Bowel sounds","Absent (paralytic ileus)"]]),
spacer(),
subHeader("INVESTIGATIONS"),
headerTable(["Test","Value","Significance"],
[["Serum Amylase","2840 U/L (>3× normal)","Pancreatitis confirmed"],
["Serum Lipase","4210 U/L","More specific than amylase"],
["WBC","18,400 (SIRS criterion)","Systemic inflammation"],
["CRP","280 mg/L (>150 = severe)","Severe pancreatitis marker"],
["Serum Ca2+","1.8 mmol/L","Hypocalcaemia (saponification)"],
["Blood glucose","240 mg/dL","Islet cell damage"],
["ALT","320 U/L (3× normal)","Gallstone component possible"],
["Creatinine","2.4 mg/dL","AKI (organ failure = severe)"],
["PaO2 on ABG","58 mmHg","Respiratory failure (ARDS)"],
["CECT Abdomen","Pancreatic necrosis 50%, peripancreatic fluid, no pseudocyst yet","Balthazar Grade E"]]),
spacer(),
h4("SEVERITY SCORING"),
headerTable(["Score","Value","Interpretation"],
[["Ranson's Criteria (at 48h)","6/11","Severe (>3 = severe; >6 = high mortality)"],
["APACHE II","18","Severe pancreatitis"],
["BISAP Score","4/5","High mortality risk"],
["Revised Atlanta","Severe (organ failure >48h + necrosis)","ICU admission required"]]),
spacer(),
subHeader("TREATMENT"),
h4("Resuscitation (IV Fluid Therapy — CORNERSTONE)"),
bullet("Aggressive crystalloid resuscitation: Ringer's Lactate 500 mL/h × 2h, then 250 mL/h"),
bullet("Ringer's Lactate preferred over NS (reduces SIRS, lactic acidosis)"),
bullet("Target: HR <90, MAP >65, UO >0.5 mL/kg/h, Hct 35–44%"),
bullet("Monitor fluid responsiveness: avoid over-resuscitation → abdominal compartment syndrome"),
spacer(),
h4("Analgesia"),
bullet("IV Morphine 2-4 mg q4h PRN (opioid analgesia safe in pancreatitis)"),
bullet("Tramadol if morphine unavailable"),
bullet("Avoid NSAIDs (AKI risk)"),
spacer(),
h4("Nutrition"),
bullet("Nil orally until pain controlled AND bowel sounds return (usually 24-48h)"),
bullet("Early enteral nutrition via NG/NJ tube preferred over TPN"),
bullet("Start NG feeds within 48-72h (reduces infectious complications, gut barrier)"),
bullet("TPN only if enteral route not tolerated"),
spacer(),
h4("Antibiotics"),
bullet("NOT routinely given in acute pancreatitis"),
bullet("Indication: Proven infected necrosis (CT-guided FNA + positive culture)"),
bullet("If infected necrosis confirmed: Imipenem 500 mg IV q8h or Meropenem"),
spacer(),
h4("Organ Support"),
bullet("Respiratory: O2 via face mask, CPAP/BiPAP if SpO2 <90% — ARDS protocol"),
bullet("Renal: IV fluids, early nephrology consult if AKI persisting"),
bullet("ICU: APACHE >8, organ failure, haemodynamic instability"),
spacer(),
h4("Intervention"),
bullet("ERCP within 24h: Only if concurrent acute cholangitis (jaundice + fever + RUQ pain)"),
bullet("NOT for acute pancreatitis alone"),
bullet("Percutaneous drainage: For symptomatic pseudocyst or infected fluid collection >4cm"),
bullet("Necrosectomy: For infected pancreatic necrosis not responding to antibiotics (step-up approach)"),
spacer(),
subHeader("DISCHARGE"),
bullet("Duration: 7-14 days for severe acute pancreatitis"),
bullet("ABSOLUTE alcohol abstinence (counselling + disulfiram referral)"),
bullet("Cholecystectomy (if gallstone cause) — elective, 4-6 weeks after recovery"),
bullet("Endocrine follow-up: Diabetes monitoring (islet destruction)"),
bullet("Exocrine follow-up: Pancreatic enzyme replacement if steatorrhoea"),
pageBreak(),
// ══════════════════════════════════════════════════════════════════════════
// CASE 5 — PSYCHIATRY: Acute Psychotic Episode (First Episode)
// ══════════════════════════════════════════════════════════════════════════
caseHeader(5, "FIRST-EPISODE ACUTE PSYCHOSIS", "Psychiatry"),
subHeader("PRESENTING COMPLAINTS (Informant — mother)"),
bullet("Talking to self and laughing inappropriately — 3 weeks"),
bullet("Refusing to eat (fearful of food being poisoned) — 2 weeks"),
bullet("Aggressive behaviour, smashing objects — 3 days"),
bullet("Not sleeping for 4 days"),
spacer(),
subHeader("HISTORY OF PRESENTING ILLNESS"),
body("22-year-old unmarried male, 1st year engineering dropout. No prior psychiatric history. 3 weeks ago, started behaving oddly — laughing and talking to himself (responding to voices the family can hear no one else speaking). Became fearful that family was poisoning his food — refused all meals. Increasingly agitated over 3 days with aggressive behaviour (broke furniture). Insomnia for 4 days. History of cannabis use for 2 years (daily). No alcohol. No physical illness. No family history of psychosis. No recent stressors (exam failure 2 months ago)."),
spacer(),
subHeader("MENTAL STATUS EXAMINATION (MSE)"),
headerTable(["Domain","Finding"],
[["Appearance","Unkempt, suspicious, poor eye contact"],
["Behaviour","Agitated, hostile, guarded"],
["Speech","Disorganised, tangential, neologisms present"],
["Mood (subjective)","'They are trying to kill me'"],
["Affect","Incongruent — laughing while describing persecution"],
["Thought form","Thought disorder — loosening of associations"],
["Thought content","PERSECUTORY DELUSIONS (food poisoning, family conspiring); IDEAS OF REFERENCE (TV speaking to him)"],
["Perceptions","AUDITORY HALLUCINATIONS — voices commenting on actions (3rd person); VISUAL — sees shadows"],
["Cognition","Alert, oriented; attention impaired"],
["Insight","Absent — does not believe he is ill"],
["Judgement","Markedly impaired"]]),
spacer(),
subHeader("INVESTIGATIONS (to rule out organic cause)"),
headerTable(["Test","Value","Purpose"],
[["MRI brain","No abnormality","Rule out encephalitis, tumour"],
["EEG","Normal","Rule out temporal lobe epilepsy"],
["TFT","Normal","Hypothyroidism can mimic psychosis"],
["Blood glucose","Normal","Hypoglycaemia"],
["Urine drug screen","POSITIVE for cannabis (THC)","Cannabis-induced psychosis component"],
["ANA, anti-NMDAR Ab","Negative","Rule out autoimmune encephalitis"],
["LFT, RFT","Normal","Baseline for medication"],
["Prolactin","Baseline 12 ng/mL","Pre-antipsychotic baseline"]]),
spacer(),
subHeader("DIAGNOSIS"),
body("First Episode Psychosis (DSM-5: Schizophrenia spectrum disorder — Acute Psychotic Episode) with cannabis-use disorder. Duration >1 month with full criteria (hallucinations + delusions + disorganised speech + negative symptoms).", { bold: true }),
spacer(),
subHeader("TREATMENT"),
h4("Acute Management (Agitation Control)"),
bullet("Safe environment — de-escalation techniques first"),
bullet("Olanzapine 10 mg IM STAT (for acute agitation — fastest sedation)"),
bullet("OR Haloperidol 5 mg IM + Promethazine 25 mg IM (Droperidol if available)"),
bullet("Avoid physical restraint unless immediate danger"),
spacer(),
h4("Antipsychotic Therapy (First-line: Second-Generation Antipsychotics)"),
headerTable(["Drug","Starting Dose","Target","Side Effects to Monitor"],
[["Risperidone","1 mg OD → 2-4 mg OD","2–6 mg/day","EPS, prolactinaemia, weight gain"],
["Olanzapine","5 mg OD → 10-20 mg","10–20 mg/day","Weight gain, metabolic syndrome, sedation"],
["Quetiapine","50 mg OD → 150-400 mg","300–600 mg/day","Sedation, orthostatic hypotension"],
["Aripiprazole","10 mg OD","15–30 mg/day","Akathisia, activating, less metabolic"]]),
note("This patient: Risperidone 2 mg BD chosen (evidence for first-episode, fewer metabolic effects)"),
spacer(),
h4("Monitoring on Antipsychotics"),
bullet("Weight, BMI, waist circumference — monthly"),
bullet("Fasting glucose, lipid profile — at 3 months"),
bullet("ECG (QTc) — baseline + at 3 months"),
bullet("Prolactin level — at 3 months"),
bullet("EPS monitoring: AIMS scale (tardive dyskinesia), akathisia rating scale"),
spacer(),
h4("Non-pharmacological"),
bullet("Psychoeducation: Patient (when insight improves) + family"),
bullet("Family therapy — expressed emotion reduction"),
bullet("Cannabis cessation counselling — MANDATORY (cannabis perpetuates psychosis)"),
bullet("Cognitive Behavioural Therapy for Psychosis (CBTp) — after acute phase"),
bullet("Social rehabilitation (occupational therapy, vocational training)"),
spacer(),
subHeader("DISCHARGE"),
bullet("Duration: 2-4 weeks typical first-episode admission"),
bullet("Risperidone 3 mg BD on discharge"),
bullet("Outpatient psychiatry weekly for first month"),
bullet("Community mental health team involvement"),
bullet("ABSOLUTE cannabis cessation"),
bullet("Duration of antipsychotic: Minimum 1–2 years first episode (risk of relapse high if stopped early)"),
pageBreak(),
// ══════════════════════════════════════════════════════════════════════════
// CASE 6 — HAEMATOLOGY: Sickle Cell Crisis
// ══════════════════════════════════════════════════════════════════════════
caseHeader(6, "SICKLE CELL DISEASE — VASO-OCCLUSIVE CRISIS (VOC)", "Haematology"),
subHeader("PRESENTING COMPLAINTS"),
bullet("Severe bone pain — bilateral legs, back, chest — 24 hours"),
bullet("Fever — 12 hours"),
bullet("Shortness of breath — 6 hours"),
spacer(),
subHeader("HISTORY OF PRESENTING ILLNESS"),
body("28-year-old male, known HbSS (Sickle Cell Anaemia) since childhood, on Hydroxyurea and folic acid. Precipitated by recent upper respiratory tract infection + cold exposure. Classic vaso-occlusive pain — diffuse bone pain (bilateral tibias, lumbosacral back, sternum). Fever 38.9°C. New-onset breathlessness — concern for Acute Chest Syndrome (ACS). 6 prior VOC admissions, 2 prior ACS episodes."),
spacer(),
subHeader("GENERAL PHYSICAL EXAMINATION"),
headerTable(["Parameter","Finding"],
[["Built","Thin, asthenic"],["Pallor","Severe +++"],["Jaundice","Mild (haemolytic)"],["BP","110/72 mmHg"],["HR","112/min"],["RR","26/min"],["SpO2","93%"],["Temp","38.9°C"],["Joints","No synovitis, but exquisite bone tenderness bilateral tibiae"]]),
spacer(),
subHeader("INVESTIGATIONS"),
headerTable(["Test","Value","Significance"],
[["Hb","6.2 g/dL","Haemolytic anaemia"],
["Reticulocyte count","12% (elevated)","Active haemolysis + marrow response"],
["Peripheral smear","Sickle cells, target cells, Howell-Jolly bodies","Sickling + functional asplenia"],
["LDH","1280 U/L","Haemolysis marker"],
["Indirect bilirubin","4.2 mg/dL","Haemolytic jaundice"],
["Blood cultures × 2","Pending","Infectious precipitant"],
["CXR","New infiltrate right lower lobe","ACUTE CHEST SYNDROME"],
["PaO2","61 mmHg","Hypoxaemia"],
["RFT","Cr 1.6 mg/dL","Sickle nephropathy (baseline slightly impaired)"],
["Echo","LV mildly dilated, PA pressure 40 mmHg","Pulmonary hypertension (chronic)"]]),
spacer(),
subHeader("DIAGNOSIS"),
body("Sickle Cell Vaso-Occlusive Crisis complicated by ACUTE CHEST SYNDROME (new infiltrate + hypoxia + fever + respiratory symptoms)", { bold: true }),
spacer(),
subHeader("TREATMENT"),
h4("Pain Management — PRIORITY"),
bullet("IV access — large bore"),
bullet("IV Morphine: 0.1 mg/kg bolus q20-30 min until pain controlled, then PCA (patient-controlled analgesia) 0.02 mg/kg/dose with 8-min lockout"),
bullet("IV/Oral Paracetamol 1g q6h (regular)"),
bullet("NSAID (Ketorolac 15-30 mg IV q6h × 5 days only — caution in sickle nephropathy)"),
bullet("Pain assessment q2h — NRS scale"),
spacer(),
h4("Acute Chest Syndrome Management"),
bullet("O2 to maintain SpO2 >95% (incentive spirometry reduces ACS)"),
bullet("Bronchodilators: Salbutamol nebuliser q4h"),
bullet("ANTIBIOTICS for ACS (atypical organisms common): Ceftriaxone 1g IV OD + Azithromycin 500 mg OD"),
bullet("BLOOD TRANSFUSION: Exchange transfusion is treatment of choice for moderate-severe ACS"),
bullet(" → Target HbS <30% after exchange transfusion"),
bullet(" → Simple top-up transfusion if Hb <6 or falling rapidly"),
spacer(),
h4("Fluids & Supportive Care"),
bullet("IV fluids: NS or D5NS 1.5× maintenance (avoid dehydration — worsens sickling)"),
bullet("Folic acid 5 mg OD (ongoing)"),
bullet("Incentive spirometry every 2h (prevents ACS progression)"),
spacer(),
h4("Hydroxyurea (long-term Disease-Modifying)"),
bullet("Continue hydroxyurea 15-35 mg/kg/day OD (reduces crisis frequency by 50%, ACS by 30%, mortality)"),
bullet("Target HbF increase to >20%"),
spacer(),
subHeader("DISCHARGE"),
bullet("Oral opioids for 48-72h tapering"),
bullet("Hydroxyurea dose review"),
bullet("Penicillin V 250 mg BD (lifelong — functional asplenia → encapsulated organism prophylaxis)"),
bullet("Pneumococcal vaccine (PCV13 + PPSV23) + Meningococcal + Hib (if not given)"),
bullet("Haematology OPD 2 weeks"),
pageBreak(),
// ══════════════════════════════════════════════════════════════════════════
// CASE 7 — ENDOCRINOLOGY: Thyroid Storm
// ══════════════════════════════════════════════════════════════════════════
caseHeader(7, "THYROID STORM (THYROTOXIC CRISIS)", "Endocrinology"),
subHeader("PRESENTING COMPLAINTS"),
bullet("Agitation and confusion — 12 hours"),
bullet("Very high fever — 6 hours"),
bullet("Heart racing and palpitations — 3 days"),
bullet("Known hyperthyroidism — on treatment but stopped medications 2 weeks ago"),
spacer(),
subHeader("HISTORY OF PRESENTING ILLNESS"),
body("35-year-old female, known Graves' disease on Carbimazole — STOPPED medications 2 weeks ago due to 'side effects'. Precipitated by URI 5 days ago. Presented with fever 41°C, extreme restlessness, confusion, tachycardia (HR 168). Nausea, vomiting, diarrhoea. Proptosis noted by family (worsening). Tremor of hands. No symptoms of adrenal insufficiency."),
spacer(),
subHeader("GENERAL PHYSICAL EXAMINATION"),
headerTable(["Parameter","Finding"],
[["Temp","41.2°C (HIGH — key feature)"],["HR","168/min (Atrial fibrillation on ECG)"],["BP","160/60 mmHg (wide pulse pressure)"],["RR","28/min"],["SpO2","96%"],["Sweating","Profuse diaphoresis"],["Thyroid","Diffuse goitre, bruit present"],["Eyes","Proptosis, lid lag, lid retraction, chemosis (Graves' ophthalmopathy)"],["Tremor","Fine tremor bilateral hands"],["Skin","Warm, moist, flushed"],["GCS","12/15 — confused"]]),
spacer(),
h4("Burch-Wartofsky Score (BWS) — Thyroid Storm Diagnostic Score"),
headerTable(["Parameter","Score Points This Patient"],
[["Temperature 41.2°C","+30"],["HR 168 (>140)","+25"],["AF","+10"],["Marked agitation","+10"],["Diarrhoea/vomiting","+10"],["Absent cardiac failure","+0"],["Total","85 (>45 = Thyroid Storm confirmed)"]]),
spacer(),
subHeader("INVESTIGATIONS"),
headerTable(["Test","Value","Significance"],
[["TSH","<0.001 mIU/L (suppressed)","Confirms hyperthyroidism"],
["Free T4","78 pmol/L (NL: 12-22)","Severely elevated"],
["Free T3","22 pmol/L (NL: 3.5-6.5)","Severely elevated"],
["TSH receptor Ab (TRAb)","Strongly positive","Graves' disease"],
["ECG","AF 168/min","Thyroid-induced AF"],
["LFT","ALT 120, Bili 2.4","Hepatic involvement"],
["CBC","Leukocytosis (infection)","URI precipitant"],
["Blood glucose","78 mg/dL","Normal"],
["Cortisol","28 mcg/dL","Rules out adrenal crisis"]]),
spacer(),
subHeader("TREATMENT — SEQUENCE CRITICAL"),
note("Give drugs in this ORDER: 1. Beta-blocker FIRST → 2. PTU/Carbimazole → 3. Iodine (1h after PTU) → 4. Steroids"),
spacer(),
h4("Step 1: Beta-Blocker (FIRST and FASTEST — controls symptoms)"),
bullet("Propranolol 40-80 mg PO q6h (OR 1-2 mg IV slowly if oral not possible)"),
bullet("Controls tachycardia, tremor, agitation, hyperthermia"),
bullet("Target HR <100 bpm"),
spacer(),
h4("Step 2: Anti-thyroid Drug (Block new hormone synthesis)"),
bullet("Propylthiouracil (PTU) 200 mg q4h (preferred in thyroid storm — also blocks T4→T3 conversion)"),
bullet("OR Carbimazole 20-30 mg q4-6h (if PTU unavailable)"),
spacer(),
h4("Step 3: Iodine (Lugol's Iodine — give 1 HOUR AFTER PTU)"),
bullet("Lugol's Iodine 5-10 drops PO TDS (inhibits thyroid hormone release — Wolff-Chaikoff effect)"),
bullet("MUST be given after PTU — if iodine given first, it can be used as substrate to make MORE T4"),
spacer(),
h4("Step 4: Corticosteroids"),
bullet("Hydrocortisone 100 mg IV q8h (prevents adrenal insufficiency + reduces T4→T3 conversion)"),
bullet("Dexamethasone 2 mg q6h is alternative"),
spacer(),
h4("Supportive"),
bullet("IV fluids: NS + D5W (replace losses from fever, vomiting, diarrhoea)"),
bullet("Cooling: Paracetamol + cooling blankets (avoid aspirin — displaces T4 from binding protein)"),
bullet("Cholestyramine: 4 g QDS (reduces enterohepatic recirculation of thyroid hormones)"),
bullet("AF rate control: Diltiazem if beta-blocker insufficient (avoid digoxin — reduced efficacy in hyperthyroid state)"),
bullet("ICU admission"),
spacer(),
subHeader("DISCHARGE"),
bullet("Thyroid storm resolved in 3-5 days with treatment"),
bullet("Carbimazole + Propranolol (tapering as euthyroid state achieved)"),
bullet("Definitive treatment: Radioiodine (I-131) or thyroidectomy after 6-8 weeks euthyroid"),
bullet("Ophthalmology referral (Graves' ophthalmopathy — selenium, steroids)"),
bullet("MEDICATION COMPLIANCE counselling — never stop anti-thyroid drugs abruptly"),
pageBreak(),
// ══════════════════════════════════════════════════════════════════════════
// CASE 8 — ENT: Peritonsillar Abscess (Quinsy)
// ══════════════════════════════════════════════════════════════════════════
caseHeader(8, "PERITONSILLAR ABSCESS (QUINSY)", "ENT / Head & Neck Surgery"),
subHeader("PRESENTING COMPLAINTS"),
bullet("Severe sore throat — 7 days (worsening despite antibiotics)"),
bullet("Difficulty swallowing liquids — 3 days"),
bullet("Muffled 'hot-potato' voice — 2 days"),
bullet("Inability to open mouth fully (trismus) — 2 days"),
bullet("Fever and neck pain — 5 days"),
spacer(),
subHeader("HISTORY OF PRESENTING ILLNESS"),
body("24-year-old male, sore throat for 7 days — was prescribed amoxicillin from pharmacy 5 days ago (no improvement). Worsening throat pain, now unable to swallow even saliva. Muffled voice (bulging pharynx elevating soft palate). Jaw stiffness preventing full mouth opening (trismus). Fever 39.2°C, right-sided neck pain. Drooling present. No rash (rules out scarlet fever). No stridor (important — airway not obstructed yet)."),
spacer(),
subHeader("GPE + ENT EXAMINATION"),
headerTable(["Parameter","Finding"],
[["BP","118/76, HR 104, Temp 39.2°C",""],
["Mouth opening","Limited — 2.5 cm (trismus)",""],
["Oropharynx","Uvula DEVIATED to LEFT side (abscess on right)",""],
["Right tonsil","Displaced medially + downward; peritonsillar BULGE right superior pole",""],
["Soft palate","Right soft palate bulging, erythematous",""],
["Cervical nodes","Right submandibular lymphadenopathy — tender",""],
["Stridor","ABSENT (airway safe currently)",""],
["Drooling","Present",""]]),
spacer(),
subHeader("INVESTIGATIONS"),
headerTable(["Test","Result"],
[["CBC","TLC 22,000, Neutrophils 90% — bacterial infection"],
["CRP","196 mg/L"],
["Blood culture","Pending"],
["Throat swab","Group A Streptococcus (GAS)"],
["CT Neck with contrast","Right peritonsillar rim-enhancing abscess 2.8 × 2.1 cm with central hypodensity (pus)"],
["Lateral neck X-ray","No epiglottitis, no deep space infection extension"],
["Monospot test","Negative (rule out EBV tonsillitis)"]]),
spacer(),
subHeader("TREATMENT"),
h4("Immediate"),
bullet("IV access + IV fluids (dehydrated — unable to swallow)"),
bullet("IV Paracetamol 1g q6h + IV Dexamethasone 10 mg STAT (reduces swelling, improves airway, reduces hospital stay)"),
bullet("IV Benzylpenicillin 1.2g q6h + Metronidazole 500 mg q8h"),
bullet("Anti-emetic: IV Ondansetron 4mg q8h"),
spacer(),
h4("Definitive — DRAINAGE (Surgical Emergency)"),
bullet("NEEDLE ASPIRATION (first-line, safe, diagnostic + therapeutic):"),
bullet(" → Local anaesthetic spray (lignocaine 10% topical)"),
bullet(" → 18G needle inserted into point of maximum fluctuance (superior pole)"),
bullet(" → Aspirate pus: Send for C/S"),
bullet(" → Can repeat if recollects (success rate 90%)"),
bullet("INCISION AND DRAINAGE (I&D): If aspiration fails or recollects"),
bullet("INTERVAL TONSILLECTOMY: 6-8 weeks after resolution (if ≥2 quinsy episodes)"),
bullet(" → HOT tonsillectomy (at time of acute): Controversial, increases bleed risk"),
spacer(),
h4("Airway Precautions"),
bullet("Monitor stridor, SpO2, ability to swallow hourly"),
bullet("ENT emergency kit at bedside (laryngoscope, ETT, cricothyrotomy kit)"),
bullet("Anaesthesia team on standby if airway compromise develops"),
spacer(),
subHeader("DISCHARGE (Day 3-5)"),
bullet("IV antibiotics → Oral Amoxicillin-Clavulanate 625 mg TDS × 10 days"),
bullet("Prednisolone tapering dose (5 days)"),
bullet("Soft diet, adequate hydration"),
bullet("ENT OPD for tonsillectomy planning"),
bullet("Throat swab culture result — target antibiotics"),
pageBreak(),
// ══════════════════════════════════════════════════════════════════════════
// CASE 9 — OPHTHALMOLOGY: Acute Angle Closure Glaucoma
// ══════════════════════════════════════════════════════════════════════════
caseHeader(9, "ACUTE ANGLE CLOSURE GLAUCOMA (AACG)", "Ophthalmology"),
subHeader("PRESENTING COMPLAINTS"),
bullet("Sudden onset severe right eye pain — 4 hours"),
bullet("Blurred vision right eye — 4 hours"),
bullet("Halos around lights — 4 hours"),
bullet("Nausea and vomiting — 3 hours"),
bullet("Severe headache — 3 hours"),
spacer(),
subHeader("HISTORY OF PRESENTING ILLNESS"),
body("62-year-old hypermetropic female (known far-sighted), no prior eye disease. Sudden severe right eye pain starting 4 hours ago after watching a film in a dark theatre (pupil dilation in dark → precipitates angle closure). Immediate blurred vision, seeing rainbow halos around lights (corneal oedema). Severe nausea and vomiting (systemic response to acute IOP rise). Severe frontal headache. Patient initially went to Emergency thinking it was a migraine or acute abdomen — correct diagnosis often delayed."),
subHeader("OPHTHALMIC EXAMINATION"),
headerTable(["Finding","Right Eye","Left Eye"],
[["Visual Acuity","6/60 (severely reduced)","6/6 (normal)"],
["IOP (Tonometry)","62 mmHg (MARKEDLY ELEVATED)","14 mmHg (normal)"],
["Cornea","CLOUDY, hazy (oedematous)","Clear"],
["Anterior chamber","SHALLOW + Flare + Cells","Normal depth"],
["Pupil","MID-DILATED, FIXED, oval, non-reactive (5-6mm)","Normal 3mm, reactive"],
["Fundoscopy","Disc margins blurred (difficult to see — cloudy cornea)","Normal"],
["Gonioscopy","Closed drainage angle (360°)","Narrow angle (prophylactic treatment)"]]),
spacer(),
subHeader("DIAGNOSIS"),
body("ACUTE ANGLE CLOSURE GLAUCOMA — Right Eye (Ophthalmic Emergency)", { bold: true }),
note("IOP >40 mmHg = ophthalmic emergency. Every hour of elevated IOP = permanent optic nerve damage and visual field loss."),
spacer(),
subHeader("TREATMENT — EMERGENCY"),
h4("Immediate Pressure Reduction (Medical — within MINUTES)"),
headerTable(["Drug","Dose","Mechanism","Route"],
[["Acetazolamide","500 mg IV STAT → 250 mg PO q6h","Carbonic anhydrase inhibitor → reduces aqueous production","IV then oral"],
["Mannitol 20%","1-2 g/kg IV over 45 min","Osmotic — reduces vitreous volume","IV drip"],
["Timolol 0.5%","1 drop right eye","Beta-blocker → reduces aqueous production","Topical"],
["Brimonidine 0.2%","1 drop right eye q8h","Alpha-2 agonist → reduces production","Topical"],
["Pilocarpine 2%","1 drop q15 min × 4 (once IOP <40)","Miotic — pulls iris away from angle","Topical"]]),
note("Do NOT give pilocarpine when IOP >40 mmHg (ischaemic iris sphincter won't respond; may worsen)"),
spacer(),
h4("Anti-emetics"),
bullet("IV Metoclopramide 10 mg (vomiting makes patient unable to take drops/oral meds)"),
spacer(),
h4("Definitive Treatment — Laser Iridotomy (within 24-48h)"),
bullet("Nd:YAG Laser Peripheral Iridotomy (LPI): Creates a hole in the iris to bypass pupil block"),
bullet("Relieves angle closure permanently"),
bullet("Should be performed in BOTH eyes (fellow eye prophylactic LPI — narrow angles bilaterally)"),
bullet("If laser not available: Surgical iridectomy"),
spacer(),
h4("Target IOP"),
bullet("Reduce IOP to <21 mmHg within 2-4 hours to prevent permanent visual loss"),
bullet("Repeat IOP measurement every 1 hour until controlled"),
spacer(),
subHeader("DISCHARGE"),
bullet("Laser iridotomy both eyes performed — confirmed patent"),
bullet("Continue Timolol + Brimonidine drops if IOP remains slightly elevated"),
bullet("Ophthalmology follow-up Day 1, Week 1, Month 1, then 6-monthly"),
bullet("Avoid dim-light environments, sympathomimetic medications (antihistamines, antidepressants)"),
bullet("Alert card: 'Patient has narrow angles — avoid mydriatic drops'"),
bullet("Visual acuity: Partial recovery expected; permanent loss depends on nerve damage sustained"),
pageBreak(),
// ══════════════════════════════════════════════════════════════════════════
// CASE 10 — DERMATOLOGY: Stevens-Johnson Syndrome (SJS)
// ══════════════════════════════════════════════════════════════════════════
caseHeader(10, "STEVENS-JOHNSON SYNDROME (SJS) / TOXIC EPIDERMAL NECROLYSIS (TEN)", "Dermatology"),
subHeader("PRESENTING COMPLAINTS"),
bullet("Skin rash with blistering — 4 days (started as red macules)"),
bullet("Painful erosions in mouth — 5 days"),
bullet("Eye redness and discharge — 4 days"),
bullet("Genital sores — 3 days"),
bullet("Started cotrimoxazole 10 days ago for UTI"),
spacer(),
subHeader("HISTORY OF PRESENTING ILLNESS"),
body("32-year-old female started cotrimoxazole (Trimethoprim-Sulphamethoxazole) 10 days ago for a urinary tract infection. 5 days ago, painful oral ulcers developed. 4 days ago, widespread tender red-purple macules appeared on trunk, face, and extremities, rapidly developing into fluid-filled blisters that ruptured leaving raw denuded areas. Bilateral conjunctivitis. Genital mucosal erosions. Fever 39°C. Painful swallowing (oesophageal mucosa involved). Similar drugs: Sulfa drugs, NSAIDs, anticonvulsants are most common culprits."),
spacer(),
subHeader("GENERAL PHYSICAL EXAMINATION"),
headerTable(["Parameter","Finding"],
[["Temp","39.1°C"],["HR","108/min"],["BP","106/72 mmHg"],["SpO2","96%"],
["Skin — trunk/extremities","DETACHMENT: Confluent dusky-red macules with blistering; Nikolsky sign POSITIVE; 25–30% BSA denudation"],
["Oral cavity","Extensive haemorrhagic erosions, crusting of lips"],
["Eyes","Bilateral conjunctival injection + pseudomembrane formation"],
["Genitalia","Erosions on labia majora"],
["Airway","Hoarse voice — mucosal involvement — ALERT"]]),
spacer(),
h4("SJS vs TEN Classification"),
headerTable(["Diagnosis","BSA Detachment","Mortality"],
[["SJS","<10%","<5%"],
["SJS-TEN Overlap (This patient)","10-30%","~15%"],
["TEN (Lyell's disease)",">30%","25-35%"]]),
spacer(),
h4("SCORTEN Severity Score (Predict mortality)"),
headerTable(["Criterion","This Patient"],
[["Age >40 years","No (0)"],
["Malignancy","No (0)"],
["Heart rate >120","No (0)"],
["BSA involvement >10%","Yes (1)"],
["Serum urea >10 mmol/L","Yes (1)"],
["Serum bicarbonate <20","Yes (1)"],
["Serum glucose >14 mmol/L","No (0)"],
["Total SCORTEN","3 → Predicted mortality 35%"]]),
spacer(),
subHeader("INVESTIGATIONS"),
headerTable(["Test","Value"],
[["CBC","Hb 9.8, WBC 14,200 (neutrophilia), PLT 88,000 (thrombocytopenia — poor prognosis)"],
["LFT","Bilirubin 2.8, ALT 190 (hepatic involvement)"],
["RFT","Creatinine 1.8 (AKI — fluid loss + sepsis)"],
["Urine","Protein 2+, RBC + (renal tubular involvement)"],
["Blood cultures","PENDING (risk of sepsis from denuded skin)"],
["Skin biopsy","Full-thickness epidermal necrosis — confirms TEN/SJS"],
["HLA-B*1502","Pending (pharmacogenomics — SJS risk for carbamazepine in Asians)"]]),
spacer(),
subHeader("TREATMENT"),
h4("IMMEDIATE — STOP CAUSATIVE DRUG"),
body("COTRIMOXAZOLE STOPPED IMMEDIATELY. Every day the drug continues worsens outcome. Document in allergy records.", { bold: true, color: "C00000" }),
spacer(),
h4("BURNS UNIT / ICU Transfer"),
bullet("Manage like major burns patient — burns unit or ICU"),
bullet("Isolated room, reverse barrier nursing (immunocompromised skin)"),
spacer(),
h4("Wound Care"),
bullet("Non-adherent dressings (Biobrane, Mepitel, petroleum gauze) — do NOT use adhesive dressings"),
bullet("Gentle debridement of necrotic epidermis"),
bullet("Hydrogel for denuded areas"),
bullet("Avoid topical antibiotics routinely (sensitisation risk)"),
spacer(),
h4("Fluid Replacement"),
bullet("Calculate as burns: Parkland formula (3-4 mL/kg per % BSA involved)"),
bullet("This patient (60 kg, 25% BSA): 3 × 60 × 25 = 4500 mL RL over 24h"),
bullet("Monitor urine output hourly — target 0.5-1 mL/kg/h"),
spacer(),
h4("Nutritional Support"),
bullet("Early NG feeding: High protein (2 g/kg/day) — massive protein losses from denuded skin"),
bullet("Vitamin C 1g OD + Vitamin E 400 IU OD"),
spacer(),
h4("Ophthalmology — URGENT"),
bullet("Lubricating eye drops every 2h (artificial tears)"),
bullet("Topical antibiotics if secondary infection"),
bullet("Amniotic membrane transplant if pseudomembranes forming"),
bullet("Daily eye review (risk of symblepharon, corneal scarring, blindness)"),
spacer(),
h4("Immunomodulatory Therapy (Controversial)"),
bullet("Cyclosporin A 3 mg/kg/day IV: Best evidence for halting disease progression (recent RCTs)"),
bullet("IVIG 1 g/kg/day × 3 days: Second option — inhibits Fas-FasL apoptosis"),
bullet("Steroids: AVOID — increase infection, mortality in most studies"),
bullet("Biologics: Infliximab (anti-TNF) — case reports, emerging evidence"),
spacer(),
h4("Infection Prevention"),
bullet("Active surveillance cultures weekly (skin/blood/urine)"),
bullet("Prophylactic antibiotics NOT recommended — treat infection when confirmed"),
bullet("Silver sulfadiazine AVOIDED (contains sulfonamide — same drug class that caused SJS)"),
spacer(),
subHeader("DISCHARGE NOTES"),
bullet("Survivors: Permanent sequelae in 35-50% — corneal scarring, dry eye, vaginal stenosis, oesophageal stricture, nail loss"),
bullet("Dermatology + Ophthalmology + Gynaecology long-term follow-up"),
bullet("Medical alert bracelet: 'ALLERGIC TO SULFONAMIDES — risk of TEN'"),
bullet("Register with pharmacovigilance database"),
bullet("Patch test NEVER — risk of recurrence"),
bullet("Educate entire family about allergy — potential genetic predisposition"),
pageBreak(),
// ── Final Page: Quick Summary Table ─────────────────────────────────────
sectionBanner("QUICK REFERENCE SUMMARY — ALL 10 CASES"),
headerTable(
["#","Specialty","Diagnosis","Key Hallmark","Critical Treatment"],
[
["1","Nephrology","AKI Stage 3","Oliguria + Creatinine ×3 baseline","STOP nephrotoxins; RRT if AEIOU met"],
["2","Pulmonology","AECOPD + Type 2 RF","PaCO2↑ + pH 7.31 + SpO2 82%","Controlled O2 (88-92%) + NIV + Steroids"],
["3","Orthopaedics","# NOF Garden IV","Short + Externally rotated leg","Cemented hemiarthroplasty within 48h"],
["4","Gastroenterology","Severe Acute Pancreatitis + ACS","Grey Turner + Cullen + Ranson 6","Aggressive Ringer's Lactate + Exchange transfusion"],
["5","Psychiatry","First Episode Psychosis","Hallucinations + Delusions + Thought disorder","Risperidone + Cannabis cessation"],
["6","Haematology","Sickle Cell VOC + ACS","New infiltrate + HbSS + bone pain","IV Morphine + Exchange transfusion + O2"],
["7","Endocrinology","Thyroid Storm","Temp 41°C + HR 168 + BWS 85","Beta-blocker → PTU → Iodine → Steroids (in order)"],
["8","ENT","Peritonsillar Abscess","Uvula deviation + trismus + bulge","Needle aspiration + Penicillin + Dexamethasone"],
["9","Ophthalmology","Acute Angle Closure Glaucoma","IOP 62 + fixed mid-dilated pupil + cloudy cornea","IV Acetazolamide + Mannitol → Laser Iridotomy"],
["10","Dermatology","SJS/TEN","Nikolsky + 25% BSA denudation","STOP drug + Burns care + Cyclosporin/IVIG + Ophthalmology"],
]
),
spacer(),
new Paragraph({
children: [new TextRun({ text: "Sources: Goldman-Cecil Medicine · Harrison's Principles 22e · Tintinalli's Emergency Medicine · Schwartz's Surgery · Brenner & Rector's Kidney · Current Surgical Therapy 14e · Rosen's Emergency Medicine", italics: true, size: 16, color: DKGREY })],
alignment: AlignmentType.CENTER,
spacing: { before: 300, after: 100 },
}),
];
// ─── Build & Save ─────────────────────────────────────────────────────────────
const doc = new Document({
title: "IPD Clinical Cases Master Guide",
description: "10 IPD cases across specialties",
styles: {
paragraphStyles: [
{
id: "Heading1", name: "Heading 1",
basedOn: "Normal", next: "Normal",
run: { size: 28, bold: true, color: WHITE },
paragraph: { spacing: { before: 400, after: 160 }, shading: { type: ShadingType.CLEAR, fill: BLUE } },
},
{
id: "Heading2", name: "Heading 2",
basedOn: "Normal", next: "Normal",
run: { size: 24, bold: true, color: BLUE },
paragraph: { spacing: { before: 300, after: 80 } },
},
],
},
sections: [{
properties: {
page: { margin: { top: 720, right: 720, bottom: 720, left: 720 } },
},
headers: {
default: new Header({
children: [new Paragraph({
children: [
new TextRun({ text: "IPD Clinical Cases Master Guide | All Specialties ", size: 16, color: DKGREY }),
new TextRun({ children: [PageNumber.CURRENT], size: 16, color: DKGREY }),
],
alignment: AlignmentType.RIGHT,
border: { bottom: { style: BorderStyle.SINGLE, size: 6, color: LBLUE } },
})],
}),
},
children,
}],
});
Packer.toBuffer(doc).then(buf => {
fs.writeFileSync("/home/daytona/workspace/ipd-cases/IPD_Clinical_Cases_Master_Guide.docx", buf);
console.log("SUCCESS: Document written.");
}).catch(err => {
console.error("ERROR:", err);
process.exit(1);
});
cd /home/daytona/workspace/ipd-cases && node generate.js 2>&1
python3 /home/daytona/skills/docx/scripts/office/validate.py /home/daytona/workspace/ipd-cases/IPD_Clinical_Cases_Master_Guide.docx 2>&1 && ls -lh /home/daytona/workspace/ipd-cases/
ls -lh /home/daytona/workspace/ipd-cases/ && python3 -c "import zipfile; z=zipfile.ZipFile('/home/daytona/workspace/ipd-cases/IPD_Clinical_Cases_Master_Guide.docx'); print('Valid ZIP/DOCX. Contents:'); [print(f.filename) for f in z.infolist()[:10]]"
IPD Clinical Cases Master Guide
Word Document · DOCX
| # | Specialty | Diagnosis | Clinical Hallmark |
|---|---|---|---|
| 1 | Nephrology | AKI Stage 3 (Post-op + ATN) | Oliguria + Cr ×4 baseline; AEIOU criteria for RRT |
| 2 | Pulmonology | AECOPD + Type 2 Respiratory Failure | pH 7.31, PaCO2 68 — NIV initiated; controlled O2 88-92% |
| 3 | Orthopaedics | Fracture NOF — Garden IV | Short + externally rotated limb; cemented hemiarthroplasty within 48h |
| 4 | Gastroenterology | Severe Acute Pancreatitis | Grey Turner + Cullen signs; Ranson 6/11; aggressive Ringer's Lactate |
| 5 | Psychiatry | First Episode Psychosis | MSE with hallucinations/delusions; Risperidone 2 mg BD + cannabis cessation |
| 6 | Haematology | Sickle Cell VOC + Acute Chest Syndrome | HbSS + new infiltrate + SpO2 93%; exchange transfusion + morphine PCA |
| 7 | Endocrinology | Thyroid Storm (BWS Score 85) | Temp 41°C + AF 168 + BWS >45; drug sequence: Beta-blocker → PTU → Iodine → Steroids |
| 8 | ENT | Peritonsillar Abscess (Quinsy) | Uvula deviation + trismus; needle aspiration + IV Penicillin + Dexamethasone |
| 9 | Ophthalmology | Acute Angle Closure Glaucoma | IOP 62 mmHg + fixed mid-dilated pupil; IV Acetazolamide + Mannitol → Laser Iridotomy |
| 10 | Dermatology | SJS/TEN (25% BSA, SCORTEN 3) | Nikolsky sign + Cotrimoxazole culprit; STOP drug + Burns care + Cyclosporin/IVIG |
ICU MASTER GUIDE
What format do you want the ICU Master Guide in? · Which areas should the guide cover?